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INTRODUCTION. There appears to be an emerging phenotype of recreational runners who 
are overweight despite being regularly active. This conflicts with the common perception 
that exercise protects against weight-gain, and it may be caused by underlying insulin-
resistance. Alternatively, recent research has brought attention to metabolically healthy 
obese (MHO) individuals, who have increased adiposity but no commonly associated 
metabolic abnormalities, such as insulin-resistance, hypertension, dyslipidaemia and 
systemic inflammation. This study aimed to determine whether overweight (OW, BMI ≥ 25 
kg.m-2) female runners were at risk of developing metabolic pathology and compare the 
findings to lean (LN, BMI < 23 kg.m-2) counterparts. A secondary aim was to explore 
potential inherent or lifestyle factors that may have predisposed or contributed to weight-
gain in OW runners.  
METHODS. Twenty (10 OW, 10 LN) female recreational runners (years of running 
experience 7.1 ± 4.4 OW; 8.0 ± 3.7 LN) matched for mean age (38.7 ± 4.6 OW; 37.7 ± 4.3 
LN), current mileage in km.week-1 (42.0 ± 10.9 OW; 44.5 ± 12.1 LN) and running calibre 
expressed as energy expenditure (kcal.min-1) in their most recent half-marathon (9.0 ± 1.1 
OW; 9.2 ± 1.1 LN) were recruited for this study. Body fat percentage (BF%) was determined 
using DXA. Participants completed questionnaires about health history, lifestyle and eating 
habits and validated questionnaires concerning recent sleep and stress. Their diet was 
recorded using 3-day diet records and analysed using the South African Food Data System 
(Medical Research Council of South Africa). Habitual sleep and physical activity were 
quantified using 7-day actigraphy (Actiwatch 2) and accelerometry (Actigraph GTX3+) 
respectively. Blood pressure and resting metabolic rate were measured after an overnight 
fast. Blood samples were analysed for cardio-metabolic parameters and an Oral Glucose 
Tolerance Test was performed for insulin-sensitivity.  
RESULTS. OW exhibited a greater body weight (74.4 ± 6.4 kg OW; 59.4 ± 7.8 kg LN, p < 0.001) 
but similar fat-free-mass (49.4 ± 5.6 kg OW; 45.4 ± 5.9 kg LN) to the LN group. OW had a higher 
BF% (32.1 ± 3.9 OW; 21.8 ± 3.9 LN, p < 0.0001), and systolic (118 ± 10 mmHg OW; 107 ± 5 
mmHg LN, p < 0.05), but not diastolic (72 ± 6 mmHg OW; 68 ± 4 mmHg LN) blood pressure. 
There was no difference between groups in serum uric acid, alanine aminotransferase, % 
HbA1c, total cholesterol, HDL-cholesterol, triglycerides or free-fatty-acids. OW had higher 
levels of C-reactive protein (1.30 ± 0.97 mg.L-1 OW; 0.59 ± 0.35 mg.L-1 LN, p < 0.05), total 
cholesterol / HDL-cholesterol (2.70 ± 0.40 OW; 2.30 ± 0.42 LN, p < 0.05) and LDL-cholesterol 
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(2.99 ± 0.65 mM OW; 2.43 ± 0.72 mM LN, p < 0.05), but these were within normal ranges. 
IDL-cholesterol constituted a significantly greater proportion of total cholesterol in OW 
compared to LN, but HDL- and LDL- cholesterol sub-fraction distributions were similar. 
Indices of hepatic (HOMA-IR, 1.06 ± 0.51 OW; 0.86 ± 0.24 LN), and whole-body (Matsuda, 
7.84 ± 2.46 OW; 9.16 ± 2.28 LN) insulin-sensitivity were variable and similar between 
groups. Total area-under-the-curve of the OGTT insulin response tended to be higher in 
OW (p = 0.08). Two OW runners had insulin-resistance (Matsuda < 5); but no participants 
had the metabolic syndrome. RMR (kcal.kg FFM-1.day-1) was lower in OW (29.5 ± 2.1 OW; 
31.6 ± 2.3 LN, p < 0.05), but there were no significant differences in lifestyle factors (diet, 
physical activity, sleep and stress). Total energy intake in kcal.day-1 (1928 ± 354 OW; 2166 ± 
489 LN) and % macronutrient composition as Protein/Fat/Carbohydrate/Alcohol 
(20/44/33/3 OW; 16/43/36/5 LN) were both similar between groups. OW and LN also 
exhibited similar activity in steps.day-1 (10 742 ± 3552 OW; 12 073 ± 3273 LN) and 
percentage accelerometer wear-time spent in Sedentary/Light/Moderate-Vigorous physical 
activity (75/14/11 OW; 72/15/13 LN). Both groups attained circa 7 hours.night-1 of sleep, 
with good sleep onset latency (7.3 ± 5.8 minutes OW; 5.8 ± 3.5 minutes LN) and sleep 
efficiency (91.6 ± 4.4% OW; 90.7 ± 2.8% LN), and they reported reduced to average levels of 
recent stress. 
DISCUSSION. OW runners presented with greater mean adiposity than LN counterparts, 
but the two groups were not as distinct as anticipated. OW runners did present with 
greater metabolic risk according to some traditional risk factors, including inflammation, 
systolic blood pressure, LDL-C and total cholesterol. However, the first three were within 
normal ranges and the clinical relevance of the latter is questionable. It was, therefore, 
concluded that on average the OW group was not at metabolic risk. Only two OW runners 
and no LN runners were insulin-resistant according to indices derived from the OGTT. 
These findings may primarily reflect the insulin-sensitising effects of regular exercise and 
the consequent fitness of the OW runners. Appetite-dysregulation is speculated to have 
played an integral role in their prior weight-gain. We did not identify any lifestyle 
discrepancies that could have explained this weight-gain. The cross-sectional nature of this 
study made it difficult to assess past behaviour during weight-gain, and inter-individual 
variation was considerable. In combination with the small sample size, these factors limited 
the generalisability of the results. Future exploration of the ‘overweight-runner’ phenotype 
is warranted to clarify the mechanisms of weight-gain in habitual runners and consequent 





1.1.) The Obesity Problem 
 
The prevalence of obesity has skyrocketed in recent decades to the point that it now 
affects at least 600 million people and is considered a global epidemic1. As of 2013, 
overweight and obesity (Body Mass Index or BMI greater than or equal to 25 kg.m-2) 
afflicted 37% of men and 38% of women worldwide, having already surpassed the number 
of people suffering from undernutrition in 20001. Most pertinently,  South Africa appears to 
be amongst the most obese nations worldwide, and South African women in particular, 
currently exhibit a striking prevalence of 69% overweight and 42% obesity1. Paradoxically, 
obesity was once considered a concern of affluent first-world countries, yet more recently, 
low-to-middle-income countries (such as South Africa) have experienced the most alarming 
increases in obesity, such that many of these countries now face concurrent burdens of 
obesity and undernutrition2,3. For example, the National Income Dynamics Study found that 
45% and 37% of South African households with a stunted or underweight child, 
respectively, had at least one obese adult 4.  
 
Obesity typically presents with increased risk for chronic non-communicable diseases 
(NCDs)2,3. It also has adverse impacts on work productivity, employment, transportation 
and the environment, and places an immense burden on both individual finances as well as 
the national healthcare system and economy1,5. In fact, a 2014 McKinsey Global Institute 
report placed obesity as the third greatest social burden, accounting for an estimated $2 
trillion in resources (almost equivalent to that of smoking or armed violence, war and 
terrorism)6. In a recent study of 70 000 members of a South African medical aid scheme, 
moderate obesity was associated with 11% greater medical expenditure, which was 
comparable to that of past or current smokers7. Further, despite the adoption of multi-level 
strategies, it has proven difficult to halt the progression of obesity and associated diseases3, 
and the majority of the global adult population is predicted to be obese by 20308. 
Therefore, it seems imperative to better understand the obesity pathology and develop 
more effective public health strategies to secure a healthier outlook and economic security 
for future generations.  
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As shall be explored in this review, the aetiology of obesity is multi-factorial, encompassing 
complex gene-environment-lifestyle interactions that may differ subtly from one individual 
to another. The complexity is compounded by peculiar metabolic phenotypes in which 
obesity and normally-associated diseases develop independently. This will be explored with 
particular reference to the emerging paradox of athletic individuals who gain weight and/or 
develop metabolic illness despite following advice to exercise regularly. It is important to 
better understand the mechanisms that differentiate these phenotypes, so as to better 
inform health guidelines that take cognisance of such discrepancies. 
 
1.2.) Obesity and obesity-associated disease 
 
Obesity has been defined as an excess accumulation of fat in adipose tissue to the extent 
that health may be impaired9. Although typically recognised on the basis of a BMI greater 
than or equal to 30 kg.m-2, this has proven contentious given that BMI is unable to 
distinguish between muscle mass (‘fat-free-mass’) and fat mass10. In fact, recent evidence 
suggests that individuals with a high BMI and elevated muscle mass, may be protected 
from premature mortality relative to individuals with lower BMI11. Given that upper-body 
obesity, indicative of greater abdominal or visceral fat, has been most commonly 
associated with disease risk,12 waist circumference (greater than or equal to 80 cm for 
females) has become a more popular construct for diagnosing obesity and consequent 
health risk in a clinical setting 10.    
 
Obesity rarely exists in isolation and affected individuals typically present with metabolic 
abnormalities, including but not limited to, hypertension, hyperglycaemia, insulin-
resistance, dyslipidaemia, endothelial dysfunction and systemic inflammation13,14. This co-
existence of multiple metabolic disturbances was first recognised in the 1920s by the 
Swedish physician Eskil Kylin, and was subsequently linked in the 1940s to the appearance 
of abdominal obesity in the same patients12. The clustering of disturbances  has since 
become associated with increased risk for type 2 diabetes (T2D) and cardiovascular disease 
(CVD)12. Although each abnormality increases risk for chronic disease, none in isolation 
increases risk to the same extent as presenting with multiple disturbances 
simultaneously14. The term ‘metabolic syndrome’ (MetS) was coined to describe this 
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clustering of T2D and CVD risk factors, which by inference are likely to share a common 
underlying pathophysiology14.  
 
There are various definitions of the MetS, which differ in the relative emphasis placed on 
its four central features (central obesity, insulin-resistance, atherogenic dyslipidaemia and 
endothelial dysfunction)14. The World Health Organisation (WHO) was first to develop its 
MetS definition in 1998, at a time when insulin-resistance was thought to be the salient 
defect15. Consequently, the WHO criteria stipulate that insulin-resistance is an absolute 
requirement for MetS15. This may be identified by impaired fasting glucose (≥ 6.1 mmol.l-1 
in plasma glucose) or impaired glucose tolerance (≥ 7.8 mmol.l-1 at the 120 minute blood 
draw during a 75 gram Oral Glucose Tolerance Test, OGTT). WHO also requires any two of 
central obesity (by a waist: hip ratio ≥ 0.80 in women or a BMI ≥ 30 kg.m-2), dyslipidaemia 
by either elevated serum triglycerides (TG, ≥ 150 mg.dl-1) or reduced serum High-Density-
Lipoprotein-cholesterol (HDL-C, < 39 mg.dl-1 in women), or hypertension (blood pressure ≥ 
140 / 90 mmHg)15. The National Cholesterol Education Program (NCEP) Adult Treatment 
Panel III (ATP III) criteria, as updated in 2005 by the American Heart Association, has been 
considered more clinically applicable since it does not make an absolute requirement that 
assumes an underlying cause16. ATP III requires the presence of three of the following five 
criteria: elevated waist circumference (≥ 88 cm), hyperglycaemia (fasting plasma glucose ≥ 
5.6 mmol.l-1), TG ≥ 150 mg.dl-1, HDL-C < 50 mg.dl-1 in women or hypertension (≥ 130 / 85 
mmHg)16. Finally for the purpose of this review, the International Diabetes Federation (IDF) 
published new criteria in 2005 that required obesity to be present (by population-specific 
waist circumference cut-points), in addition to any two of the following: abnormal TG or 
HDL-C, elevated blood pressure or impaired fasting glucose, as per the thresholds set out 
by ATP III17. The latter has received criticism for having considered obesity as opposed to 
insulin-resistance as the primary pathophysiology18. Regardless, abdominal obesity and 
insulin-resistance have both been hypothesised to be the primary regulators of MetS. The 
exact mechanisms by which they foster related metabolic pathologies are complex and 
require further delineation. For example, whilst weight-loss interventions in the context of 
MetS have benefitted other risk factors, other research has found obese persons who do 
not present with metabolic complications (‘Metabolically Healthy Obesity’), and normal-
weight individuals who unexpectedly present with insulin-resistance, hypertension and 
dyslipidaemia18. Therefore, it seems likely that insulin-resistance is the primary defect 
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underlying MetS and links increased adiposity to metabolic illness in persons predisposed 
to obesity18.  
 
1.3.) Insulin-resistance as the underlying pathology 
 
Insulin is released into systemic circulation by pancreatic beta cells, primarily in response to 
carbohydrate ingestion19. Insulin is crucial to blood glucose homeostasis by stimulating the 
rapid uptake of postprandial blood glucose into insulin-dependent peripheral tissues19. This 
includes adipose tissue, but most glucose is taken up by skeletal muscle, where it may be 
oxidised or stored as glycogen19,20. At the cellular level, insulin binds to insulin receptors at 
the plasma membrane, which stimulates the glucose transporter (GLUT4) to be 
translocated to the membrane via the ‘IRS-1 – PI3K – Akt’ enzymatic pathway20. GLUT4 
translocation is required for the uptake  of glucose into the cell20. At the liver, when 
exogenous glucose is ingested, insulin acts to potently suppress glucose output from 
glycogenolysis and partially suppresses (approximately 20%) gluconeogenesis21,22, 
significantly reducing endogenous glucose production.  Additionally, insulin promotes fat 
synthesis and storage in both adipose tissue and the liver, and inhibits both adipose tissue 
lipolysis (fat breakdown) and fat oxidation in the muscle19. Insulin also exerts important 
physiological functions at the endothelium (increased nitric-oxide dependent vasodilation 
and capillary recruitment), brain (neuronal development, eating behaviour and cognitive 
functioning) and heart (increased myocardial blood flow and cardiac contractility) and 
therefore plays a central role in regulating overall metabolic and cardiovascular 
homeostasis23. In the insulin-resistant condition, however, certain tissues appear to 
experience a reduced response to the insulin signal18.  
 
Although there is no consensus as to the exact pathogenesis of insulin-resistance, it has 
been acknowledged that different tissues develop insulin-resistance at different times.18 
Additionally, while some insulin pathways develop resistance, other pathways in the same 
tissue may remain insulin-sensitive18,24. The primary defects initiating metabolic pathology 
appear to be an inability of insulin to suppress endogenous glucose production from the 
liver, and impaired insulin-stimulated glucose uptake in skeletal muscle (and to a lesser 
extent in adipose tissue), especially for glycogen synthesis24,25. The former promotes fasting 
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hyperglycaemia, whilst the latter reduces glucose tolerance considerably, since skeletal 
muscle normally accounts for 80% of whole-body glucose disposal24. In such cases, regular 
carbohydrate ingestion, combined with increased hepatic glucose output, causes a relative 
hyperglycaemia, for which pancreatic beta cells attempt to compensate by secreting more 
insulin12,20. This pattern promotes the development of chronically elevated blood insulin 
(known as ‘hyperinsulinaemia’) and metabolic pathology20. 
 
Early in the MetS pathophysiology, adipose tissue itself appears to develop insulin-
resistance12. Most importantly, the normal inhibition of lipolysis becomes impaired, which 
increases the breakdown of stored TG to free-fatty-acids (FFA) that enter into circulation24. 
The fat synthesis pathway, however, remains insulin-sensitive and in the context of 
prolonged insulin exposure, promotes fat storage and adipocyte hypertrophy24. In turn, 
abdominal adiposity may exacerbate the insulin-resistant condition via several 
mechanisms26. Firstly, expanding adipose tissue becomes infiltrated with pro-inflammatory 
monocyte-derived macrophages24. These secrete pro-inflammatory ‘adipocytokines’, such 
as tumour-necrosis-factor-α (TNF-α) and interleukin-6 and reduce the secretion of the anti-
inflammatory, insulin-sensitising hormone adiponectin24. Consequently, insulin-resistance 
and obesity have been commonly linked to a chronic low-grade pro-inflammatory state18,27. 
TNF- α and interleukin-6 , appear to impair skeletal muscle insulin-signalling by activating 
certain serine-kinase enzymes (e.g. c-Jun N-terminal kinases) that phosphorylate key 
regulatory serine residues on the insulin receptor and Insulin Receptor Substrate-1, and 
thereby down-regulate insulin-stimulated GLUT4 translocation28.  
 
Increased FFA flux from insulin-resistant adipose tissue, in concert with prolonged 
hyperglycaemia, have also been associated with mitochondrial dysfunction and impaired 
glucose and fat oxidation capacity27,29. The latter may cause incomplete fat oxidation27, 
resulting in the production of deleterious fatty acid derivatives (such as diacylglycerols and 
ceramides) that appear to aggravate insulin-resistance in a similar manner to inflammatory 
cytokines27. It has also been proposed that such mitochondrial defects increase reactive 
oxygen species (ROS) production, which may cause detrimental oxidative damage to 
cellular components and further exacerbate insulin-resistance27,29. Furthermore, un-
regulated lipolysis increases substrate availability for fat accumulation in ectopic (non-
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adipose) tissues, including skeletal muscle, the pancreas and the liver27,30. Although the 
liver develops resistance to the insulin-mediated inhibition of glucose output, becomes 
resistant to the insulin signal to reduce glucose output, the pathway that activates hepatic 
lipogenesis retains normal function18,24. Ectopic fatty acid deposition at the liver manifests 
as non-alcoholic fatty liver disease (NAFLD)18,24. This may be further compounded by de 
novo lipogenesis, whereby excess carbohydrate directed to the liver, is converted to fat and 
stored as TG30. Indeed, NAFLD has been commonly associated with traits of the MetS, 
which is likely mediated by the mutually-aggravating relationship between NAFLD and 
insulin-resistance31. Overall, insulin-resistance coupled with adipose tissue expansion, seem 
to initiate widespread metabolic disturbances by fostering hyperinsulinaemia, 
inflammation, oxidative stress and toxic lipid accumulation in non-adipose tissues. 
However, the strongest link between obesity, insulin-resistance and cardiovascular risk is 
the atherogenic dyslipidaemia that stems from abnormal liver function18. 
 
The dyslipidaemia that characterises the MetS includes elevated plasma FFA and TG, low 
concentrations of high-density-lipoproteins (HDL) and a predominance of small, dense low-
density-lipoprotein (LDL) particles24. Circulating lipids are largely influenced by hepatic 
insulin-resistance and hyperinsulinaemia18,24. As mentioned, hyperinsulinaemia up-
regulates hepatic lipogenesis, which increases TG synthesis and export via very-low-
density-lipoprotein (VLDL) particles (VLDL-TG)14. Simultaneously, both hepatic LDL-receptor 
expression and lipoprotein lipase activity are down-regulated12,14. This increases the 
secretion of apolipoprotein B particles (predominant in LDL and VLDL) and impairs VLDL-TG 
clearance respectively12,14. The resultant ‘hypertriglyceridaemia’ reduces circulating HDL by 
increasing the TG-cholesteryl ester exchange with HDL particles, producing small dense 
HDL-TG that are more readily cleared from circualtion12. The predominance of small LDL 
particles (known as a ‘Pattern B’ LDL profile) appears to arise from the cleavage of larger 
VLDL particles, which are subsequently enriched with triglyceride and hydrolysed to form 
small dense LDL12,32. These pose greater cardiovascular risk because they have lower 
affinity for clearance by the LDL-receptor. They are also more easily able to transit through 
the basal membrane of the endothelium, adhere to the vasculature walls and foster arterial 
plaque build-up that is susceptible to oxidative damage12. Other remnant particles of VLDL-
TG hydrolysis, including intermediate-density lipoproteins (IDL) and chylomicron remnants, 




Endothelial dysfunction (recognised as hypertension in the MetS) is also closely linked to 
insulin-resistance and dysregulated adipose tissue14. Endothelial cells line the inner surface 
of blood vessels and respond to external stimuli by releasing vasoactive molecules14. For 
example, insulin is a potent vasodilator and acts on functioning endothelial cells to produce 
nitric oxide that stimulates blood flow and capillary recruitment14. Insulin thereby exerts an 
an indirect effect on blood pressure and facilitates both glucose delivery to and uptake by 
peripheral tissues14,24. Endothelial expression of cell adhesion molecules also mediates 
circulatory inflammation and coagulation and protects against the development of 
atherosclerotic plaques14. Endothelial insulin-resistance appears to develop from the 
associated conditions of hyperglycaemia, increased FFA, ROS and pro-inflammatory 
cytokines (e.g. TNF-α) and reduced anti-inflammatory adiponectin14,24. These collectively 
impair insulin signalling and reduce nitric oxide production and its normal physiological 
effects14. In the context of other insulin-mediated processes that remain functional (renal 
sodium reabsorption and sympathetic-nervous-system activation), vasoconstriction and 
hypertension are further aggravated12.  Combined with the increased vascular 
inflammation and oxidative susceptibility, these disturbances foster a significantly pro-
atherogenic vasculature12.  
 
Although not recognised as a component of the MetS, dysregulated leptin signalling 
appears to be strongly associated with obesity and MetS33,34. Leptin (the ‘satiety hormone’) 
is a hormone secreted from adipose tissue in proportion to the mass of adipocytes34,35. 
Leptin targets the hypothalamus in the brain to regulate appetite, metabolism and overall 
energy balance35,36. High leptin normally signals that energy stores are adequate, and the 
body does not require further energy intake but should rather expend energy (by physical 
activity) at a normal rate35,36. Low leptin conversely stimulates appetite and hunger, 
thereby promoting energy intake and inhibiting physical activity to conserve energy36. 
Therefore, leptin signalling has been implicated for its likely role in preventing humans 
from starvation and overeating36,37. Obese individuals typically present with systemically 
elevated leptin levels33,35. Theoretically this would promote satiety and reduce food 
consumption33,35. However, evidence suggests that the hypothalamus has developed 
resistance to the leptin signal such that it no longer responds appropriately35. Instead, the 
brain ‘thinks’ that the body is starving, which triggers overconsumption and reduced 
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energy expenditure to  conserve the energy stores it thinks are threatened38.   This would 
further aggravate the obese condition in a vicious cycle35,38. Apart from expanding adipose 
tissue, evidence has implicated the modern diet for disrupting leptin’s normal appetite-
suppressing effects (‘diet-induced leptin-resistance’)37,39,40. Although the mechanisms 
remain unclear, excess consumption of highly palatable, high-sugar, high-fat foods may 
dysregulate satiety mechanisms and foster both insulin-and- leptin-resistance37,41. These 
defects may well be the primary drivers of obesity, and they appear to be both self-
aggravating and integral to the development of associated metabolic abnormalities37. 
 
Much remains to be determined about the pathogeneis of obesity and MetS. However, the 
available evidence supports an integral role for insulin-(and leptin)-resistance in promoting 
these conditions. Although genetic predisposition significantly influences individual 
susceptibility, the recent surge in chronic NCDs implicates modern environmental and 
lifestyle causes. Specifically, contemporary patterns of unhealthy diet, physical inactivity, 
sedentary behaviour, sleep deprivation and chronic stress represent the most plausible 
culprits. 
 
1.4.) Causes of obesity and associated metabolic disturbances 
 
1.4.1.) Non-modifiable factors (Genetics) 
 
Considerable research has been dedicated to identify ‘fat genes’ that predispose individuals 
to obesity. This has proven complex since obesity-related phenotypes (except for rare 
monogenic cases) are influenced by multiple genetic loci variants, single-gene mutations 
and single-nucleotide-polymorphisms (SNPs)42. Indeed, genome-wide association studies 
(GWAS) have identified over 50 genes associated with obesity, the majority of which impart 
small individual effects, but when presenting together may significantly influence the 
observed phenotype43. Most of the implicated genes play a role in the central regulation of 
food intake, eating behaviour and body-weight43. For example, SNPs in the anorexigenic 
genes, MC4R (melanocortin-4-receptor) and POMC (pro-opiomelanocortin) have been 
linked to impaired satiety, snacking behaviour and increased total energy intake43,44. 
Variants in the FTO (Fat mass and obesity-associated) gene have been routinely associated 
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with increased food intake, appetite and dysregulated appetite-related hormones (e.g. 
leptin and ghrelin)43,44. The latter has been supported by extensive animal research that has 
shown increased food intake and obesity in response to the overexpression of FTO43. In 
humans, several genetic variants of FTO have been shown to confer risk for obesity45. The 
FTO gene has also been associated with individually variable weight-loss in response to 
lifestyle (diet and exercise) interventions: individuals who carried the homozygous obesity-
predisposing allele (A) lost more weight compared to non-carriers44.  Another study found 
that the cumulative obesity susceptibility from 12 SNPs was blunted by up to 40% by high 
levels of physical activity46. This implicates genetic variance for mediating individual 
responses to external stimuli. 
 
Genetic variance may further influence obesity predisposition by modulating resting 
metabolic rate (RMR) or the rate of energy utilisation required for basal bodily functions to 
continue at rest. RMR may be modified by multiple factors, including age, physical activity, 
lean muscle mass, diet-induced weight loss and thyroid function, however, it has been 
reported to be up to 40% heritable47. Not much is known about the influence of human 
genetic variance on RMR, but recent evidence has shown that variants involved in energy 
homeostasis and nutrient processing may predispose certain individuals to reduced RMR 
and weight-gain48. The kinase suppressors of Ras protein 2 (KSR2) interacts with the ‘Raf-
MEK-ERK’ enzymatic pathway as part of the regulation of cellular metabolism and substrate 
utilisation48. Specific KSR2 variants associated with obesity in humans were found to disrupt 
signalling in a manner which impaired fatty acid and glucose oxidation and lowered RMR48. 
Given that RMR normally accounts for the predominant portion of daily energy expenditure 
(60 - 70%), a reduced RMR may increase the difficulty of maintaining energy balance and a 
healthy weight49.  
 
It seems logical that co-occurring features of the MetS, and consequent CVD risk, share 
common genetic determinants50. Although evidence supports this contention, the 
estimated heritability differs significantly between studies50. For example, BMI has been 
estimated to be between 25% and 60% heritable, fasting glucose between 10% and 75% 
and hypertension approximately 50%50. Insulin-resistance and T2D both appear to have a 
large genetic component, estimated to be 46% to 90% heritable40. In line therewith, a 
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positive family history of diabetes is strongly predictive of future offspring pathology, and 
relatives of diabetics exhibit increased glucose intolerance18,50. In this regard, evidence has 
implicated the peroxisome proliferator-activated receptor (PPAR) – ϒ gene that modulates 
adipogenesis, as well as genetic variants that influence pancreatic beta cell function50. 
Other studies of twin pairs and families have explored pleiotropic genetic variants that 
influence two or more phenotypic traits and hence may explain the typical clustering of 
MetS risk factors50. For example, the Swedish Adoption/Twin Study of Aging found that BMI 
and insulin-resistance in particular, but also TG and HDL-C concentrations and systolic 
blood pressure, were all influenced by a single latent genetic factor51. Similarly, in the San 
Antonio Heart Study, nondiabetic individuals with a parental history of T2D exhibited a 
significantly more atherogenic lipid profile compared to individuals without such history, 
and this was largely explained by differences in BMI, waist-to-hip ratio and fasting insulin 
levels52. Furthermore, recent meta-analyses of GWAS indicated relatively strong evidence 
for pleiotropic genetic influence on the clustering of CVD traits, particularly coronary artery 
disease with an atherogenic lipid profile50. On the other hand, genetic variation also 
appears to contribute to the disassociation between obesity-related phenotypes. For 
example, a specific SNP in the visfatin gene, which codes for the insulin-mimicking 
adipocytokine visfatin, was recently found to protect against insulin-resistance and CVD risk 
in both obese and non-obese sub-groups53. Therefore, there has been considerable 
evidence for the heritability of obesity, insulin-resistance and associated cardio-metabolic 
outcomes. However, in the majority of cases, genetic predisposition may explain part of the 
observed phenotype, but it requires interaction with ‘modifiable’ or environmental factors 
to trigger the pathology. 
 
1.4.2.) Modifiable factors 
 
1.4.2.1.) At the Global level  
 
The recent rise in obesity prevalence has coincided with significant transitions in global 
economic structures, living and work environments and nutritional exposures3. 
Globalisation and the economic growth, urbanisation and trade liberalisations that have 
accompanied it, have improved widespread aspects of life3. Particularly in low-to-middle-
income countries, more people have access to basic amenities, food security and 
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opportunities to earn an income3. However, such advancements have also fostered an 
‘obesogenic environment’ that is characterised by a built living-environment, office-based 
work, mechanised transport, screen-oriented leisure activity, year-round produce 
availability, and aggressive food marketing strategies that promote ‘over-nutrition’ of 
nutritionally-poor foods2,3. This environment has promoted the two leading (‘the Big Two’) 
causes of a positive energy balance and associated diseases, namely excess caloric intake 
and increased sedentary behaviour with reduced physical activity54,55. It follows that 
mainstream advice to reverse this trend has been to simply reduce energy intake and 
increase energy expenditure3,41. However, more recently it has been proposed that weight 
regulation has a more complex aetiology: that different types of calories have different 
metabolic implications, and that these may counteract the benefits of ‘moving more’ to 
foster weight-gain41,56. 
 
1.4.2.2.) Dietary Exposures 
 
According to the Lancet Global Burden of Disease reports, unhealthy diet may account for 
more disease than physical inactivity, alcohol consumption and smoking combined57. 
Profound changes in food choice, availability, production and guidelines appear to have 
fostered a dominant dietary pattern that promotes weight-gain and obesity-associated 
disease3. Research on the primary dietary culprits has been contentious, owing largely to 
conflict between nutrition research and health authorities. In 1977, the US Senate Select 
Committee on Nutrition and Human Needs published the Dietary Goals for the United 
States. It advised people that if they were to remain healthy and control their body weight, 
they should reduce their consumption of fat, particularly saturated fat and cholesterol. This 
was based on the prevailing ideas at the time, which persist to an extent today: i.) that 
saturated fat intake associates with increased serum cholesterol and deaths from coronary 
heart disease39, and ii.) that body weight regulation is as simple as matching energy intake 
to energy expenditure41,58. The notion that saturated fat consumption increases CHD risk 
appears to have been spurious and recent findings suggest that the underlying ‘Diet-Heart 
Hypothesis’ was incorrect58,59. Ironically, recovered data from the Minnesota Coronary 
Experiment, which was designed to prove said hypothesis, showed that although replacing 
saturated fat with vegetable oils did reduce serum cholesterol, the latter was associated 
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with increased risk of death58,59. Similar studies have found no association between total 
cholesterol and mortality58.  
 
The second prevailing idea was that obesity is a quantitative problem of excess caloric 
intake, which disregards the qualitative notion of caloric quality and its subsequent 
biological effects41. Since fat constitutes more energy per gram (9 kcal.gram-1) compared to 
protein or carbohydrate (both 4 kcal.gram-1), public health messages have been biased 
against fat intake, but in favour of less calorie-dense lean meats, whole-grains, fruits, 
vegetables and low-fat dairy products41. Indeed, the ‘demonization’ of fat and particularly 
saturated fat intake, has had a profound nutritional impact56. Big food industry has 
capitalised by mass producing foods that contain cheap vegetable oils such as corn, 
soybean and rapeseed oils (rich in omega 6 polyunsaturated fatty acids), as well as simple 
carbohydrates in the form of refined grains and sugars2,40. There is now compelling 
evidence that refutes caloric equivalence and suggests that such dietary components have 
actually contributed to the epidemics of obesity and MetS. 
 
Omega 6 (n-6) polyunsaturated fat and trans fat intake have increased considerably in 
recent decades, while omega 3 (n-3) intake has declined60. It has been proposed that the 
optimal dietary n-6 : n-3 ratio, as consumed during hunter-gatherer periods, is 1:161, 
whereas the modern Western diet, rich in vegetable oils, has been reported to average 
between 10:1 and 20:160. Furthermore, owing to the integration of dietary fatty acids into 
cellular membranes, the quantity of n-6 fatty acids in human adipose tissue biopsies has 
dramatically increased (by 3-fold) since the 1960s62,63. Although some polyunsaturated n-6 
fatty acids are essential (e.g. linoleic acid) , their higher unsaturated derivatives (e.g. 
arachidonic acid) give rise to pro-inflammatory ‘eicosanoids’ via fatty acid desaturation and 
elongation reactions60,64. Consequently, excess dietary n-6 fatty acids can promote 
inflammation, vasoconstriction, platelet aggregation and lipogenesis, which has been 
suggested to increase risk for CVD60. However, as reviewed by Russo (2009), many studies 
have failed to show any meaningful relationship between tissue n-6 fatty acid presence and 
CVD risk64. In contrast, the evidence that n-3 fatty acids (particularly eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA)) are cardio-protective, has been consistently 
strong60,64. Indeed, n-3 fatty acids, have anti-inflammatory, vasodilatory effects and 
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enhance both lipid oxidation and insulin-sensitivity by activation of the PPAR-alpha(α) 
transcription factor60. This has motivated the viewpoint that reducing n-6 fatty acid 
consumption is not necessarily as important as increasing n-3 fatty acid consumption65. In 
contrast, there is strong evidence implicating trans fatty acids for increasing CVD risk66. 
Trans fatty acids are produced during the ‘partial hydrogenation’ of polyunsaturated 
vegetable oils that is performed during the production of processed foods to render them 
more stable and prolong their shelf life. Trans fatty acid consumption has been associated 
with insulin-resistance, dyslipidaemia (low HDL and high TG), inflammation, endothelial 
dysfunction and thrombosis67,68. Trans fatty acids are particularly atherogenic owing to 
their incorporation into endothelial cell membranes, where they foster characteristics of 
endothelial dysfunction and atherosclerotic plaque formation68. Furthermore, they are 
highly susceptible to oxidative damage (during cooking, processing, storage and inside the 
body), which produces reactive compounds (e.g. ROS) that are systemically harmful 60. For 
example, increased lipid peroxidation causes oxidative stress, platelet aggregation and 
immune cell adhesion to the vascular endothelium60. Therefore, excess consumption of 
processed foods rich in trans fatty acids, possibly exacerbated by excess n—6 and/or too 
little n-3 fatty acids, appears to foster an atherogenic vasculature. 
 
Global consumption of simple carbohydrates (primarily refined grains and sugars) has also 
increased in parallel with obesity and MetS prevalence41,69. Simple carbohydrates have a 
high-glycaemic index (GI) since they are rapidly absorbed compared to proteins, fats and 
complex carbohydrates70. Refined grains such as white rice and white flour, have had their 
bran and germ portions removed, which contain the fibre, antioxidants, vitamins and 
minerals, leaving an energy dense but nutrient poor food71. Fibre has multiple health 
benefits: it functions as a prebiotic that feeds ‘good’ bacteria in the intestine, it slows 
nutrient absorption, promotes greater satiety, and reduces the GI of carbohydrate-
containing foods72. The removal of fibre alters the physiological and hormonal effects of 
the consumed grain, such that they become more similar to sugar. Indeed, refined grains 
and sugar cause a pronounced insulin spike to dispose of the glucose load and to inhibit 
lipolysis19,41. This can cause a rapid decline in blood glucose (‘reactive hypoglycaemia’), and 
a simultaneous reduction in available FFA41,70, promoting a recurring loop of hunger and 
overconsumption of simple carbohydrates41,70. In predisposed individuals, this may 
manifest as chronic hyperinsulinaemia, insulin-resistance, and eventually pancreatic beta 
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cell dysfunction20,73. Consequently, refined grain consumption has been consistently 
associated with increased risk of weight-gain, systemic and gut inflammation, digestive 
problems, T2D and CVD71,74. 
 
It is now generally accepted by most researchers and health organisations that sugar in 
particular, has a detrimental impact on weight gain and metabolic health40,75. However, this 
is not without some dispute40. Concomitant with the rise in overweight and obesity, global 
consumption of sugar, largely in the form of sugar-sweetened beverages, has significantly 
increased over the past few decades3,76,77. In the USA for example, National Health and 
Nutrition Examination Survey (NHANES) data from 2005 to 2010 showed that men and 
women consumed an average of 335 kcal/day and 239 kcal/day from added sugars, 
representing 12.7% and 13.2% of total caloric intake respectively78. As comprehensively 
reviewed elsewhere79, increased sugar consumption as part of free-living diets has been 
strongly associated with weight-gain67. Sugar intake has further been associated with 
components of the MetS, as well as T2D and CVD, independent of BMI and total energy 
intake40,80. This suggests that independent of its caloric value, sugar can promote metabolic 
pathology40. Randomised controlled trials of added sugar consumption in humans, both in 
the context of ad libitum diets and energy-controlled, weight-maintenance diets, have 
strongly suggested that sugar adversely impacts metabolic risk (e.g. increased TG, reduced 
HDL-C and reduced insulin-sensitivity)40. However, the ad libitum studies were confounded 
by variable individual diets and controlled studies were limited by methodological flaws40. 
Consequently, a recent review remarked on the absence of definitive trials concerning 
sugar’s potentially independent role in metabolic disease40. The controversy has been 
compounded by the null findings of sugar-industry-funded studies40,81. Despite this 
uncertainty, robust mechanisms have been proposed40.  
 
Sugar (sucrose) is a disaccharide composed of glucose and fructose monomers. Whereas 
hepatic glucose metabolism is regulated by insulin and hepatic energy need such that much 
of the ingested glucose reaches circulation, dietary fructose is not regulated by hepatic 
energy status and is predominantly metabolised in the liver40. Dietary fructose, therefore, 
provides excess substrate for the liver, which stimulates de novo lipogenesis40. This 
increases hepatic lipid stores, promotes hepatic insulin-resistance, NAFLD, VLDL-TG 
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production and consequent dyslipidaemia40. Fructose metabolism to fructose-1-phosphate 
also converts significant amounts of adenosine triphosphate (ATP) to adenosine 
monophosphate, which leads to uric acid production via the purine degradation pathway82. 
Uric acid appears to be a potent mediator of hypertension and T2D, by promoting 
inflammation, oxidative stress, insulin-resistance and endothelial dysfunction40,75. In 
addition, studies conducted in rat models suggest that fructose induces leptin-resistance, 
independent of increased adiposity or elevated leptin levels37. In the presence of a highly 
palatable diet (high-sugar, high-fat), impaired satiety would promote over-consumption 
and weight-gain37. Nonhuman animal models have found that sugar consumption 
stimulates the same reward and hedonic neural pathways as psychostimulant and opiate 
drugs, by binding to opioid and dopamine receptors and stimulating the release of 
dopamine and acetylcholine83,84.  In this manner, sugar consumption induces a reward and 
craving that is comparable in magnitude to that of cocaine85, and fosters sugar-
addiction83,84. Further research is required to confirm these findings in humans. However, 
human studies have reported that sugar consumption fails to induce normal satiety 
mechanisms, which may cause excess energy intake (beyond caloric need) at subsequent 
meals3,40. Despite the lack of definitive clinical trials, the epidemiological data and plausible 
mechanisms suggest that sugar consumption does promote obesity-associated disease, 
both directly via dysregulated metabolism and indirectly via dysregulated appetite 
control40.  
 
Overall, evidence suggests that the modern Western diet, characterised by highly refined 
high-sugar, high fat foods, has contributed considerably to obesity and MetS. The 
assumption that any two foods with the same potential energy (calorie) would influence 
satiety, food intake and body weight similarly, now seems inherently flawed41. More 
recently, alternative dietary practices to the low-calorie, low-fat model have been 
advocated to better regulate the hormones (e.g. insulin, leptin) involved in food intake and 
metabolism41,86,87. Low-GI carbohydrates (e.g. oatmeal, apples, pearl barley), have been 
theorised to induce a smaller and more sustained postprandial rise in blood glucose86,88. 
This would induce a lower relative insulinaemia and increase the availability of metabolic 
fuels, such as hepatic glucose and adipose-derived FFA86,88. Low-GI foods have, therefore, 
been advocated to make one ‘feel fuller for longer’ than equivalent high-GI foods and 
reduce subsequent food intake88. Studies of short-term satiety differences between low-GI 
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and high-GI meals, have suggested this may be effective88. Sixteen such studies were 
reviewed by Ludwig et al. (2000), and 15 of them found increased satiety, delayed onset of 
hunger or decreased food intake after a low-GI compared to a high-GI meal86. The authors 
of a 2007 review speculated that this may be partly due to differences in fibre content and 
palatability88. Long-term studies of low-GI diets in relation to weight loss, however, have 
generally failed to show significant benefits to spontaneous energy intake or body weight 
regulation88. Future studies are needed that are better controlled and compare diets 
differing only in GI, to make definitive conclusions88.  
 
Rather than focusing on the GI of individual food components, Zeevi et al. (2015) recently 
brought attention to the postprandial glycaemic response (PPGR) to real-life meals that 
consisted of arbitrary food combinations89. They reported substantial inter-individual 
variability in the PPGR to identical test foods, and developed an algorithm to predict 
personalised PPGRs based on variables including meal content, daily activity, blood 
parameters and microbiome features89. Individually-tailored dietary prescriptions 
significantly improved PPGRs and associated metabolic characteristics89.  Based on these 
findings, the authors speculated that dietary advice for optimal body weight regulation and 
metabolic health should be individualised89.  Indeed, consumption of foods that induce a 
low PPGR seems to be important for minimising both postprandial insulinaemic responses 
and the long-term risk of hyperinsulinaemia and insulin-resistance86. A couple of earlier 
randomised controlled trials have explored varying macronutrient composition or 
glyceamic load appropriately for individuals with varied insulin-sensitivity and insulin 
secretory profiles90,91. Pittas et al. (2005) found that overweight but healthy men and 
women, who had higher OGTT insulin secretion, lost significantly more weight on a low-GI 
diet (30% fat, 40% carbohydrate, 30% protein) compared to a high-GI diet (20% fat, 60% 
carbohydrate, 20% protein)91. The latter was particularly adverse for participants with the 
highest insulin secretion owing to regular postprandial hypoglycaemia, hunger and excess 
energy intake91. Similarly, Cornier et al. (2005) randomised nondiabetic obese women, who 
had been identified as insulin-resistant or insulin-sensitive, to calorie-restricted high-
carbohydrate, low-fat (HCLF, 20% fat, 60% carbohydrate, 20% protein) or so-called low 
carbohydrate, high-fat (LCHF, 40% fat, 40% carbohydrate, 20% protein) diets for 16 
weeks90. Although all groups (insulin-resistant-HCLF, insulin-resistant-LCHF, insulin-
sensitive-HCLF and insulin-sensitive-LCHF) lost significant weight, the extent of weight loss 
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was determined by insulin-sensitivity status90. Specifically,  the insulin-resistant group lost 
most weight on a LCHF diet and the insulin-sensitive group on the HCLF diet90. These 
studies show the importance of tailoring diets to be appropriate for individual physiology, 
and suggest that appropriate carbohydrate restriction may attenuate the risk of 
hyperinsulinaemia and weight-gain most successfully. 
 
‘Carbohydrate restriction’ refers to a dietary pattern that is low in all carbohydrates, 
including wholegrains, refined grains and sugars. It has recently received significant 
attention for its purported potential in addressing obesity and metabolic illness56,87. 
Carbohydrate restriction may take many forms, including high-protein, low-carbohydrate 
(e.g. Atkins), LCHF, very-low carbohydrate, high-fat (VLCHF), ketogenic (VLCHF with 
elevated blood ketone concentrations) and intermittent fasting. Proponents of 
carbohydrate restriction have advanced that the human body has adapted evolutionarily 
from our hunter-gatherer ancestry to the use of fat as its predominant fuel source92. The 
human genome may thus be ill-adapted to the agricultural-based, high-carbohydrate 
dietary practices of modern society92. This has created a gene-environment mismatch with 
deleterious health consequences92. Given that obesity-associated disease appears to be 
driven by insulin-resistance and compensatory hyperinsulinaemia18, appropriate 
carbohydrate restriction that minimises insulin secretion would theoretically benefit body 
weight regulation and metabolic health87.  
 
Although the carbohydrate ‘threshold’ differs on an individual basis, numerous studies that 
restricted carbohydrate intake to less than 50 grams per day (VLCHF diets) have reported 
improvements in MetS. For example, a 2013 meta-analysis of randomised controlled trials 
with at least 12 months follow-up concluded that well formulated ad libitum VLCHF diets 
were more effective than calorie-restricted HCLF diets for reducing body weight and 
improving MetS risk factors, including TG, HDL-C and blood pressure93. Other studies 
conducted  for a range of time periods (3 months up to 2 years) have shown VLCHF diets to 
be at least as effective as HCLF, Mediterranean or so-called ‘Healthy Eating’ diets for 
improving fasting blood insulin, glucose and glycosylated haemoglobin (HbA1C) 
concentrations, insulin-sensitivity, adiposity and improving lipid profiles by increasing LDL-C 
particle size and HDL-C concentrations whilst reducing serum TG94–101. In light of these 
findings, a recent critical review of the role of nutrition in metabolic health concluded that 
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VLCHF diets represent the most effective intervention for reducing all symptoms of the 
MetS and preventing the development of T2D independent of weight loss87.  Additionally, 
ad libitum VLCHF diets appear to be most beneficial for promoting weight loss in both 
diabetic and non-diabetic individuals87. The latter may result from increased protein and fat 
consumption that, in the absence of simple carbohydrates, appears to improve satiety and 
promote spontaneous caloric reduction despite unlimited access to food87. Additionally it 
has been proposed that the limited selection of foods on a VLCHF diet enforces this caloric 
restriction98. Indeed, avoiding carbohydrate-rich foods may be particularly difficult for 
many individuals and has been raised as a concern to the long-term adherence to VLCHF 
diets, on the basis that sustained diet adherence rather than any specific diet seems to 
determine weight management success102. However, evidence from clinical trials suggests 
that at least up to 12 months, adherence to VLHF diets is comparable to that of other 
dietary strategies87,103. For example, Hu et al. (2016) recently reported comparable 
adherence from 148 adults randomised to low-carbohydrate (< 40g.day-1) or low-fat (<30%) 
diets, with greater weight-loss experienced by those following the low-carbohydrate 
diet103. Despite the increasing anecdotal evidence, it remains to be clinically determined if 
free-living individuals would be able to sustain similar adherence to VLCHF diets over the 
long-term. Regardless, individualised nutrition regimes (carbohydrate restriction for some) 
that are easily sustained seem integral to improving the global burden of non-
communicable disease 87,104. 
 
1.4.2.3) Physical Inactivity and Sedentary Behaviour 
 
It is widely believed that decreased physical activity has contributed to the increased 
prevalence of overweight and obesity105, based on the assumption that reduced daily 
energy expenditure promotes positive caloric balance41,86. For this discussion, it is 
important to distinguish between ‘physical inactivity’ and ‘sedentary’. The former 
specifically refers to not meeting physical activity guidelines92, in which health authorities 
commonly prescribe 30 minutes of moderate-intensity physical activity on at least 5 days 
every week, 20 minutes of vigorous-intensity physical activity on at least 3 days per week or 
an equivalent combination thereof106,107. ‘Sedentary’ specifically refers to time spent sitting, 
lying down or expending low levels of energy108. Indeed, self-reported data indicates that 
globally 31% of adults do not meet physical activity guidelines107, and 2010 data showed 
that 52% of South Africans were well below the age-standardised recommendations109. 
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Interestingly, data from the USA suggests that leisure-time physical activity (e.g. gym, 
recreational sport) has remained stable or increased over the past 50 years, however, 
activity associated with employment, transportation (e.g. walking or cycling) and household 
chores has declined substantially3. Instead, American adults for example spend an average 
of 55% of their waking time sedentary, and various population-based studies report adults 
sitting for more than 5 hours.day-1 1110. In this regard, health authorities have 
recommended the public limits sedentary behaviour as far as possible, using strategies 
such as active transport, standing desks or prompts to break up sitting time, in an attempt 
to improve body-weight regulation86,110. However, whether or not reduced energy 
expenditure has contributed meaningfully to overweight and obesity, and conversely 
whether or not exercise reduced sedentariness would protect against weight-gain, remains 
controversial56,105.  
 
Observational studies of physical activity and future weight-gain have reported conflicting 
findings, with positive associations having been weak41,105. This may have been due to 
inherent confounding, difficulty in quantifying physical activity and sedentary behaviour 
accurately, inconsistent measurement methods, and potential reverse causality41,105. 
Previous systematic reviews and meta-analyses have reported that exercise interventions 
without caloric restriction have achieved minimal weight-loss111,112.  Further, some  studies 
have found no change, or even weight-gain, in response to exercise interventions with ad 
libitum dietary intake113. This evidence would suggest that exercise needs to be combined 
with conscious caloric restriction to achieve meaningful weight-loss113. Indeed, multiple 
systematic reviews have reported significant and clinically meaningful weight-loss from 
interventions that combined exercise with diet (caloric restriction)112,114,115. Furthermore, 
the significant improvements from ‘diet only’ arms motivated the interpretation that diet is 
the primary determinant of body composition112,114. In support of these concepts, for 
example, Pontzer et al. (2012) compared the energy expenditure of Hadza hunter-
gatherers in Tanzania to those of comparable American adults living sedentary 
‘Westernised’ lifestyles116. There was no difference in total energy expenditure between 
populations despite the Hadza being more physically active and significantly leaner116. The 
two populations were, however, differentiated by dietary intake: the Hadza consumed 
natural, raw foods, while the American adults consumed a highly refined high-sugar, high-
fat diet116. Prospective associational studies between sedentary behaviour and weigh- gain 
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have proven unclear110. Specifically, studies have found no association, weak positive 
associations or even reverse causality, in which baseline adiposity predicted future 
sedentary behaviour110. Therefore, the notion that physical inactivity and a sedentary 
lifestyle have caused obesity does not appear to be as convincing as has been conveyed. 
This may be due to the overwhelming influence of some of the aforementioned dietary 
factors on the hormones that regulate food intake41,56. 
 
Energy intake and energy expenditure are tightly coupled by hunger-satiety signalling 
pathways between the brain, adipose tissue and gut38. This neuro-hormonal regulation of 
food intake (a functional ‘appestat’) is integral to body-weight regulation41,117. Increased 
physical activity (energy expenditure) has been shown to trigger signals to the brain to 
consume more calories in order to restore energy balance41,117. For example, hormonal 
tracking of professional cyclists during the gruelling Giro d’Italia cycling stage race, showed 
a steady decrease in leptin and concomitant rise in adiponectin, indicating an increasing 
need for energy or refuelling in these athletes118. Conversely, a 7-day simulation of the Tour 
de France in 13 highly trained cyclists found that athletes did not replenish their energy 
stores adequately, suggesting that the appestat may be overwhelmed or does not in such 
intensive scenarios119. However, in the general population, where energy surplus is more of 
a concern and exercise intensity is relatively low and constrained to an hour or two on any 
given day, it may be that compensatory mechanisms contribute significantly to the limited 
success of exercise interventions that do not restrict dietary intake41,113,120. Further, the 
often-cited overestimation of exercise energy expenditure121, may increase the degree of 
overconsumption41.  Particularly in the context of a highly processed diet individuals 
engaging in exercise may remain susceptible to impaired satiety regulation41,117.  The brain 
would be instructed to ‘exercise less and eat more’, thus promoting a vicious cycle of 
hunger, overeating of non-satiating food and subsequent inactivity37,41,117,122. In this 
context, the pro-weight-loss effects of exercise may be effectively nullified38,34, and reduced 
population-wide physical activity levels may be a consequence rather than a cause of the 
obesity epidemic41,117,122.   
 
The evidence relating physical inactivity and sedentary behaviour to metabolic disease is 
more compelling109,117,123. According to the WHO, physical inactivity is the fourth leading 
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cause of NCD-related mortality109. Moreover, individuals who are insufficiently active have 
been reported to have a 20% to 30% increased risk of all-cause mortality compared to 
those meeting recommendations109. Approximately 3.2 million deaths.year-1 have been 
attributed to physical inactivity109. Prospective studies have associated physical inactivity 
with increased risk of hypertension, stroke, T2D and CVD, depression and certain cancers, 
often in a dose-response manner109,124. Conversely, it has been well-established that 
regular exercise improves cardio-metabolic outcomes, including blood pressure, insulin-
sensitivity and blood lipid profile, independent of weight-loss124–126. Furthermore, such 
benefits have been accrued by lean and overweight individuals alike, and favourable 
cardiovascular fitness, independent of body weight, appears to be protective against 
metabolic diseases127–129. The mechanisms of ‘exercise as medicine’ appear to be 
widespread. 
 
Insulin-sensitivity is improved both acutely and chronically in response to exercise 
training108. The former relates to the contraction-mediated translocation of GLUT4 to the 
muscle cell membrane, which enhances glucose uptake124,126. Exercise training may 
improve insulin-sensitivity by reduced adiposity, with increased muscle mass as well as 
increased muscle GLUT4 content, glycogen storage capacity, mitochondrial density and 
oxidative capacity124,126. Exercise training also increases HDL-C concentrations, reduces TG 
and increases LDL particle size, which may be related to altered insulin-sensitivity126. 
Systolic and diastolic blood pressure are both improved by exercise training, particularly in 
individuals with existing hypertension126. This may result from exercise-induced 
improvements in both cardiac and endothelial function, as well as enhanced insulin-
sensitivity and vasodilation124,126. Despite an acute exercise bout inducing an inflammatory 
response and oxidative stress, these are necessary for adaptation, and over the long-term 
improved cardiorespiratory fitness reduces systemic inflammation126. Exercise has been 
found to have remarkable benefits for mental health and preventing or delaying the onset 
of neurodegenerative diseases130. Therefore, engaging in regular physical activity is crucial 





Sedentary behaviour, particularly increased sitting time, has been found to increase risk of 
MetS, CVD and all-cause mortality, independent of leisure time spent in physical activity 
and other potential confounders131–133. Specific sedentary behaviours, particularly time 
spent watching television, have also been independently linked to MetS133. This evidence 
suggests that frequent engagement in physical activity may not compensate adequately for 
long periods of sedentary time131,132. Although the underlying mechanisms appear unclear, 
the pathology may relate to prolonged periods of absent muscle contraction134. In fact, the 
effects of sedentary predominance have been likened to those of bed-rest on cardiac 
function, deep vein thrombosis, impaired glucose tolerance and lipoprotein lipase activity, 
the latter of which reduces TG clearance and HDL production131,134. However, other studies 
have suggested that performing sufficient moderate-to-vigorous activity and maintaining 
cardiorespiratory fitness would be protective against illness, regardless of time spent 
sedentary135,136. Indeed,  ‘sedentary research’ is an emerging field and it appears that the 
potential risks of significant sedentary time have been largely based on association137. 
Definitive studies are required to determine whether or not sedentary behaviour 
independently promotes metabolic disease131. 
 
1.4.2.4.) Sleep Curtailment 
 
It is well established that sleep is critical for brain restorative processes and for maintaining 
overall well-being138. Although much about sleep physiology remains unexplained, evidence 
suggests that sleep is integral to learning, memory processing, brain development, cellular 
repair, neuroendocrine function, autonomic balance and glucose metabolism138–140. 
Reproducible patterns of pituitary- and adrenal hormone release, which are integral to 
most bodily functions, are dependent on similarly reproducible patterns of  specific stages 
of sleep140. Current consensus is that adults should get at least 7 hours of sleep per night141. 
However, modern society, with its long work and commuting hours, night-based leisure 
activities and shift-work is experiencing an endemic of behavioural sleep curtailment138.  
Exposure to artificial light after sunset and before sunrise, especially from screen-based 
entertainment, may delay bed time and sleep onset, disturb sleep quality and reduce 
overall sleep time138. As a result, data from the 2014 Behavioural Risk Factor Surveillance 
System in the USA found that more than one-third of the 444, 306 adult respondents 
reported sleeping less than 7 hours per night142. Over the long-term this would accumulate 
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as a significant sleep ‘debt’, which has been linked to poor subjective and objective 
measures of general, physical and mental health and impaired quality of life143–145.  
 
Numerous studies have demonstrated the adverse effects of sleep deprivation on body-
weight and adiposity146. Cross-sectional studies, using both self-report and 
polysomnography, typically report a U-shaped relationship between sleep duration and 
weight or measures of central adiposity138,146,147. Specifically, short sleep (recognised as less 
than 6 hours.day-1 for adults) and prolonged sleep (more than 9 hours.day-1) appear to 
promote weight-gain, whilst 7 to 8 hours of sleep per night (considered optimal) has been 
associated with reduced weight and adiposity147,148. Similarly, prospective cohort studies 
have consistently found increased risk of weight-gain in individuals with shorter sleep 
durations, independent of caloric intake and physical activity146. These findings may relate 
to impaired glucose and lipid metabolism or altered neuro-hormonal signalling that 
disrupts appetite regulation (e.g. decreased leptin and increased ghrelin) and promotes 
unhealthy eating habits146. Further physiological studies are required to better elucidate 
the pathways at play146. 
 
Partial sleep deprivation also appears to promote cardio-metabolic abnormalities139. 
Healthy individuals exhibit a daily variation in glucose tolerance and adequate sleep is 
crucial to regulating this natural rhythym149. Recurrent partial sleep deprivation has been 
shown to alter glucose-regulation, and six consecutive nights of curtailed sleep was found 
to impair glucose tolerance by 40% in healthy young men143,149.  Both objectively-measured 
poor sleep quality and perceived sleep debt have been associated with poor glycaemic 
control, and epidemiological evidence has independently associated short sleep duration 
with increased risk of T2D149. Similar effects have been seen in studies that induced 
circadian misalignment to mimic shift-work and air-travel across time zones150. Multiple 
mechanisms have been proposed to link impaired sleep to compromised glucose 
metabolism; these include reduced cerebral glucose metabolism as well as increased 
sympathetic nervous system activity that reduces insulin secretion and increases the 
counter-regulatory hormones, glucagon and cortisol140,149. Partial sleep deprivation 
dampens the immune system, foster low-grade inflammation and insulin-resistance, 
increases risk of hypertension, dyslipidaemia, MetS and CVD, as well as depression and 
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mortality from all causes141,151. Indeed, good sleep habits appear to be crucial to 
maintaining cardio-metabolic health and will likely receive increased attention in 
forthcoming years.   
 
1.4.2.5) Chronic Stress 
 
Stress refers to any challenge to an organism’s natural homeostasis, including infection, 
pollution, and temperature variations152. Under normal circumstances these induce a stress 
response (behavioural and physiological) that attempts to restore equilibrium, and is 
primarily mediated by changes in the autonomic nervous system and the neuroendocrine 
hypothalamic-pituitary-adrenal (HPA) axis152. Stress responses normally facilitate beneficial 
adaptation to acute stressors, however, they are susceptible to becoming maladaptive in 
the context of chronic stress153. This is exemplified by the stress caused by traits of modern 
society, such as frenetic work schedules, ultra-competitive capitalist job markets, economic 
strain, congested commutes, and sleep deprivation153. Such relentless demands foster a 
chronic stress response within the body, which may promote pathology153. Cross-sectional 
studies attempting to link stress in the work environment with components of the MetS 
have been inconsistent, possibly because of the restricted snapshot of individual stress 
levels154. The Whitehall II case-control study found elevated cortisol (the ‘stress hormone’), 
impaired autonomic nervous system regulation with greater sympathetic activation, and 
increased systemic inflammation, in working men with the MetS compared to healthy 
controls155. In a 14-year prospective study, Chandola et al. (2006) found a dose-response 
relationship between job-related stress and increased risk of MetS, independent of 
occupation and confounding health behaviours154.  Therefore, it appears that chronic 
psychosocial stress and metabolic disease may be closely connected. 
 
Multiple studies have shown altered HPA axis function in obesity-related conditions. For 
example, elevated 24 hour and postprandial urinary or salivary cortisol have been 
associated with abdominal obesity and indices of glucose intolerance, high blood pressure 
and insulin-resistance152. Cortisol also appears to interact with other causes of obesity, 
including altered appetite regulation and sleep deprivation152. For example, whilst leptin 
levels normally increase during sleep to inhibit food intake, sleep deprivation has been 
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found to suppress leptin levels, concurrent with elevated cortisol and increased food 
intake152. This would suggest that the stress of chronic sleep deprivation promotes obesity 
partly through HPA axis dysregulation152. Chronic stress appears to promote unhealthy 
eating habits and obesity via similar pathways156. Individuals with greater cumulative stress 
(associated with higher glucocorticoid secretion) have been found to be more likely to 
exhibit addictive eating habits, binge eating and snacking, and increased desire for highly-
palatable Western foods152,156,157. Elevated cortisol secretion in this context would 
compromise glucose metabolism and appetite-regulation in a manner that promotes 
insulin-resistance and abdominal obesity156.  Therefore, it is plausible that chronic stressors 
increase metabolic disease risk, yet further research is required to better elucidate the 
mechanisms involved.  
 
1.4.2.6) Other potential contributors 
 
Contemporary society has developed other traits that, although lesser acknowledged, 
appear to have aggravated the epidemics of obesity and metabolic illness.  These will be 
briefly described here, since they have been comprehensive reviewed by McAllister et al. 
(2009)54. Firstly, there has been a wealth of recent research into the adverse effects of 
mismatched intra-uterine exposures with early-life environments54,55. Early developmental 
exposures influence the functional and organ development of new-borns to adapt them to 
their forthcoming environment, referred to as ‘developmental plasticity’54. When there is a 
mismatch between the resulting phenotype and the early childhood environment (e.g. 
malnutrition in utero compared to abundance in childhood), individuals are more 
susceptible to insulin-resistance and pathogenic adiposity54. Maternal over-nutrition, and 
the resultant hyperinsulinemia, promote adipogenesis and altered appetite regulation 
during late foetal life, such that offspring are predisposed to adulthood obesity54. Further, 
maternal obesity may cause epigenetic modifications (e.g. DNA methylation, histone 
modifications), that alter gene and protein expression and influence individual 
susceptibility to obesity-associated illness54. Consequently, many overweight adults may 
have been pre-determined by their in utero and early childhood exposures to become 




Recent changes in smoking prevalence, pharmaceutical administration, industrial 
production of environmentally harmful substances, and reproductive habits also warrant 
examination54. Whilst smoking is a well-established CVD risk factor, the appetite-
suppressant effect of nicotine has been suggested to reduce the risk of weight-gain in 
smokers158. Given the increased public advocacy and health warnings against smoking, its 
prevalence has declined significantly over recent decades54. This may have caused ex-
smokers to gain weight54. On another note, the exponential growth of industry has 
increased the infiltration of harmful substances (e.g. heavy metals, solvents, 
organophosphates) into the environment and human food chain54. When ingested these 
may disrupt endocrine functions (e.g. agonists/antagonists for receptors) that adversely 
influence fat metabolism and nutrient partitioning159. Many of the contemporary 
pharmaceuticals that have been introduced to treat chronic conditions such as psychosis, 
depression, diabetes and hypertension, appear to have had adverse side-effects on 
adiposity160. Furthermore, a high BMI has been associated with increased reproductive 
fitness, which implicates the increasing prevalence of obesity itself for imparting selective 
pressure for obesity-associated phenotypes54,161. In combination, these and other societal 
factors, although seemingly unrelated, may have contributed to the complex phenomenon 
of obesity. 
 
In summary, the aetiology of obesity and MetS is clearly multifactorial. This has made it 
difficult to generate a unifying and generalisable theory to explain their increasing 
prevalence. However, the most plausible primary pathophysiology appears to have been 
insulin-(and-leptin)-resistance and the compensatory hyperinsulinaemia. These conditions 
have probably been promoted and aggravated by various modern environmental 
exposures (e.g. poor diet quality, physical inactivity, sleep deprivation, stress, and 
developmental conditions) to foster pathological glucose and lipid metabolism, increased 
risk for T2D and CVD, accompanied by weight gain in predisposed individuals18,87,104. In 
order to mitigate the negative health effects of insulin-(and leptin)-resistance, at-risk 
individuals would benefit mostly from minimising systemic exposure to insulin and foods 
that impair satiety mechanisms. This may be achieved primarily by reducing carbohydrate 
consumption below the threshold that causes chronic hyperinsulinaemia13,20,87, and 
avoiding highly processed high-sugar, high-fat foods37. Ensuring adequate sleep, regularly 
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engaging in moderate-to-vigorous physical activity and minimising exposure to stressors 
are also integral strategies to improving overall well-being.  
 
At the same time, it is important to recognise the existence of individuals who may not 
exhibit the classic clustering of obesity with metabolic pathology, but rather exhibit  obesity 
or metabolic illness independently. Indeed, recent attention has been drawn to the 
Metabolically Healthy Obese / Overweight and Metabolically Unhealthy Normal Weight 
phenotypes. These individuals are attractive prospects for learning more of the complex 
interplay between genetic predisposition, adiposity, and physical fitness in determining 
cardio-metabolic health.   
 
1.5.) Alternative metabolic phenotypes 
 
1.5.1.) ‘Metabolically Unhealthy Normal Weight’ phenotype 
 
In contrast to conventional thought, apparently normal weight persons are not always ‘thin 
inside’. The metabolically unhealthy normal-weight phenotype was initially recognised in 
1981 as individuals presenting with a BMI below 25 kg.m-2, but with metabolic 
abnormalities more characteristic of MetS, including hyperinsulinaemia, hypertension, 
hypertriglyceridaemia, greater HbA1c, reduced HDL-C and/or  a pro-inflammatory state 162–
164. This sub-group is of particular concern as their elevated risk of disease may easily go 
unnoticed163. Due to variations in MetS diagnostic criteria and cohort (ethnicity, sex and 
age) differences, estimates of the prevalence of this phenotype have been unclear163; 
however, Wildman et al. (2008) found that in the 1999-2004 NHANES cohort, 23.5% of 
normal-weight adults exhibited at least two cardio-metabolic abnormalities and were 
deemed metabolically at-risk165.  
 
A number of cohort studies have indicated greater T2D risk in metabolically unhealthy 
normal weight persons relative to their metabolically healthy counterparts164. 
Unfortunately, studies have utilised inconsistent criteria for identifying metabolically 
unhealthy normal weight persons163, with some using indices of insulin-resistance166, others 
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visceral fat area167, or the presence of at least three metabolic abnormalities analogous to 
the MetS described above168. Meigs et al. (2006)  assessed CVD and T2D risk over a 7 to 11 
year follow-up, and found that 7% and 21% of metabolically unhealthy normal weight 
participants, who fulfilled the ATP III MetS criteria, developed T2D or experienced CVD 
events respectively168. Both of these were considerably higher than the observed risk in 
healthy normal-weight or healthy obese participants168. Interestingly, it has been estimated 
that 15% to 20% of incident T2D cases in prospective studies have arisen from normal-
weight persons. In a case-cohort study, Eckel et al. (2015) identified metabolically 
unhealthy normal weight persons as those who developed T2D over a mean 7 year follow-
up164. Many of those who developed T2D had not been identified as insulin-resistant nor 
did they fulfil MetS criteria at baseline164. Furthermore, despite their greater metabolic risk 
compared to normal-weight controls, their mean waist-circumference in particular 
(associated with BMI), as well as TG and HDL-C levels, were within the upper range of 
‘normal’ but below MetS thresholds163,164. This evidence has led some to suggest that 
existing MetS criteria and parameter cut-offs are insensitive for identifying risk in normal-
weight persons163,164. However, given that metabolically unhealthy normal weight persons 
appear to be at a lower risk than metabolically unhealthy overweight or obese 
persons163,164, it may suffice to incorporate other metabolic markers that associate with the 
metabolically unhealthy normal weight phenotype, including HbA1c or CRP, when 
determining risk in normal-weight individuals164. Regardless, a clear definition of 
metabolically unhealthy normal weight is required to allow for more consistent criteria to 
be applied in determining risk across clinical and research settings.   
 
The pathophysiology of the metabolically unhealthy normal weight phenotype is unclear; 
however, increased abdominal fat and reduced physical activity appear to be integral 
factors. Firstly, metabolically unhealthy normal weight persons exhibit elevated abdominal 
and visceral adiposity and reduced fat-free-mass compared to BMI-matched controls, and 
this has been associated with impaired insulin-sensitivity163. Eckel et al. (2015) recently 
reported waist circumference was particularly sensitive to increased risk of incident T2D in 
normal-weight individuals164. This may reflect the functional heterogeneity of different 
adipose tissue compartments169. TG storage in subcutaneous adipose tissue (SAT), located 
around the hips and thighs, as opposed to visceral adipose tissue (VAT) located in the 
abdominal area, has been shown to be protective against metabolic abnormalities in 
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predominantly Caucasian populations169,170. Conversely, studies on South African and 
American black women have shown that at the same BMI or waist circumference, black 
women present with worse insulin-resistance despite lower VAT171. Furthermore, whilst 
insulin-sensitivity associates most strongly with VAT in white women, it associates more 
closely with abdominal SAT (ASAT) in black women (particularly deep ASAT rather than 
superficial ASAT)171. This evidence suggests ethnic differences in the relationship between 
regional fat distribution and metabolic health, for which potential mechanisms include 
differences in lipolytic activity, sex hormones, and glucocorticoid exposure, and have been 
reviewed elsewhere171. Regardless, it is clear that more research is needed to better 
understand the functional heterogeneity of different adipose tissue depots172.  
 
A further consistent finding is that metabolically unhealthy normal weight persons spend 
less time physically active, more time sedentary and may exhibit reduced aerobic capacity, 
in comparison to their healthy lean counterparts163,164. This agrees with the 
aforementioned benefits of regular exercise for metabolic health. There is limited literature 
on dietary components contributing to the metabolically unhealthy normal weight 
phenotype. However recently, Suliga et al, (2015) associated distinct dietary patterns in 
normal-weight individuals with the prevalence of MetS173. After controlling for 
confounders, the authors reported significantly lower risk of metabolically unhealthy 
normal weight in individuals consuming the “prudent” dietary pattern, rich in whole-grains 
and fish and low in refined flour products, sugar and sweets173. This seems to reinforce the 
role of the modern Western diet in driving pathology even in normal-weight persons. Prior 
history of smoking may further contribute to increased risk of T2D in normal-weight 
persons164, and a certain genetic predisposition has been acknowledged in those with a 
positive family history of T2D or hypertension163. Specialised treatment strategies do not 
currently exist for at-risk normal-weight persons. However, lifestyle modifications that are 
typically prescribed for the unhealthy-obese, particularly increased physical activity, seem 






1.5.2.) ‘Metabolically Healthy Obese’ phenotype 
 
MHO generally refers to those individuals who have a BMI greater than or equal to 30 kg.m-
2 but two or less accompanying MetS conditions129,175. Owing to inconsistent MHO 
definitions, prevalence estimates have been highly variable174. A recent systematic review 
found that from 27 prospective studies, MHO prevalence ranged from 6% to 75%, 
depending upon the definition of obesity (e.g. BMI or body fat percentage) and MetS 
criteria used176. Despite similar total body fat to unhealthy obese persons, MHO individuals 
normally present with less visceral adiposity, normal insulin-sensitivity and glucose control, 
more favourable lipid and hepatic enzyme profiles, reduced systemic inflammation, and up 
to 54% less liver fat170,174,175. They also exhibit significantly lower VAT and ectopic fat 
deposition, which may account for their healthier inflammatory and lipid profiles170. 
Interestingly, MHO individuals had smaller fat cells in omental and subcutaneous adipose 
tissue biopsies compared to unhealthy obese persons, and this was associated with lower 
levels of the inhibitor of preadipocyte differentiation, preadipocyte factor-1, as well as 
reduced macrophage infiltration and inflammatory signals177. In agreement, genetic studies 
of the MHO phenotype have implicated genes involved in transcriptional regulation of 
adipogenesis174. Collectively, this evidence suggests that healthy obese persons benefit 
from greater adipogenic capacity and a more favourable fat distribution.  
 
There have been conflicting opinions as to whether obesity independently increases future 
risk of disease or if these differences in adipose tissue mitigate risk in MHO 
persons127,129,168,178. Importantly, MHO is often a transient phenotype as many individuals 
progress from MHO to metabolically unhealthy obese with increasing age129,178. Soriguer et 
al. (2013) found that after a 6 year follow-up, 37% of MHO were re-classified as their 
metabolic health had deteriorated179. Schroder et al. (2014) similarly found that after 10 
years, 50% of MHO participants regressed to metabolically unhealthy180. Thus, despite their 
apparently ‘healthy’ metabolic profiles at the time of assessment, MHO individuals may be 
at long-term risk174. Indeed, Ärnlov et al. (2010) and Ärnlov et al. (2011) found that 
overweight and obese men, regardless of metabolic health status, had greater risk than 
normal-weight controls of developing CVD and T2D over a 30 year and 20 year follow-up 




However, Ortega et al. (2013) recently suggested that such findings resulted from not 
having accounted for cardiorespiratory fitness127. These authors compared disease risk (co-
varying for cardiorespiratory fitness) between MHO, metabolically unhealthy obese and 
metabolically healthy normal-weight individuals, in a sample of 43 265 adults over a 
median follow-up of 7 to 15 years127. They concluded that when adjusted for fitness, MHO 
was a benign condition, with reduced risk for all-cause mortality, non-fatal and fatal CVD 
and cancer mortality, compared to metabolically unhealthy obese persons and they were 
at no higher risk than metabolically healthy normal-weight participants127. Similarly, Meigs 
et al. reported that, after a 7 to 11 year follow-up, MHO persons had reduced risk of T2D 
and CVD compared to unhealthy obese persons, and were at no greater risk compared to 
healthy normal-weight individuals168. Multiple studies have reported higher levels of 
physical activity129 and higher proportions of MHO cohorts meeting physical activity 
guidelines compared to unhealthy obese controls178. Camhi et al. (2015) found MHO 
persons spent significantly less time in sedentary behaviour, but greater time in light 
physical activity compared to matched unhealthy-obese persons175. Collectively, this 
evidence strongly supports the notion that regular physical activity and consequent fitness 
is profoundly protective against metabolic disease, independent of adiposity, and largely 
explains the spectrum of cardio-metabolic risk found in the obese population178. The 
extreme end of this rationale would suggest that athletic individuals, regardless of body 
weight, should be amongst the healthiest of individuals. While this may often be the case, 
there is an emerging subset of both professionally and recreationally athletic individuals 
who are metabolically unhealthy56. 
 
1.5.3.) Overweight athletes: MHO or Metabolically Unhealthy Overweight? 
 
There is limited research both on the prevalence of overweight or obesity in the athletic 
population and on the metabolic health of normal-weight or overweight athletes. This may 
be due to the assumption that regular exercise protects against ill cardio-metabolic health.  
Studies have reported impaired insulin-sensitivity183, and increased risk of MetS184 in heavy 
field-throwing athletes and weightlifters respectively, compared to physically active 
controls. Existing American Football linemen, players that typically exhibit significant 
stature, have also been found to have a high prevalence (up to 50%) of the MetS185.  An 
assessment of 302 athletes of varying BMI at the dental clinic of the London 2012 Olympic 
Games, reported poor dental health, including dental caries, erosion and periodontal 
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disease186, which has been positively linked to systemic inflammation and the MetS187. 
Most pertinently, a high prevalence of overweight athletes was reported at the Beijing 
2008 Olympic Games188. In response, Berglund et al. (2011) introduced the concept of 
‘Adipositas athletica’ to describe a higher than “athletic normal” fat mass in elite 
athletes188. They separated the phenotype into ‘adaptiva’ (intentional increase in body fat 
to gain a competitive advantage), ‘secondaria’ (increased body fat secondary to increased 
strength and body size required for competition), and ‘accidentalis’ (unintentional increase 
in body fat that is disadvantageous during competition, found particularly in low-intensity 
sports including golf, darts, archery)188. Berglund and colleagues implicated unhealthy 
eating of high-sugar, high-fat foods as the primary driver of fat gain in the latter sub-
group188. Experienced marathon runners have also been reported to have unexpectedly 
high sub-clinical atherosclerotic burden and coronary events, comparable to sedentary 
individuals matched for age and coronary risk factors189. Noakes et al. (2014) speculated 
that this too may have had a dietary component190. On the other hand, overweight athletes 
have been found to have impressive cardiorespiratory fitness as well as capable of 
sustaining vigorous exercise without expected ventilatory constraints191. Further, as 
mentioned above, increased fitness in obese individuals has been found to reduce cardio-
metabolic risk to levels comparable with normal-weight individuals127. Therefore, the 
question remains as to whether high fitness, independent of adiposity, protects against 
cardio-metabolic disease, or if the benefits of regular exercise may become overwhelmed 
with time by unhealthy lifestyle (especially dietary) habits. The increasingly large 
representation of overweight recreational runners presents a convenient opportunity to 
explore these questions.  
 
Over the past couple of decades, South Africa, in line with trends in the secular world192, 
has experienced a surge in the popularity of recreational running by members of the 
general population. Interestingly, anecdotal reports have suggested that many participating 
runners have been overtly overweight or obese, yet capable of completing the races. For 
example, unpublished data from the 2014 Two Oceans Ultra and Half-marathons in Cape 
Town, indicated that, of approximately 17 000 runners between the ages of 30 and 45,  
more than 50% of men and 25% of women had a BMI (from self-reported weight and 
height) greater than 25 kg.m-2. These proportions were approximately double that of the 
overweight and obese runners under the age of 30. This seems contradictory to 
conventional wisdom, given that regular exercise has been advised for promoting weight-
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loss or, at least, maintaining a healthy weight105. It may be that many of the observed 
overweight runners had only recently started running (as a means to lose weight); 
however, it could also be that they had gained weight over the years despite running 
consistently. Perhaps these recreational runners, who one may speculate typically run at a 
low intensity, would fall within the realm of the ‘accidentalis’ sub-group put forward by 
Berglund and colleagues188. Indeed, they may have gained weight unexpectedly owing to 
inappropriate dietary habits, or in the words of a recent editorial, maybe “you cannot 
outrun a bad diet”56. 
 
Although not specifically investigated in the aforementioned studies, a diet high in 
carbohydrate, in particular sugary sports drinks, may well have contributed to the negative 
outcomes in these professionally and recreationally athletic individuals56,92. Since the 
1960s, exercise science and sporting authorities have advised athletes to obtain a 
significant proportion of their energy intake in the form of carbohydrate (6 to 10 grams per 
kg body weight per day)193,194. This has been exemplified by the ubiquitous practice of 
carbohydrate–loading during the days leading up to endurance event, with the intention to 
saturate the muscle glycogen stores that are rapidly used during high-intensity activity194.  
Furthermore, athletes have been advised to prioritise consumption of easily-digestible 
(high-GI) carbohydrates immediately before, during and after prolonged exercise to 
saturate liver glycogen stores, maintain blood glucose levels during exercise and restore 
muscle glycogen during recovery, respectively193,194. Such nutritional strategies have proven 
advantageous for young, lean insulin-sensitive athletes in various sporting domains, 
including endurance and aesthetic sports194,195. However, for athletes with underlying 
insulin-resistance, such emphasis on carbohydrate intake may have promoted the 
hyperinsulinaemia, obesity and associated cardio-metabolic disturbances described 
above92. Furthermore, it may be that young, lean athletic individuals develop metabolic 
health concerns and performance decrements as they age, since the health returns of 
regular exercise may become overwhelmed by the detrimental effects of excess dietary 
carbohydrate (particularly processed carbohydrates) in predisposed individuals92. It seems 
reasonable to speculate further that an inappropriate diet would have had more 
pronounced adverse effects in insulin-resistant recreational athletes. However, as far as the 
author of this thesis is aware, the relationship between dietary intake, weight-gain and 




Therefore, the overweight and obese runners that have been reported to frequent 
recreational endurance events represent a unique and important sub-group of overweight 
individuals to study. In contrast to what public health and sporting authorities have 
advised, regular exercise has not been successful in maintaining a healthy weight. A 
number of questions remain unexplored, including 
i.) are overweight/obese runners metabolically healthy despite being overweight, 
probably  because they engage in physical activity, or 
ii.) are they overweight as a result of being metabolically unhealthy despite regular 
exercise, and 
iii.) what inherent factors, such as resting metabolic rate, and lifestyle or 
environmental factors, including dietary intake, sedentary behaviour, sleep quality 
and stress levels, may have contributed to their elevated adiposity and metabolic 
health?  
This study sought to answer these questions through a comprehensive metabolic and 
lifestyle profiling of the emerging overweight or obese female runner, and contribute to 





This thesis was a pilot study to characterise the ‘Overweight runner’ phenotype. It will 
inform the feasibility and design of a subsequent randomised controlled dietary 
intervention trial that will aim to reduce weight in these runners.  
 
The primary aim of this study was to determine the degree of insulin-resistance and other 
risk factors for MetS, including dyslipidaemia, hypertension, impaired glucose tolerance 
and inflammation, in a cohort of overweight or obese female endurance runners in 
comparison to lean runners that were matched for age and running experience. 
 
The secondary aim was to investigate resting metabolic rate, habitual diet, competition-
specific dietary habits, physical activity, sedentary behaviour, sleep and stress in these 
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cohorts. We sought to determine whether these would be associated with elevated body 




The primary hypothesis of this study was that overweight or obese female runners would 
present with underlying metabolic pathology (primarily a higher degree of insulin-
resistance) compared to their lean counterparts.  
 
Secondly, we hypothesised that overweight or obese runners would have been consuming 
a diet too high in carbohydrate for their level of insulin-resistance, contributing to 
hyperinsulinaemia, weight-gain and potentially other negative outcomes. The other 
lifestyle factors that were investigated were largely exploratory, and no hypotheses were 




















2.1.) Overview of Study Design 
 
This was an analytical, observational, cross-sectional study of overweight female endurance 
runners compared to lean female runners, who were matched for age, running experience 
and running calibre.  
 
2.2.) Ethical considerations 
 
This study was approved by the Human Research Ethics Committee, Faculty of Health 
Sciences, University of Cape Town (UCT) (REF: 816/2014, approved 22 December 2014). All 
participants provided a written informed consent prior to enrolment in the study. This 
indicated that they understood and were satisfied with the nature of the study procedures. 
 
2.3.) Participants and Inclusion / Exclusion Criteria 
 
Twenty female recreational endurance runners (10 ‘Overweight’ and 10 ‘Lean’) participated 
in the study. Participants were eligible if they satisfied the following criteria: 
i.) between 30 and 45 years of age,  
ii.) adequate endurance running experience by firstly, having completed annual 
running events of 21.1 km or longer for at least the past 5 years and secondly, 
having run consistently (on average 3 times per week) during the preceding 6 
months, 
iii.) deemed ‘safe to exercise’ in accordance with the Physical Activity Readiness 
Questionnaire (PAR-Q, Appendix A),  
iv.) weight-stable (experienced weight fluctuations of less than  5% of their body 
weight) during the preceding 3 months, and  
v.) not made any significant changes to their diet during the preceding 6 months.  
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Finally, in order to group participants as ‘Overweight’ and ‘Lean’, they had to exhibit 
suitable BMI, Waist Circumference and Body Fat Percentage (BF%, with a degree of 
leniency) according to the table below. The latter was estimated during eligibility screening 
using skinfold thicknesses (section 2.5.2). 
 






Body measurements for the ‘Lean’ group were chosen to be slightly stricter than 
convention in an effort to enhance the degree of comparison between Overweight and 
Lean runners. The BF% criterion for the Overweight group was less strict than normal for 
initial screening purposes. This was aimed at avoiding the exclusion of respondents who 
were on the overweight threshold from screening measures but may have been eligible 
according to BF% from Dual Energy X-ray Absorptiometry (DXA, section 2.5.3). 
 
2.3.) Recruitment and Screening 
 
Female recreational runners based around Cape Town (Western Cape) were recruited. 
Advertising relied primarily on electronic media. Frequent posts were made on the social 
media accounts of Western Cape running clubs, upcoming running events, the Sport 
Science Institute of South Africa (SSISA) and the Exercise Science and Sports Medicine 
(ESSM) Division of UCT. Electronic adverts were regularly distributed to running club 
mailing lists. In addition, poster adverts were distributed around the SSISA building, at 
running club venues, and directly to runners at the finish of select popular events. Initially, 
advertisements were aimed at recruiting the Overweight participants. Once ten of them 
had been tested, advertisements were released for Lean controls. These were designed 
with the intention to match Overweight and Lean groups closely in terms of age, years of 
Measure Overweight Lean 
Body Mass Index (kg.m-2)196 ≥ 25.0 < 23.0 
Waist Circumference (cm)196 ≥ 80.0 < 75.0 
Body Fat Percentage (%)197 ≥ 28.0 < 25.0 
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running experience, recent running volume and running calibre. The latter was expressed 
as energy expenditure per kg bodyweight for their fastest 21.1 km race within the past year 
(section 2.5.4.). Interested respondents were initially screened in terms of the 
aforementioned eligibility criteria using the Eligibility Questionnaire (Appendix B). 
Respondents who were potentially eligible were scheduled for Visit 1 of the study.  
 
2.4.) Testing Protocol 
 
Participants were required to visit SSISA, on Boundary Road, Newlands on three occasions.  
 
2.4.1) Visit 1  
 
Participants arrived at the laboratory at any time that suited them, provided that they were 
at least 2 hours fasted and had not performed any exercise during that day or the day prior 
to testing. We explained the study procedures, after which participants were asked to sign 
their informed consent and confirm their readiness to exercise. They then completed the 
Detailed Participant Questionnaire (Appendix C) to assess their current and past health and 
nutritional practices, followed by questionnaires concerning their perceived eating habits 
(Appendix D), perceived recent sleep quality (Appendix E), perceived recent stress levels 
(Appendix F) and recent experience of gastrointestinal complaints (Appendix G). 
Anthropometric measurements were subsequently recorded to estimate body composition 
and determine participants’ eligibility (BMI, waist-circumference and BF%). Participants 
were then asked to perform a Peak Treadmill Running Speed (PTRS) Test to assess their 
fastest running speed. Lastly, participants were asked to recall their prior day’s dietary 
intake (24-hour diet recall, section 2.5.5.1) , which served primarily as familiarisation for 
recording their 3-day diet record (section 2.5.5.2).  
 
2.4.2.) Between Visits 1 and 2 
 
Participants were allowed 7 to 8 days between visits 1 and 2. During this period, 
participants were provided with an accelerometer to measure their physical activity, a 
55 
 
sleep monitor to measure their sleep duration and quality, an exercise logbook to indicate 
their exercise training schedule, and a logbook to complete their 3-day diet record. 
Participants were asked to continue with their normal daily activities as much as possible, 
in order to obtain representative data of their habitual lifestyles. 
 
2.4.3.) Visit 2 
 
Participants were required to arrive at the thermo-neutral laboratory (23°C) in the morning 
between 06h00 and 08h00. They had to be at least overnight (approximately 12 hours) 
fasted and were asked to have abstained from both exercise and alcohol consumption 
during the day prior to testing and on the morning of testing. Participants rested in a supine 
position on a bed for 10 minutes before measuring resting blood pressure. They were 
asked to remain relaxed on the bed and refrain from movement or speech for the 
subsequent measurement of resting metabolic rate. Thereafter, a cannula was inserted 
into a forearm vein, obtained fasting blood samples to assess health parameters, and 
conducted an OGTT to measure insulin-sensitivity. Participants were required to remain in 
a supine position throughout the OGTT. During this period, the accuracy of the participants’ 
3-day diet records was confirmed. This entailed theassisted recall of commonly forgotten 
food items, and the use of photographic food manuals and common utensils to assist in 
portion size estimations. 
 
2.4.4.) Visit 3 
 
Visit 3 was scheduled on any available day in between Visits 1 and 2. Participants were 
required to arrive at any time that suited them, but at least 2 hours fasted, well hydrated 
and having performed no exercise on the morning of the testing day. Participants were 
required to rest supine on a bed and undergo a DXA scan for a detailed determination of 





2.5.) Testing and Analytical Procedures 
 
2.5.1.) Personal and family health history (visit 1) 
 
Participants completed the Detailed Participant Questionnaire (Appendix C) to assess their 
family and personal history of disease, their current health status, perceived quality of life, 
habitual and running-specific nutritional practices, smoking status and alcohol intake. This 
questionnaire was newly drafted for the purposes of this study.  
 
2.5.2.) Anthropometry (visit 1) 
 
Participants wore undergarments and light running shorts during anthropometric 
measurements. Height (to the nearest 0.5 cm) and weight (to the nearest 0.1 kg) were 
measured using a standard stadiometer and calibrated electronic scale (UWE BW-150 
Personal scale). Waist (at the level of the umbilicus), hip (over the area of largest girth), 
thigh, calf, chest and upper arm circumferences were each measured twice (to within 1 
mm) with an anthropometric tape as described by Lean et al. 1995196. Skinfold thicknesses 
were measured using calibrated skinfold callipers (Holtain, Crosswell, Wales), and in 
accordance with the International Standards for Anthropometric Assessment (2006). 
Measures were repeated three times, and the average of the nearest two was accepted. 
Eight skinfold sites were used: bicep, tricep, subscapular, supraspinale, iliac crest, 
abdominal, thigh and calf. The ‘sum of seven skinfolds’ was calculated as the sum of these 
thicknesses, excluding the iliac crest198.  
 
BF% was estimated from skinfold thickness measures to assess eligibility. This was 
performed using the Durnin and Womersley method to estimate body density (BD)199, 






L = log (triceps + subscapular + biceps + iliac crest)199 
BD = 1.1423 – (0.0632 * L) for ages 30 – 39199 
BD = 1.1333 – (0.0612 * L) for ages 40-45199 
BF% = 495 / (BD) – 450200 
 
2.5.3.) Body Composition and Bone Mineral Density (visit 3) 
 
The participants arrived at the UCT DXA scanning facility at least 2 hours fasted, well 
hydrated and having performed no exercise on the morning of testing. The participants 
removed all clothing and jewellery, dressed in a light gown and lay supine on a padded 
table for approximately 20 minutes. Scans were performed by a registered radiographer 
using a Hologic QDR Series Bone Densitometer (Discovery W, Serial Number 80191, 
Hologic, Inc., Bedford, US). Body composition (fat and lean tissue distribution) was 
measured using a whole body scan and bone mineral density was assessed at the lumbar 
spine and both proximal hips. Images were recorded and bone mineral density, lean mass, 
fat mass, and BF% were computed using Apex System Software v 4.0.1. (Hologic Inc., 
Bedford, US).   
 
2.5.4.) Peak Treadmill Running Speed (PTRS) test and running calibre (visit 1)  
 
The PTRS test was performed on a treadmill (HP Cosmos, VIASYS LE 500CE, Germany) using 
an incremental (VAMEVAL) ramp protocol at a constant gradient of 1%201,202. After a self-
paced 10 minute warm up and 5 minute rest the test was started at 8 km.hour-1. The  speed 
was increased by 0.5 km.hour-1 at the end of each minute. The participants were verbally 
encouraged to run for as long as possible, and the test was terminated when they indicated 
they could not run any longer. The PTRS test was considered valid if it fulfilled the following 
2 criteria203: a maximum heart-rate (HRmax) within 10 beats per minute (bpm) of age-
predicted maximum (220 – age), and a final RPE ≥ 18 on the Borg 6 – 20 RPE scale204. PTRS 
was calculated as the sum of the speed of the final completed stage and the fraction of the 
stage at which the test was terminated, as follows: 
58 
 
PTRS = Completed full intensity (km h⁄ ) + (
Seconds at final speed
60 seconds
) ×  0.5 km/h 
 
Heart rate data were recorded during the test, at 1-sec intervals, using a Suunto Ambit 2 
heart rate monitor (Suunto Oy, Vantaa, Finland). HRmax was taken as the highest HR 
reached during the test. 
 
Overweight and Lean runners were matched in terms of running calibre by calculating their 
energy expenditure (kcal.minute-1) during their fastest 21.1 km race within the previous 12 
months. This was performed by adapting the equation of Loftin et al. (2010), which was 
developed for estimating energy expenditure per mile in runners of varying bodyweight205. 
This equation was based on the assumption that it is more difficult for a heavier runner to 
run a certain distance in a specific amount of time, compared to a lean runner completing 
this distance in the same time. The formula as per Loftin et al. (2010) was205: 
 
Kcal.mile-1 = [mass (kg) × 0.789] – [gender (men = 1, women = 2) × 7.634] + 51.109 
This was converted into kcal.minute-1 as per the following: 
 Kcal.km-1 = (kcal.mile-1) / 1.60934 
 Kcal.minute-1 = (kcal.km-1) x 21.1 km / (minutes to complete 21.1km) 
 
 
2.5.5.) Diet Records and Analysis 
 
Three different dietary assessment tools were used to characterise the participant’s 
habitual dietary intake. Given the inherent limitations in each method, it has been 






2.5.5.1) 24-Hour Diet Recall (24HR, visit 1) 
 
At the end of Visit 1 and without prior warning, participants were asked to recall, in as 
much detail, and as accurately as possible, what they had consumed during the previous 
day. Participants were lead through the process of recalling their previous day’s diet from 
the time of waking until going to sleep. They were prompted to remember any easily-
forgotten foods and drinks (e.g. added sugar, cooking oil, snacks). Detailed information was 
obtained regarding food preparation methods, ingredients in mixed dishes, brand names of 
commercial products and portion size estimates relative to common household measures 
(e.g. bowls, spoons, cups) and visual aids (Dietary Assessment and Education Kit, DAEK, 
South African Medical Research Council, MRC). The 24HR served to familiarise and counsel 
participants as to the level of detail required in the subsequent 3-day diet record.  
 
2.5.5.2.) 3-Day Diet Record (3DR, between visits 1 and 2) 
 
During the period between visits 1 and 2, participants were provided with a logbook in 
which to record their dietary intake, in as much detail as possible, for 3 consecutive days. 
This included one weekend day and two non-weekend days, and at least one exercising 
day. The 3DR served as the primary tool to estimate habitual dietary intake at the time of 
testing. 
 
2.5.5.3.) Food Frequency Questionnaire (between visits 1 and 2) 
 
Participants completed a 123-item Food Frequency Questionnaire (FFQ, Appendix H). The 
FFQ was based on that developed by the South African Medical Research Council (MRC) in 
2009, which was used to quantify dietary intake amongst South African Marathon Runners 
during the month leading up to an Ultra Marathon. Although the original questionnaire 
remained unchanged, participants in the current study were asked to report on their 
average consumption over the previous 6 months. This was used to obtain a perspective of 
their longer term dietary practices compared to 3DR. The FFQ asked participants to answer 
firstly, how often, on average over the past 6 months, they had consumed each item, and 
secondly, the average amount they had consumed on each occasion. Answers were 
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computed to provide average daily intakes so as to be comparable with results from the 
other diet assessment tools used. One Overweight participant did not submit a completed 
FFQ; therefore, her dietary data could not be compared between assessment tools (Results 
section).  
 
2.5.5.4.) Diet Analysis (after testing) 
 
Quantitative dietary data (from the 24HR, 3DR and FFQ) were analysed in accordance with 
the South African Food Data System (SAFOODS) of the MRC. Briefly, food items listed by 
participants were translated into their corresponding codes on the SAFOODS database. 
Where a specific item was not present on the database, the participant helped select the 
nearest surrogate. Participants estimated portion sizes in terms of common household 
utensils with the assistance of the Food Quantities Manual of the MRC and appropriate 
food models. These were converted into gram amounts of each individual item or 
ingredient using the Food Quantities Manual. The resulting spreadsheet, containing a list of 
food codes and corresponding gram values per day, was analysed by Ms Ria Laubscher at 
the Biostatistics Unit of the MRC. The composition of each participant’s diet, in regards to 
energy, macronutrients, vitamins and minerals, was computed in accordance with the 
updated South African Food Composition Database (2015). This has been specifically 
developed to reflect foods found in South Africa. The 3DR and FFQ were compared to 
assess the level of agreement in energy intake and macronutrient composition between 
tools. Qualitative data of nutritional practices during normal daily living and in relation to 
running races (Appendix C), were assessed using normal statistical procedures.  
 
2.5.5.5.) Psychological eating traits (visit 1) 
 
We assessed subjective food-related traits using the Three-Factor-Eating Questionnaire 
(TFEQ-21, Appendix D). The TFEQ is a self-rating questionnaire that has been validated in 
diverse populations to assess the extent of food-related disinhibition (regular episodes of 
overeating that result from excessive dietary restraint), with obesity207,208. Participants 
were asked to respond to 21 questions: items 1 - 20 on a four-point Likert scale and item 21 
on an eight-point numerical scale. Each response was given a score between 1 and 4; items 
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1 - 16 were reverse coded and item 21 was coded as follows: 1 to 2 scored as 1; 3 to 4 as 2; 
5 to 6 as 3 and 7 to 8 as 4. Three separate domain scores were calculated as the mean of 
the items allocated to each domain: Cognitive Restraint (the conscious restriction of food 
intake to control body weight), Uncontrolled Eating (the tendency to eat more than usual 
owing to loss of control over intake) and Emotional Eating (overeating during despondent 
mood states). Domain scores also ranged from 1 to 4, with higher scores indicating greater 
propensity for that trait.  
 
2.5.5.6.) Gastrointestinal Complaints (visit 1) 
 
Participants were asked to recall their recent experience of gastrointestinal symptoms in 
relation to food consumption. The Gastrointestinal Symptoms Questionnaire (Appendix G) 
was based on a previously published questionnaire209. In its original form, the questionnaire 
was used to assess the frequency of abnormal gastrointestinal symptoms experienced by 
respondents during normal daily activities. It was modified for this study to evaluate 
symptoms firstly, during normal daily activities and secondly, during exercise sessions. 
Participants were also asked to recall specific foods that had tended to elicit these 
symptoms.  
 
2.5.6.) Sleep Assessment and Analysis 
 
2.5.6.1.) Subjective (perceived) sleep assessment (visit 1) 
 
The Pittsburgh Sleep Quality Index (PSQI, Appendix E) Questionnaire was used to assess 
participants’ self-perception of their recent sleep quality. The PSQI has been validated to 
assess sleep quality and disturbance in recent months210. The global PSQI score of sleep 
pathology ranges from 0 to 21. Higher numbers indicate worse sleep quality and values > 5 
indicate possible sleep pathology. Participants were scored from 0 to 21 and were 




2.5.6.2.) Objective sleep assessment (between visits 1 and 2) 
 
Sleep was objectively assessed using Actigraphy, which has been validated as a low-cost 
alternative to polysomnography for measuring sleep time and quality in free-living 
settings212,213. Participants wore a small, lightweight (± 16 grams) and unobtrusive 
Actiwatch 2 (Philips / Respironics, Pittsburgh, US) for the seven consecutive days in 
between Visit 1 and Visit 2. This was worn around their wrist at all times, excluding 
swimming. The Actiwatch 2 uses a piezoelectric accelerometer to generate an electric 
charge or voltage proportional to accelerations of the wrist (frequency response of 0.35 – 
7.50 Hz), from which it generates activity counts for a given epoch. Epochs are allocated 
activity counts as a weighted average of activity for the current epoch and that of 
surrounding epochs. These are measured against activity thresholds for determination of 
sleep and wake periods. The Actiwatch 2 was configured to record ‘Activity Only’ in 15 
second epochs. Participants were asked to mark the times they went to sleep and woke up 
every day, using both the Actiwatch 2 event-marker and written on a logbook provided. 
The data was downloaded and the recorded epochs were identified as sleep or wake by 
algorithms in the Actiware 5.0 software (Philips / Respironics). The latter was confirmed 
with reference to the sleep and wake times that had been indicated by the participants214. 
This enabled the software to compute the sleep parameters of interest, including Total 
Sleep Time, Sleep Efficiency (percentage of time in bed that was spent asleep), Sleep Onset 
Latency (time lapse between going to bed and falling asleep), and Wake After Sleep Onset 
(WASO, time spent awake after falling asleep). Data from one Overweight participant was 
excluded from the analysis, because she performed shift-work at nights and slept during 
most days, which skewed the data.  
 
2.5.7.) Physical Activity and sedentary behaviour (between visits 1 and 2) 
 
Participants were provided with an accelerometer (GTX3+, ActiGraph LCC, Florida, US) to 
wear around the hip for the seven consecutive days in between Visit 1 and Visit 2215,216. This 
included all waking hours but excluded water-based activities (e.g. bathing, swimming). It 
has been acknowledged that the inability of accelerometers to capture non-ambulatory 
activities, including swimming and cycling, obscures the accuracy of step-count 
measurements217. As has been previously recommended, 200 ‘bonus steps’ per minute of 
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activity were allocated to participants on the days they performed either cycling or 
swimming217.  Four participants reported cycling and three participants reported swimming 
in their exercise logbooks. Actigraph accelerometers have been extensively used and 
validated for measuring physical activity and sedentary behaviour 218–220. The GTX3+ is a tri-
axial capacitative accelerometer with a Micro-Electro-Mechanical-System sensor, which is 
capable of detecting both static and dynamic accelerations in three axes, based on changes 
in the capacitance of the sensor221. Briefly, changes in capacitance cause changes in electric 
flow, proportional to the detected acceleration. These are subsequently amplified, digitised 
and the direction of the acceleration is determined, before final phase frequency-filtering 
ensures that all measurements fall within realistic human movement frequencies221. The 
resultant activity ‘counts per minute’ (cpm) were compared to pre-set activity thresholds to 
identify when the wearer was performing different levels of activity (below).  
 
The accelerometer was initialised and the recorded data was downloaded and analysed, 
using Actilife v.6.10.1 Data Analysis Software (Actigraph, Florida, US).  Data sampling rate 
was set at 80Hz and extracted in 15 second epochs for analysis. Uniaxial (axis 1) analysis 
was performed for comparison with previous studies222.  
 
Non-wear-time was defined as any period of at least 60 consecutive minutes containing 
zero activity counts223. Allowance was made for a maximum of 2 minutes within the non-
wear period with non-zero activity counts223. Non-wear-time was excluded from the 
present analysis. A minimum of 600 minutes of daily wear-time for four days (three 
weekdays and one weekend day) was required for data inclusion212. All Overweight and all 
except two Lean participants (n=18) provided adequate data for inclusion in the analysis. Of 
these, seven participants had seven valid days of data, ten provided six valid days and one 
provided five valid days of data. 
 
In accordance with the 2008 ACSM Physical Activity Guidelines for Americans, activity was 
only designated ‘Light’, ‘Moderate’ and/or ‘Vigorous’ if performed in bouts of at least 10 
minutes. Various cut-point recommendations exist for classifying accelerometer count 
values as the following discrete classes of physical activity: sedentary behaviour (SED), light 
(LIPA), moderate (MPA) and vigorous (VPA) physical activity. ’Matthews’ cut-points were 
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developed with the aim of reflecting both structured (treadmill) walking and running, as 
well as free-living, lifestyle activities219. These cut-points were preferred for analysing the 
Actigraph data since they purportedly reflect free-living activity most accurately215,222. In 
accordance therewith, SED was considered as any activity < 100 cpm, LIPA was 
acknowledged as 100 - 759 cpm, 760 – 5998 cpm was deemed MPA, and ≥ 5999 cpm was 
VPA (MVPA or moderate-to-vigorous physical activity was ≥ 760 cpm). Raw data was 
analysed according to these cut-points for time spent in different activity levels and this 
was used to calculate the proportion of wear-time spent in each activity domain.    
 
Based on prior associations with clinical changes in cardio-metabolic biomarkers, a 
‘sedentary bout’ was identified as ≥ 20 consecutive minutes below 100 cpm224,225. A 
‘sedentary break’ was any interruption in sedentary time from one minute < 100 cpm to 
≥100 cpm the following minute.  
 
Daily physical activity was expressed as  
i.) the average percentage of wear-time spent in SED, LIPA, MPA and VPA,  
ii.) total volume of activity (average number of steps taken per day),  
iii.) number of and time spent in sedentary bouts and  
iv.) profile of activity fluctuations throughout an average day (counts in the vertical 
Axis 1).  
 
 
2.5.8.) Perceived Stress (visit 1) 
 
The Perceived Stress Questionnaire (PSQ, Appendix F), a validated psychosomatic tool, was 
used to evaluate recent levels of stress (past month)226. Participants were asked to respond 
to 30 questions on a four-point Likert scale. Negative statements were scored 1 to 4 as per 
the questionnaire; positive statements were scored as (5 – answer). The PSQ score ranges 
from 30 to 120 with higher values indicating higher levels of stress. Participants were 
categorised as having experienced a ‘Reduced’ (score of 30 – 60), ‘Average’ (score of 60 – 
90) or ‘High’ (score of 90 – 120) level of stress.  
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2.5.9.) Resting Blood Pressure (visit 2) 
 
Overnight-fasted participants rested in a supine position on a bed for 10 minutes. Resting 
blood pressure was measured by auscultation using a blood pressure cuff (Aneroid 
sphygmomanometer, Hi-Care, Seoul, Korea). This was performed on three occasions that 
were separated by at least one minute and taken on alternating arms. Outlier measures 
were repeated and the nearest three measures were averaged to calculate individual blood 
pressure results. 
 
2.5.10.) Resting Metabolic Rate (RMR) and Total Energy Expenditure (visit 2) 
 
RMR was determined with indirect calorimetry using the ventilated hood technique (Quark 
RMR, COSMED, Rome, Italy). Immediately prior to each test, the Quark was calibrated using 
a certified calibration gas of known 16% O2 and 5% CO2, and a 3 litre syringe cylinder. 
Following 10 minutes of rest on the laboratory bed and the measurement of resting blood 
pressure, overnight-fasted participants remained in this supine position, and were asked to 
relax, keep their eyes open, breathe normally and refrain from any movement or speech 
during the subsequent 20 minute RMR measurement. A clear ventilated hood was placed 
over their head. During the initial 5 minutes, the flow rate of the Quark blower was 
manipulated until the FeCO2 (fractional amount of carbon dioxide expired) was stable 
between 0.90% and 1.10%. This was taken as an indication that the participants had 
reached metabolic steady-state. Data recording was started and oxygen consumption and 
carbon-dioxide production were measured continuously for the subsequent 15 minutes. At 
the end of the measurement, the data were averaged over 15 second intervals and RMR 
was calculated as the average of the final 10 minutes. Correct calibration of the Quark was 
checked periodically by performing a calibration ‘burn’ of pure ethanol (5 ml) and 
comparing the recorded data (total CO2 collected and average respiratory exchange ratio, 






The energy requirements of the participants were estimated using the formula for Total 
Energy Expenditure (TEE)227. 
TEE = Resting Metabolic Rate (RMR) x Physical Activity Level (PAL) 
PAL is determined by the level of daily activity, and in the general population has been 
found to range from 1.4 (sedentary, minimal daily activity) to 2.5 (vigorous activity). For the 
purpose of this study, participants were allocated an individual PAL based on their level of 
activity during the days of their 3DR. All participants were allocated a PAL of either 1.8 or 
2.0, which represented ‘active’ or ‘very active’ lifestyles respectively 227,228. 
 
2.5.11.) Fasting Blood Sampling (visit 2) 
 
Resting blood samples were taken after the RMR measurement and immediately prior to 
starting the OGTT. A cannula was inserted into the antecubital vein and attached to a 
three-way stopcock. Blood samples for determination of serum insulin, FFA, lipids (total 
cholesterol, TG, HDL-C, LDL-C), HDL and LDL particle size distributions, uric acid and alanine 
aminotransferase (ALT) were collected in collection tubes containing a clot activator and a 
serum-separating gel. Blood samples were collected in tubes spray-coated with the 
anticoagulant K2EDTA for determination of whole-blood HbA1C. Blood was collected in a 
tube containing the anticoagulant heparin for determination of plasma C-reactive protein 
and in a tube containing oxalate and fluoride for determination of plasma glucose. All tubes 
were inverted a minimum of five times to ensure the blood was thoroughly mixed with the 
tube additives and were processed as described below (section 2.5.13.).  
 
2.5.12.) Insulin Sensitivity and Glucose Tolerance (visit 2) 
 
After fasting blood draws, insulin-sensitivity was assessed by performing an OGTT. 
Participants were fasted overnight and had abstained from exercise and alcohol 
consumption the day before testing and the morning of testing. Venous blood samples (5 
ml) were collected at -10 and -5 minutes, relative to glucose ingestion, for determination of 
plasma glucose and serum insulin. These were averaged to calculate the baseline (fasting) 
plasma glucose and serum insulin of the OGTT. The participants ingested 75 grams of 
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glucose (Re Fuel Products, Cape Town) that had been dissolved in 250 ml of water. Blood 
samples were taken at 15, 30, 45, 60, 90 and 120 minutes after glucose ingestion for 
determination of plasma glucose and serum insulin responses. Fasting and OGTT glucose 
and insulin concentrations were used to calculate various indices of insulin-sensitivity. 
Where applicable, total area-under-the-curve (AUC) of plasma glucose (GAUC) and serum 
insulin (IAUC) were calculated using the trapezoid rule.  
 
Hepatic insulin-sensitivity was initially calculated using the validated Homeostatic Model 
Assessment of Insulin-Resistance, HOMA-IR229, as follows:   
HOMA-IR = (FPG x FI) / 22.5 
Where FPG is fasting plasma glucose and FI is fasting serum insulin (average of - 10 and - 5 
minute measures). A higher value represented greater hepatic insulin-resistance and a 
threshold value of 2.29 was used to identify insulin-resistance230. 
 
Since HOMA-IR only incorporates basal glucose and insulin concentrations, it is unable to 
indicate the sensitivity of the liver to the suppressive effects of insulin on hepatic glucose 
output231. Therefore, we calculated the hepatic insulin-resistance index recommended by 
Abdul-Ghani et al. (2007), since it takes into consideration both the basal insulin and 
glucose concentrations and the suppression of hepatic glucose output by insulin during the 
first 30 minutes of the OGTT231, as follows: 
Hepatic insulin-resistance index = GAUC30 x IAUC30 
Where GAUC30 represents the total area under the glucose curve during the first 30 
minutes of the OGTT and IAUC30 represents the total area under the insulin curve during 
the same period. A higher value represented greater hepatic insulin-resistance, and this has 
been validated against the hepatic insulin-resistance index from the gold-standard 
hyperinsulinaemic-euglyceamic clamp231. 
 
A specific index of skeletal muscle insulin-sensitivity was also calculated. This takes into 
account the rate of glucose disposal from its highest value during the OGTT to its lowest 
value, in relation to the mean concentration of insulin during the OGTT231. Since this 
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normally occurs after 60 minutes, it is assumed that there is no significant change in 
hepatic glucose output. Thus, the decline in glucose concentration primarily reflects 
glucose uptake by the peripheral tissues, especially skeletal muscle. The calculation was as 
follows: 
Muscle insulin-sensitivity index = (dG / dT) x (1 / 𝐼)̅ 
Where dG / dT is the rate of decline in plasma glucose concentration from its peak to its 
nadir (where glucose rebounded after its nadir, the rebound was not taken into 
consideration), and 𝐼  ̅represents the mean insulin concentration during the OGTT. A lower 
value, indicative of a slower rate of decline in plasma glucose and / or a higher insulin 
concentration, represented greater skeletal muscle insulin-resistance. This has been 
validated against insulin-stimulated glucose disposal during the gold-standard 
hyperinsulinaemic-euglycaemic clamp231. 
 
The Matsuda Index (Matsuda) has been validated as a surrogate for measuring whole-body 
(hepatic and skeletal muscle) insulin-sensitivity232. Matsuda incorporates basal glucose and 
insulin as well as the mean concentrations during the OGTT. A Matsuda Index score was 
calculated as follows: 
10 000
√(𝐹𝑃𝐺 𝑋 𝐹𝐼) ∗ (Ḡ X 𝐼)̅ 
 
Where FPG is Fasting Plasma Glucose and FI is Fasting Insulin; Ḡ is the mean plasma glucose 
during the OGTT and 𝐼  ̅ is the mean serum insulin during the OGTT. A lower value 
represented greater whole-body insulin-resistance, and a threshold value of 5.0 was used 
to diagnose insulin-resistance230. 
 
Total area-under-the-curve of plasma glucose and serum insulin during the 120 minute 
OGTT (GAUC120 and IAUC120 respectively) were used to calculate an index of insulin 
secretion during the OGTT as follows233: 




2.5.13.) Blood Processing and Storage (after testing) 
 
Blood tubes used for determination of total cholesterol, TG, HDL-C, LDL-C, Uric Acid, ALT, C-
reactive protein and HbA1c were stored on ice, and sent immediately after the OGTT to 
Metropolis Pathology Laboratory (Taljaard Incorporated, Century City, Cape Town) for on-
the-day analysis. The remainder of the resting and OGTT blood samples were kept on ice 
until the end of the OGTT. They were then centrifuged for 10 minutes at 4°C and 3000 rpm. 
Samples were aliquoted into separate tubes for storage at -80°C (except for glucose 
samples which were stored at -20°C) until they were analysed at the end of data collection.  
 
2.5.14.) Substrate Analyses 
 
Unless otherwise specified, all substrate analyses were performed by the author of this 
thesis. Serum insulin was determined using an Automated Chemiluminescence System 
(Centaur CP, Siemens Healthcare Diagnostics Inc., NY, US).  Plasma glucose was measured 
using the glucose oxidase method (YSI 2300 STAT Plus Analyser, Ohio, US). Both insulin and 
glucose analyses were conducted by the analyst at the laboratory of the ESSM Division of 
UCT. Concentrations of plasma lipid species (including total cholesterol, TG, HDL-C and LDL-
C), as well as C-reactive protein, HbA1C, Uric Acid and ALT were measured by Metropolis 
Pathology Laboratory (Century City, Cape Town). 
 
Serum FFA was determined spectrophotometrically using a commercial kit (FFA half-micro 
test; Roche Applied Science, Mannheim, Germany). Briefly, 10 µl of serum sample was 
added to a 200 µl solution containing acyl-CoA synthetase, ATP and coenzyme A (CoA) and 
incubated for 10 minutes at 25°C. This activated the FFA to form acyl-CoA. Surplus CoA was 
removed by adding N-ethyl-maleinimide. Acyl-CoA was oxidised to enoyl-CoA and H2O2 by 
adding acyl-CoA oxidase. In the presence of added peroxidise enzyme, 2,4,6-tribromo-3-
hydroxy-benzoic acid and 4-aminoantipryne were converted to a red dye. The intensity of 
the red dye was measured in the visible wavelength range at 546 nm (Bio Tek Synergy HT 
Multi-Mode Microplate Reader, Bio Tek Instruments Inc., Vermont, US) and used to 




Lipoprotein fraction and sub-fraction analysis was performed in collaboration the UCT 
Hatter Institute for Cardiovascular Research in Africa (MRC, Cape Town). HDL sub-fractions 
were analysed using the Lipoprint ® HDL Sub-fractions test (Quantimetrix, Redondo Beach, 
CA); VLDL, IDL and LDL fraction and sub-fraction analysis was performed using the Lipoprint 
® LDL Sub-fractions test (Quantimetrix). Both systems used polyacrylamide-gel-
electrophoresis to separate lipoprotein fractions according to size (the procedures were 
similar). Briefly, 25 µl of serum sample was mixed with a 300 µl Lipoprint loading gel, 
containing Sudan black dye, which binds proportionately to the cholesterol present in the 
sample. The mixture was placed onto the upper part of a high resolution 3% 
polyacrylamide gel. Following 30 minutes of photopolymerisation at room temperature, 
electrophoresis was performed in an electrolyte (Tris) buffer for 50 minutes at a current of 
3 mA per gel tube. After 30 minutes rest, gel tubes were scanned and analysed for the level 
of cholesterol in each sub-fraction using the Lipoware software. In the resulting HDL profile, 
the VLDL remained at the origin [Retention Factor (Rf) = 0.0] while albumin migrated as the 
leading front (Rf = 1.0). IDL and LDL were also located at the origin, followed by 10 
distinguishable HDL bands: HDL-1, -2 and -3 were defined as ‘Large HDL’; HDL-4, -5, -6 and -
7 were defined as ‘Intermediate HDL’ and HDL-8, -9 and -10 were defined as ‘Small HDL’. 
Each subclass was quantified and expressed as a percentage of total HDL concentration. In 
the LDL profile, VLDL remained at the origin but HDL was visualised as one band near the 
end of the gel. Between these, Mid-bands – C, - B and –A (constituting IDL) were seen 
below the VLDL band, followed by the separate LDL sub-fractions that were present in the 
samples.  LDL – 1 and – 2 were defined as ‘Large buoyant’ LDL, whilst LDL - 3, - 4, - 5, - 6 and 
- 7 were defined as ‘Small dense’ LDL. Each subclass was quantified and expressed as a 
percentage of total LDL concentration. A predominance of Large buoyant LDL particles was 
indicative of LDL ‘Pattern A’, whilst a predominance of small dense LDL was indicative of 
LDL ‘Pattern B’32,234. 
 
2.5.15.) Metabolic Syndrome Diagnosis 
 
Three different sets of established criteria were used to assess whether or not individual 
participants exhibited the MetS, namely the World Health Organisation (WHO, 1998)15, the 
National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) as 
updated by the American Heart Association (2005)16, and the International Diabetes 
Federation (2005)17. They all encompass the four features of the MetS, central obesity, 
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insulin-resistance, dyslipidaemia, and endothelial dysfunction, but vary slightly in the 
relative emphasis placed on them and the cut-off values used for the relevant parameters. 
The specific criteria for women, and which were applied in the present study, are 
summarised in Table 2 below14. 
 
Table 2. Summary of the three sets of criteria used to investigate the presence of 
Metabolic Syndrome in participants. 
WHO, World Health Organisation; NCEP ATPIII, National Cholesterol Education Program 
Adult Treatment Panel III (as updated by the American Heart Association); IDF, International 
Diabetes Federation; IFG, Impaired Fasting Glucose; IGT, Impaired Glucose Tolerance 
 WHO NCEP ATP III IDF 
Absolutely required 
Insulin-resistance (e.g. 
IFG, IGT or Matsuda) 
None 
Central obesity (waist 
circumference ≥ 80 cm) 
Additional criteria Plus 2 of the following Any 3 of the following Plus 2 of the following 
Central obesity 
Waist : hip ratio 
≥ 0.85 or 




≥ 88 cm 







≥ 6.1 mM 
Fasting glucose 
≥ 6.1 mM 
Dyslipidaemia 
Triglycerides 
≥ 1.70 mM 
or 
HDL-C < 1.00 mM 
Triglycerides 
≥ 1.70 mM 
or 
HDL-C < 1.30 mM 
Triglycerides 
≥ 1.70 mM 
or 
HDL-C < 1.30 mM 
Hypertension ≥ 140 / 90 mmHg 
> 130 mmHg systolic 
or 
> 85 mmHg diastolic 
> 130 mmHg systolic 
or 
> 85 mmHg diastolic 
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2.5.16.) Statistical Analyses 
 
Statistical analyses were performed using Statistica software (version 13, Statsoft, Tulsa, 
US) and graphical representations were performed using GraphPad Prism (version 5, 
GraphPad Software Inc., La Jolla, CA, US). Before performing statistical tests, data were 
checked for normality using the Shapiro-Wilks test, and checked for homogeneity of 
variance using Levene’s test. Normally distributed data were reported as mean ± standard 
deviation (SD) and non-parametric data were reported as median (interquartile range). 
Differences between Overweight and Lean groups were determined using an independent 
t-test if normally distributed, and a Mann-Whitney-U test if not normally distributed. Paired 
t-tests were used to explore within-group differences between diet assessment tools, 
between individual energy intake (3DR) and estimated TEE, as well as physical activity 
differences between weekdays and weekend days. Between-group differences in dietary 
macronutrient composition, the proportion of accelerometer wear-time spent in different 
activity levels, and the proportion of groups following select nutritional practices, were all 
analysed using chi-square tests. Fisher’s exact test was used to explore differences in 
categorical variables in 2 x 2 contingency tables. Between-group differences in lipoprotein 
composition, as well as within-group macronutrient differences between diet assessment 
tools, were explored using independent t-tests and appropriate Bonferroni correction 
factors for multiple comparisons. Correlations between variables were investigated using 
the Pearson (parametric) or the Spearman (non-parametric) correlation coefficients. 
Multiple regression analysis was explored to adjust for potential confounders that may 
have contributed to significant between-group differences. Given the small sample size, 
‘group’ was included as the primary predictor variable and potential confounders were 
included one after another (including a maximum of two predictor variables). OGTT glucose 
and insulin curves, as well as daily physical activity profiles, were both analysed for 
between-group differences and group * time interactions using a repeated-measure two-
way ANOVA. Significance was accepted at p < 0.05 for all tests except where a Bonferroni 








3.1.) Participant Characteristics  
 
As intended, the Overweight and Lean groups were well-matched for age, but differed 
considerably in body composition (Table 3). BMI and waist circumference (which were used 
to group participants) were significantly higher in the Overweight group (p < 0.0001) with 
no overlap. Hip girth was also larger in the Overweight group (p < 0.001), but the waist-to-
hip ratio was the same. The sum of seven skinfolds (p < 0.001), which was used to estimate 
BF% during screening, was significantly higher in the Overweight group (Table 3). However, 
there was considerable intra-group variation (Table 3). The ratio of android (abdominal) fat 
to gynoid (hip and thigh) fat (p < 0.001), as well as the ratio of abdominal fat mass to limb 
fat mass (p < 0.01), were greater in the Overweight group than the Lean group. Whole-
body bone density was similar between groups (p = 0.44) and there were no regional 
differences in bone density (not shown).  
 
Mean BF% from the gold-standard measure of body composition (DXA, Figure 1), was also 
significantly higher in the Overweight group (32.1 ± 3.9 vs. 21.8 ± 3.9, p < 0.0001). 
However, there was a considerable range of approximately 11% in both groups. According 
to DXA, three of the participants that had been recruited as ‘Overweight’ had BF% values 
below 30% (Figure 1). This has been regarded as the lower threshold for excess body fat in 
the general population197.  No Lean participants exhibited an ‘Athletic’ BF% of between 8% 
and 15%197. Conversely, four of them had BF% above 25% and one participant overlapped 
with the Overweight group (27.6%). This participant was an interesting anomaly given that 
her BMI (19.7 kg.m-2) and waist circumference (67.0 cm) were amongst the lowest 
recorded in this study. Interestingly, she was the only participant to exhibit bone mineral 
density lower than age-based expectations (Z score < -2.0). Her estimated BF% from 
skinfolds had also predicted a lower BF% compared to DXA. This was likely due to the 
limitation of having used a formula that did not incorporate lower-body skinfolds 
(Discussion section). However, this participant met the original criteria of being overtly lean 
and she had easily maintained a low body weight. Furthermore, neither excluding her from 
the analysis, nor moving her to the Overweight group based on BF% alone, meaningfully 
altered the metabolic or lifestyle results. Therefore, it was decided to include her in the 
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Lean group for the analysis. These BF% results meant that despite distinct BMI and waist 
circumference, the two groups were less distinct in terms of actual adiposity than 
expected. The resultant spectrum of BF%, however, facilitated the correlation analyses with 
relevant metabolic and lifestyle parameters in the sections that follow. 
 
Table 3. Age, anthropometric measures and DXA indices of adiposity and bone mineral 
density in Overweight (n=10) and Lean (n=10) groups. 
Variable Overweight Lean p value 
Age (years) 38.7 ± 4.6 (31 – 45) 37.7 ± 4.3 (31 – 45) 0.62 
Height (cm) 166 ± 7 (157 -178) 170 ± 6  (160 – 179) 0.12 
Weight (kg) 74.4 ± 6.4  (67.1 – 86.4) 59.4 ± 7.8 (51.6 – 71.4) < 0.001 
BMI (kg/m
2
) 27.1 ± 1.6 (25.3 – 29.6) 20.4 ± 1.7  (18.0 – 23.1) < 0.0001 
Waist (cm) 83.7 ± 4.4 (76.3 – 88.1) 69.7 ± 4.3 (63.2 – 75.5) < 0.0001 
Hip (cm) 107.6 ± 5.4 (101.2 – 116.9) 93.0 ± 4.2 (87.0 – 101.5) < 0.0001 
Waist : Hip * 0.77 (0.09) 0.74 (0.05) 0.24 
Sum of seven skinfolds 
(mm) * 
146 (28) 83 (19) < 0.001 
Android / Gynoid Ratio 0.8 ± 0.1 (0.7 – 1.0) 0.6 ± 0.1 (0.5 – 0.8) <0.001 
Trunk/Limb Fat Mass 
Ratio 
0.9 ± 0.2 (0.6 – 1.2) 0.6 ± 0.1 (0.5 – 0.9) <0.01 




1.2 ± 0.1 (1.1 – 1.3) 1.1 ± 0.1 (0.9 – 1.3) 0.44 
 Values are mean ± SD (range) or median (interquartile range). Where normally 
distributed, p values were determined using independent t-tests; where not normally 
distributed (*), p values were determined using Mann-Whitney-U tests. Bold p values 














3.2.) Running Characteristics 
 
The groups were well-matched for years of running experience, current volume of training 
(both in terms of distance per week and hours per week), as well as running calibre, which 
was expressed as energy expenditure (kcal.min-1) during their fastest half-marathon of the 
previous 12 months (Table 4). The latter was calculated by taking into account the different 
bodyweights of the participants (Methods section), which meant that the groups were 
matched despite the Lean runners having had significantly faster half-marathon times (p < 
0.05). Consistent therewith, the Lean participants attained a higher peak treadmill running 
speed (PTRS, p < 0.05), and there was a significant negative correlation between BF% and 
PTRS (Pearson r = -0.70, p < 0.001). Both groups reported a final RPE of 18 and a similar 
maximum heart rate (p = 0.97 and p = 0.74 respectively). This would suggest that they gave 
a similar degree of effort during the PTRS test. 
 
Figure 1. Body fat percentage (DXA) in Overweight (n=10) and Lean (n=10) groups. Data 
are shown as individual values (markers) and as mean ± SD (solid line ± whiskers). Dashed 



























Table 4. Running-related matching criteria, and results from the PTRS for Overweight 
(n=10) and Lean (n=10) groups. 
Values are mean ± SD (range) or median (interquartile range)(*). 21.1 km, half-marathon 
distance race, HRmax, maximum heart rate; RPE, Rating of perceived exertion. Where 
normally distributed, p values were determined using independent t-tests; where not 
normally distributed (*), p values were determined using Mann-Whitney-U tests. Bold p 





Variable Overweight Lean p value 
Running 
experience 
Total  years  * 6.0 (5.3) 9.0 (8.6) 0.11 






42.0 ± 10.9 
(30-60) 
44.5 ± 12.1 





4.8 ± 1.1 
(3.3 – 7.0) 
4.9 ± 1.7 
(3.0 – 8.0) 
0.91 
Fastest 21.1 km 
during last 12 
months 
Time (minutes) 
136 ± 15 
(110 – 159) 
123 ± 11 













12.6 ± 1.0 
(11.1 - 14.1) 
14.0 ± 1.3 
(12.0 – 16.5) 
0.01 
Time to exhaustion (minutes) 
10.3 ± 2.0 
(7.0 – 13.2) 
13.0 ± 2.6 





182 ± 12 
(156 – 199) 
180 ± 6 
(172 – 193) 
0.74 
Final RPE * 18.0 (0.5) 18.0 (0.5) 0.97 
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3.3.) Resting Blood Pressure 
 
Systolic and diastolic blood pressure were not normally distributed and they are 
represented as median ± interquartile range in Figure 2. The median systolic blood pressure 
of the Overweight group was higher than that of the Lean group (p < 0.05), however, 
median diastolic blood pressure was similar. When expressed as the mean blood pressure, 
both Overweight (118 / 72 mmHg) and Lean (109 / 68 mmHg) groups exhibited ‘normal’ 
values (< 120 / 80 mmHg). On an individual level, there were four Overweight participants 
who exhibited pre-hypertensive systolic blood pressure (≥ 120 mmHg), two of which also 
exhibited pre-hypertensive diastolic blood pressure (≥ 80 mmHg). One of these participants 
was also insulin-resistant by the Matsuda Index (3.5), and another participant with pre-
hypertensive systolic blood pressure only, was insulin-resistant. In agreement therewith, 
multiple regression analysis with ‘group’ and ‘IAUC’ included as predictor variables, showed 
that IAUC during the OGTT was more predictive of systolic blood pressure than the 
distinction of Overweight and Lean groups (Table 5).   
 
Figure 2. Distribution of Systolic (Syst) and Diastolic (Diast) blood pressure within 
Overweight (n=10) and Lean (n=10) groups. Data are presented as individual values 
(markers), and median ± inter-quartile range (solid line ± whiskers). p value was 
determined by a Mann-Whitney-U test. 




























Table 5. Regression analysis for systolic blood pressure, when group (Overweight or Lean) 
and insulin area-under-the-curve (IAUC) during the OGTT were predictor variables (R2=0.41, 




p values were determined using multiple regression analysis 
 
3.4.) Cardio-metabolic Blood Parameters 
 
Participants were free of any known illness or injury and had not been diagnosed by a 
clinician with any component of the MetS, although this was not an eligibility criterion. No 
participants were taking statins or any blood-pressure-lowering, cholesterol-lowering or 
sugar-lowering medication. One Overweight participant was on hormone-replacement 
medication, one Lean participant was on medication for an under-active thyroid gland, and 
two Lean participants were taking oral contraceptive pills.  
 
Table 6 shows cardio-metabolic health markers that were measured in fasting blood 
samples. HbA1c, a measure of glucose control during recent months, was similar between 
groups (p = 0.76), as was serum uric acid (p = 0.73). All individual and both group mean 
results of these tests were well within normal ranges. There was considerable intra-group 
variation in ALT, particularly the Lean group, and two Lean participants had ALT 
concentrations above the normal range. However, there was no between-group difference 
in median ALT (p = 0.24). Although the Overweight group had a higher level of systemic 
inflammation, as indicated by higher plasma C-reactive-protein (CRP) concentrations (p < 
0.05), CRP values for all participants were normal by clinical standards (< 3.0 mg/L)235. CRP 
did exhibit a significantly positive correlation with BF% (Spearman r = 0.52, p < 0.05). There 
were no between-group differences in serum TG, total cholesterol (TC) or the TG / HDL-C 
ratio. However, the TC / HDL-C ratio and LDL-C concentrations were significantly higher in 
the Overweight group (p < 0.05), and HDL-C concentrations tended to be lower in the 
Overweight group (p = 0.08). Further HDL-C concentrations correlated negatively with BF% 
 
B Standard error of b p value 
Intercept 110.832 8.55 <0.0001 
Group -5.336 3.46 0.14 
IAUC 0.003 0.001 0.04 
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(r = -0.49, p < 0.05). FFA concentrations of all participants were within the normal range, 
however there was considerable intra-group variation and no between-group difference (p 
= 0.72).  
 
Table 6. Cardio-metabolic health markers from overnight-fasted blood samples in 
Overweight (n=10) and Lean (n=10) groups. 

















 Values are mean ± SD or median (interquartile range) (*). HbA1c, glycosylated 
haemoglobin; ALT, alanine aminotransferase; CRP, C-reactive protein; C, 
cholesterol, HDL, high-density-lipoprotein; LDL, low-density-lipoprotein; FFA, 
Free-Fatty-Acids. Where normally distributed, p values were determined using 
independent t-tests; where not normally distributed (*), p values were 
determined using Mann-Whitney-U tests. Bold p values indicate statistically 
significant differences between groups (p < 0.05). 
Blood marker Normal range Overweight Lean p value 
Uric acid (mM) * 0.15 - 0.37 0.24 (0.05) 0.27 (0.12) 0.73 
HbA1c (%) 4.5 - 6.3 5.1 ± 0.2 5.1 ± 0.2 0.76 
ALT (IU/L) * 10 – 31 13.0 (3.5)  16.0 (13.8)  0.24 
CRP (mg/L) * 0.0 - 3.0 0.95 (1.4) 0.50 (0.53)  <0.05 
Total cholesterol (mM) < 5.00 5.07 ± 0.72 4.90 ± 0.90 0.65 
HDL-C (mM) > 1.20 1.88 ± 0.22 2.17 ± 0.44 0.08 
Total Cholesterol / HDL-C < 4.0 2.70 ± 0.40 2.30 ± 0.42 <0.05 
LDL-C (mM) * < 3.0 2.82 (0.73)  2.24 (0.96) <0.05 
Triglycerides (mM) < 1.70 0.68 ± 0.18 0.65 ± 0.13 0.60 
Triglycerides / HDL-C < 0.90 0.37 ± 0.11 0.31 ± 0.09 0.21 
FFA (mM) 0.00 - 0.72 0.29 ± 0.12 0.26 ± 0.16 0.72 
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Table 7 shows a.) the contribution of VLDL, IDL, LDL and HDL lipoprotein fractions to total 
cholesterol (TC), and b.) the sub-fraction composition of each lipoprotein fraction. The 
former was investigated for statistical differences using independent t-tests and a 
Bonferroni correction factor (α = 0.05/4). Only IDL-C contributed significantly more to TC in 
the Overweight group compared to in the Lean group (p < 0.0125). There was a tendency 
for HDL-C to contribute more to TC in the Lean group, but this did not reach statistical 
significance after Bonferroni correction (p = 0.03). Within the IDL, HDL and LDL fractions, 
there were no between-group differences in the proportions constituted by the respective 
sub-fractions. Specifically, in both groups, IDL-C was the dominant sub-fraction of IDL, 
followed by IDL-A and IDL-B. Large HDL (HDL – 1, - 2, - 3) and intermediate HDL (HDL – 4, - 
5, - 6, - 7)  each accounted for  approximately 45% of the HDL fraction, with small HDL (HDL 
– 8, - 9, - 10) making up approximately 10%. LDL-1 represented the vast majority of LDL 
particles in both groups, followed by LDL-2. The majority of participants exhibited only 
these ‘large buoyant’ LDL particles. One Overweight and two Lean participants exhibited a 
very small proportion of ‘small dense’ LDL-3 particles. However, none of these were near 
sufficient to suggest a ‘Pattern B’ LDL profile that has been associated with greater 

































Figure 3.  Percentage contributions of the different lipoprotein fractions to Total Cholesterol in 
Overweight (n=10) and Lean (n=10) groups. C, cholesterol, VLDL, very-low-density-lipoprotein, 
IDL, intermediate-density-lipoprotein, LDL, low-density-lipoprotein, HDL, high-density-
lipoprotein. Bars represent mean ± SD. p value was determined using an independent t-test 
and significance (α = 0.05/4) was determined by applying a Bonferroni correction factor.  
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Table 7. Lipoprotein sub-fraction contributions to the respective lipoprotein fractions in 
Overweight (n=10) and Lean (n=10) groups. 
 
Values are percentages expressed as mean ± SD or median (interquartile range) (#). α, 
lipoprotein fractions that are percentages of total cholesterol; * , sub-fractions of each 
lipoprotein fraction, that are percentages of the respective lipoprotein fraction; NS, non-
significant difference. p values were determined using independent t-tests, except where 
not normally distributed (#) they were determined using Mann-Whitney-U tests. Statistical 
significance (α = 0.05/4) was determined by applying a Bonferroni correction factor. Bold p 
values indicate significant differences between groups (p < 0.05). 
 
 
Lipoprotein fraction / sub-fraction Overweight Lean p value 
VLDL-C (α) 10.84 ± 1.84 12.41 ± 1.43 0.05 (NS) 
Total IDL-C (α) 27.77 ± 4.72 20.97 ± 5.19 < 0.01 
IDL – C * 33.21 ± 6.56 34.05 ± 8.01 0.80 
IDL – B * (#) 20.70 (2.97) 20.80 (7.93) 0.97 
IDL – A * 43.80 ± 6.71 43.20 ± 10.11 0.88 
Total LDL-C (α) 29.30 ± 4.29 30.44 ± 6.79 0.66 
LDL - 1 (Large) * 80.40 ± 7.07 77.89 ± 11.58 0.57 
LDL - 2 (Large) * 18.98 ± 5.81 20.64 ± 8.79 0.61 
LDL - 3 (Small) * (#) 0.0 (0.0) 0.0 (1.84) 0.50 
LDL - 4, 5, 6 (Small) * 0.00 ± 0.00 0.00 ± 0.00 N/A 
Total HDL-C (α) 31.94 ± 2.99 35.99 ± 4.66 0.03 (NS) 
HDL - 1, 2, 3 (Large) * 44.31 ± 8.55 43.47 ± 3.79 0.81 
HDL – 4, 5, 6, 7 (Intermediate) * 45.61 ± 6.13 45.24 ± 2.91 0.87 
HDL – 8, 9, 10 (Small) * (#) 10.35 (6.10) 11.30 (1.0) 0.60 
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3.5.) Insulin-Resistance and Glucose Tolerance 
 
Figure 4 shows the distribution of fasting plasma glucose (FPG), fasting serum insulin (FI) 
and the HOMA-IR index of hepatic insulin-resistance within Overweight and Lean groups. 
There were no between-group differences in mean FPG (Overweight, 5.13 ± 0.49 vs. Lean, 
5.28 ± 0.36, p = 0.43) or median (inter-quartile range) of FI (Overweight, 4.05 (1.82) vs. 
Lean, 3.67 (1.27), p = 0.32). No participant exhibited impaired fasting glucose (IFG), as 
defined by the World Health Organisation15 (≥ 6.1 mmol.L-1, Figure 4A), and all FI levels 
were within laboratory norms (< 25 mU.L-1). FI exhibited a strong positive correlation with 
BF% (Pearson r = 0.53, p < 0.05). Median (inter-quartile range) HOMA-IR values were 
similar between groups (Overweight, 0.95 (0.54) vs. Lean, 0.83 (0.30), p = 0.34). However, 
there was considerable intra-group variation, particularly in the Overweight group (Figure 
4C) and HOMA-IR also correlated significantly with BF% (Spearman r = 0.46, p < 0.05). The 
majority of Overweight participants had HOMA-IR values comparable to those of the Lean 
group, but two runners did exhibit noticeably higher values. However, these were not high 



































































The plasma glucose responses during the OGTT were largely similar between groups (Figure 
5A). Both groups exhibited a significant change in plasma glucose over time (time effect, p 
< 0.0001, F = 12.28, partial eta squared = 0.41). However, the two groups did not differ in 
their mean glucose level at any time-point (group effect, p = 0.66, F = 0.19, partial eta 
squared = 0.01). As a result, the shape of the glucose curve was similar between groups 
(interaction effect, p = 0.79, F = 0.47, partial eta squared = 0.03), which was indicative of no 
significant difference in blood glucose response to the glucose load. Despite this, there was 
substantial individual variation at every time point within both groups (Figure 5C and 5E). 
Mean plasma glucose at 120 minutes was below 6.0 mmol.L-1 in both groups (Overweight, 
5.91 ± 1.22 vs. Lean, 5.99 ± 1.61), and there were even Overweight and Lean participants 
Figure 4. Distribution of individual fasting plasma glucose (FPG), fasting insulin (FI) and 
HOMA-IR in Overweight (n=10) and Lean (n=10) groups. A. Distribution of FPG. Data are 
presented as individual FPG (markers), and mean ± SD (solid line ± whiskers). Dashed line 
indicates the lower threshold for impaired fasting glucose (WHO)15. p value was 
determined using an independent t-test. B. Distribution of FI. Data are presented as 
individual FI (markers) and median ± interquartile range (solid line ± whiskers). p value was 
determined using a Mann-Whitney-U test. C. Distribution of HOMA-IR. Data are presented 
as individual HOMA-IR (markers) and median ± interquartile range (solid line ± whiskers). 
Dashed line indicates the lower threshold for insulin-resistance230. p value was determined 




















whose glucose levels had returned to baseline by 60 minutes. However, there was one 
participant in each group who had impaired glucose tolerance (IGT, plasma glucose of 
between 7.8 and 11.1 mmol.L-1 at 120 minutes, World Health Organisation)15. Consistent 
with these findings, the mean ± SD of total area under the glucose curve (GAUC) was 
similar between groups (Overweight, 830 ± 169 vs. Lean, 853 ± 173, p = 0.76) but varied 
considerably: 575 to 1110 in the Overweight group and 667 to 1147 in the Lean group.  
 
The mean serum insulin response during the OGTT was also similar between groups (Figure 
5B). Both exhibited a significant change in insulin over time (time effect, p < 0.0001, F = 
31.83, partial eta squared = 0.64) and the shape of the curves was similar (interaction 
effect, p = 0.58, F = 0.76, partial eta squared = 0.04), both peaking at 60 minutes before 
returning to below 30 mU.L-1 at 120 minutes. There was a trend for a greater insulin 
response in the Overweight group (group effect, p = 0.10, F = 2.93, partial eta squared = 
0.14), but this did not reach statistical significance. This was likely due to the considerable 
intra-group variation (Figures 5D and 5F). Some participants within each group had early, 
sharp insulin peaks; others had wide, gradual increases, whilst a few showed very little 
change. This was reflected in the comparison of the groups’ total area under the insulin 
curve (IAUC). Both mean IAUC (Overweight, 4847 ± 1850 vs. Lean, 3653 ± 922) and the ratio 
of IAUC / GAUC (Overweight, 5.94 ± 2.22 vs. Lean, 4.48 ± 1.60) were highly variable and 
tended to be higher in the Overweight group (p = 0.08 and p = 0.11 respectively), but 
neither were statistically significant. However, IAUC exhibited a significant positive 
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Figure 5. Plasma glucose and serum insulin curves in Overweight (n=10) and Lean (n=10) 
groups during the 120 minute 75 gram Oral Glucose Tolerance Test (OGTT). A. Mean 
plasma glucose response during the OGTT. IGT, Impaired glucose tolerance (WHO)15. Data 
are displayed as mean ± SD at each time-point. Statistical significance was investigated 
using a repeated measures two-way ANOVA. B. Mean serum insulin response during the 
OGTT. Data are displayed as mean ± SD at each time point. Statistical significance was 
investigated using a repeated measures two-way ANOVA. C. Individual plasma glucose 
responses during the OGTT in the Overweight group. D. Individual serum insulin responses 
during the OGTT in the Overweight group. E. Individual plasma glucose responses during 














































































































Indices of hepatic, skeletal muscle and whole-body insulin-sensitivity were calculated from 
the OGTT glucose and insulin responses (Methods section). There was no between-group 
difference in the median (interquartile range) of either the hepatic insulin-resistance index 
(Overweight, 15.5 (6.5) vs. Lean, 13.0 (7.8), p = 0.45) or skeletal muscle insulin-sensitivity 
index (Overweight, 14.0 (18.3) vs. Lean, 15.5 (16.3), p = 0.85). There was again significant 
intra-group variation but neither index correlated with BF% or other metabolic markers. 
Figure 6 shows the distribution of the Matsuda index, which was calculated as a marker of 
whole-body insulin-sensitivity. There was considerable intra-group variation and no 
between-group difference in the median (interquartile range) of Matsuda scores 
(Overweight, 8.8 (3.8) vs. Lean, 8.7 (1.8), p = 0.85).  However, Matsuda exhibited a 
significant, negative correlation with BF% (Pearson r = -0.47, p < 0.05). Two Overweight 
participants were classified as ‘insulin-resistant’ as they were below the threshold of 5.0 
used to identify insulin-resistance230. It was these participants who had exhibited the 
greatest and most sustained insulin response during the OGTT (Orange and Blue curves in 











Figure 6. Distribution of the Matsuda Index of insulin-sensitivity in Overweight 
(n=10) and Lean (n=10) groups. Lower values indicate worse insulin-sensitivity. IR, cut-
point (< 5.0) for insulin-resistance230. Data are shown as individual Matsuda indices 
(markers), and as median ± interquartile range (solid lines ± whiskers).  p value was 
















3.6.) Metabolic Syndrome 
 
Individual participants were assessed for the presence of MetS according to the WHO, 
NCEP ATP III and IDF criteria (Methods section). Overall, despite a few participants 
exhibiting certain abnormalities in isolation or in pairs (e.g. central obesity, systolic and/or 
diastolic blood pressure and/or impaired glucose tolerance or insulin-resistance), no 
participant had a metabolic profile that satisfied any of the three sets of criteria. It was 
largely the absence of dyslipidaemia (abnormal TG or HDL-C concentrations) that precluded 
a few participants from a MetS diagnosis. One participant in particular had considerable 
abdominal adiposity (waist-to-hip ratio of 0.86), insulin-resistance by Matsuda (3.26), and 
pre-hypertensive systolic blood pressure (129 mmHg); however, the latter fell short of the 
WHO requirement for hypertension, and her lipid profile was healthy. Another participant 
had pre-hypertensive systolic and diastolic blood pressure (137 / 83 mmHg), impaired 
glucose tolerance (plasma glucose concentration of 8.04 mmol.L-1 at 120 minutes during 
the OGTT) and central obesity by DXA (35.7% body fat). However, her other central 
adiposity measures were normal according to MetS criteria and her lipid profile was 
favourable.  
 
3.7.) Genetic Influence 
 
We did not explore genetic factors specifically in this study. However, participants were 
asked in the Detailed Participant Questionnaire about their family history of obesity and 
metabolic disease. Interestingly, six overweight participants had a positive family history of 
obesity (five participants with obese parents and one participant with an obese sibling), 
whereas only one Lean participant reported an obese parent. This tended towards 
statistically significance (Fisher’s exact, p = 0.06). Furthermore, four Overweight 
participants had parents with diagnosed T2D in contrast to no Lean participants, but this 






3.8.) Dietary Intake 
 
3.8.1.) Between-group comparison 
 
Table 8 summarises the mean energy intake and macronutrient gram intake as derived 
from the analysis of the 3DR. Total energy intake was approximately 2000 kcal.day-1 and 
was similar between groups (p = 0.23), as were the absolute gram intakes of protein (p = 
0.62), fat (p = 0.47) and carbohydrate (p = 0.23). The proportions of energy derived from 
protein (Overweight, 19.9 ± 4.4% vs. Lean, 16.4 ± 4.1%), fat (Overweight, 43.9 ± 9.9% vs. 
Lean, 43.0 ± 8.4%), carbohydrate (Overweight, 32.8 ± 11.3% vs. Lean, 35.8 ± 11.3%) and 
alcohol (Overweight, 3.3 ± 3.4% vs. Lean, 4.8 ± 4.0%) were almost identical between groups 
(chi-square test, p = 0.78). However, there was considerable intra-group variation. 
 
The 3DR was also analysed for total sugar and fibre intake, and vitamins and minerals 
(Table 8). Interestingly, the Lean group consumed a greater amount of both total sugar and 
fibre (p < 0.05). There was considerable intra-group variation in vitamin and mineral intake. 
For example, vitamin C intakes ranged from 9.6 to 173.2 mg.day-1 in the Overweight group 
and from 16.4 to 177.6 mg.day-1 in the Lean group. Therefore, the mean intakes of most 
micronutrients were similar between groups (p > 0.05), although the Lean group had a 
statistically higher intake of copper, folic acid and vitamin E (p < 0.05). Overall, these and 
the aforementioned dietary findings should be interpreted with a degree of caution, given 
the inherent error associated with self-report dietary intake (Discussion section). No dietary 






Table 8. Daily dietary intake, in terms of total energy, macronutrients, vitamins and 







Variable Overweight Lean p value 
Energy intake (kcal) 1928 ± 354 (1351 - 2494) 2166 ± 489 (1649 - 2968) 0.23 
Macronutrients 
Protein (g) 93.9 ± 16.4 (63.7 - 125.7) 88.5 ± 29.3 (45.8 - 151.4) 0.62 
Total Fat (g) 94.6 ± 25.8 (40.7 - 123.9) 105.7 ± 39.5 (64.9 - 168.5) 0.47 
- Saturated (g) * 37.7 (15.7)  26.2 (25.3)  0.74 
- Mono-unsaturated (g) 34.5 ± 12.5 (14.1 - 52.8) 40.5 ± 18.1 (18.9 - 75.4) 0.40 
- Polyunsaturated (g) 15.5 ± 6.7 (8.7 - 28.1) 18.8 ± 7.4 (9.3 - 33.3) 0.32 
Cholesterol (mg) * 410 (208)  376 (130)  0.48 
Carbohydrate (g) 157.4 ± 56.0 (49.0 - 255.7) 188.0 ± 54.4 (94.4 - 246.5) 0.23 
Total sugar (g) 47.0 ± 18.6 (25.4 - 86.9) 72.6 ± 32.5 (28.0 - 132.3) 0.04 
Total fibre (g) 14.3 ± 5.2 (1.9 - 19.9) 20.8 ± 5.1 (14.4 - 31.6) 0.01 
Alcohol (g) 10.1 ± 10.7 (0.0 - 33.4) 15.5 ± 14.7 (0.0 - 44.5) 0.36 
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Table 7 continued 
Values are mean ± SD (range) or median (interquartile range)(*). Where normally 
distributed, p values were determined using independent t-tests; where not normally 
distributed (*), p values were determined using Mann-Whitney-U tests. Bold p values 





Variable Overweight Lean p value 
Vitamins and Minerals 
Calcium (mg) 807 ± 249 (497 - 1178) 1094 ± 602 (385 - 2506) 0.18 
Iron (mg)* 11.5 (4.0)  13.0 (10.2)  0.28 
Copper (mg) 1.2 ± 0.4 (0.6 - 2.0) 1.9 ± 0.8 (0.8 - 3.4) 0.02 
Sodium (mg) 2700 ± 636 (976 - 3110) 2818 ± 667 (1305 - 3405) 0.69 
Potassium (mg) 2368 ± 673 (2088 - 4061) 2103 ± 752 (1446 - 3630) 0.42 
Vitamin B6 (mg) 2.1 ± 0.7 (0.6 -3.4) 2.0 ± 0.8 (0.9 - 3.6) 0.82 
Vitamin B12 (µg)* 5.1 (3.5)  4.6 (3.4)  0.68 
Folic Acid  (µg)* 9.3 (19.2)  29.3 (37.2)  0.05 
Vitamin C (mg) 89.9 ± 56.0 (9.6 - 173.2) 93.7 ± 47.2 (16.4 - 177.6) 0.87 
Vitamin D (µg)* 5.9 (5.2)  5.4 (4.9)  1.00 
Vitamin E (mg)* 7.3 (5.4)  10.9 (2.6)  0.04 
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3.8.2.) Dietary assessment tool comparison 
 
The 24HR served as familiarisation for completing the 3DR. The data obtained from the 
24HR is not shown, but it did not differ statistically from that of the 3DR. The 3DR and FFQ 
data were compared to assess the level of agreement between tools that represented 
habitual dietary intake at the time of testing and during the prior 6 months, respectively. On 
average, estimated energy intake from the 3DR and FFQ were similar within both groups 
(Overweight, 1916 ± 374 kcal.day-1 vs. 1821 ± 658 kcal.day-1 respectively; Lean, 2166 ± 489 
kcal.day-1 vs. 2023 ± 837 kcal.day-1 respectively). The within-group variation of the FFQ was 
more pronounced than that of the 3DR.  The Bland-Altman comparison plot of energy 
intake from the 3DR and FFQ (Figure 7), however, illustrates the large within-individual 
differences between methods. The mean bias was for the 3DR to report 120.4 kcal.day-1 
higher than the FFQ, and the 95% limits of agreement were substantial (-1282 to + 1523 
kcal.day-1).  Estimated energy intake appeared to differ systematically between methods. 
Specifically, the FFQ tended to under-report at lower intakes, but over-report at the higher 
intakes.  
 
The estimated macronutrient compositions from the 3DR and FFQ were analysed for 
statistical differences using paired t-tests and an appropriate Bonferroni correction factor (α 
= 0.05/4). In the Overweight group only, the percentage of energy derived from fat was 
significantly lower (p < 0.01) as per the FFQ compared to the 3DR (33.28 ± 6.23% vs. 42.69 ± 
9.72% respectively). This also tended to be significant in the Lean group (FFQ, 36.11 ± 7.19% 
vs. 42.99 ± 8.37%) but did not reach statistical significance (p = 0.02). Conversely, the 
proportion of energy derived from alcohol was significantly higher (p < 0.001) according to 
the FFQ compared to the 3DR in the Overweight group (8.46 ± 4.25% vs. 3.35 ± 3.63% 
respectively). Again, this tended to be the case in the Lean group (7.89 ± 2.61% vs. 4.80 ± 
3.98%) but was not statistically significant (p = 0.017). Within both groups, proportional 
carbohydrate intake was slightly higher according to the FFQ compared to the 3DR 
(Overweight, 38.40 ± 9.10% vs. 34.00 ± 11.26%, respectively; Lean, 38.90 ± 9.83% vs. 35.75 
± 11.29%, respectively), but these were not statistically significant (Overweight, p = 0.06 
and Lean p = 0.38). Proportional protein intake was relatively consistent between the 3DR 











































Figure 7. Bland-Altman representation of individual energy intake (kcal.day-1) as 
estimated from the 3DR compared to the FFQ in Overweight (n=9) and Lean (n=10) 
groups. Difference, calculated as the 3DR energy intake minus the FFQ energy intake. 
Average, calculated as the mean energy intake from the 3DR and FFQ. 2SD, two standard 
deviations of the mean difference between 3DR and FFQ. Dashed line indicates where there 






3.9.) Resting Metabolic Rate (RMR) 
 
Mean absolute RMR, as determined by indirect calorimetry, was similar between groups (p 
= 0.74). However, when it was expressed relative to both body mass (p < 0.0001) and fat-
free-mass (FFM, p < 0.05), it was significantly higher in the Lean group. The latter shows 
that the specific metabolic rate of FFM (the main determinant of RMR) was higher in the 
Lean group. However, the intra-group variation was considerable (Figure 9). Specifically, 
half of the Lean group had appreciably higher RMR.FFM-1 compared to the Overweight 
group, whilst the other five Lean participants were comparable to the Overweight group. 
Neither absolute nor relative RMR were meaningfully correlated with or predictive of BF%.  
 
Figure 8. Comparison of the proportional contributions of protein, carbohydrate, fat and 
alcohol to total energy intake, in Overweight (n=9) and Lean (n=10) groups, according to 
the 3DR compared to the FFQ. Data are presented as mean ± SD (bar ± whiskers). p values 
were determined using paired t-tests and significance (α = 0.05/4) was determined by 
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RMR was used to estimate the total energy expenditure (TEE) of the participants by taking 
into account each participant’s level of activity during the days of diet recall (Methods 
section). TEE effectively represents the participants’ daily energy requirements to maintain 
energy balance. Both Overweight and Lean groups had an estimated TEE of approximately 
2750 kcal.day-1 (Table 9). This was appreciably higher than their respective energy intakes, 
which were both approximately 2000 kcal.day-1 (paired t-tests, Overweight p < 0.01 and 
Lean p < 0.05, Figure 9). Further, the mean proportion of estimated TEE that was provided 
for by caloric intake was only 72% and 80% in Overweight and Lean groups respectively 
(Table 9).  Assuming that the estimates of energy intake and TEE were accurate (Discussion 
section), this would imply that participants were in caloric deficit during testing. Indeed, 
two Overweight participants were found to have consumed less than half of their 
estimated energy requirements (Figure 9), whereas one participant from each group did 
match their estimated energy intake and expenditure. 
 
Table 9. Parameters pertaining to the resting metabolic rate (RMR) and total energy 
expenditure (TEE) of Overweight (n=10) and Lean (n=10) groups. 
Values are mean ± SD (range). FFM, Fat Free Mass; TEE, Total Energy Expenditure. All 
variables were normally distributed and p values were determined using independent t-
tests. Bold p values indicate statistically significant differences between groups (p < 0.05) 
 
 
Variable Overweight Lean p value 
RMR (kcal.day
-1










) 29.5 ± 2.1 (26.5 – 33.3) 31.6 ± 2.3 (28.7 – 35.7) < 0.05 
TEE (kcal.day
-1
) 2728 ± 340 (2353 – 3320) 2742 ± 346 (2218 – 3328) 0.93 






3.10.) Physical Activity and Sedentary Behaviour 
 
Mean daily GTX3+ accelerometer wear-time (Overweight, 919.5 ± 106.3 vs. Lean, 884.8 ± 
76.2 minutes.day-1) was similar between groups (p = 0.45). Figure 10 depicts the proportion 
of absolute wear-time that Overweight and Lean groups spent in different activity levels as 
determined by the accelerometers. There were no between-group differences (chi-square 
test, p = 0.97). Overweight and Lean groups spent the majority of wear-time sedentary (74 
± 6% vs. 72 ± 6% respectively), and comparable proportions of wear-time in light (14 ± 4% 
vs. 15 ± 5% respectively) and moderate-to-vigorous physical activity (MVPA, 11 ± 3% vs. 13 
± 4% respectively). Overall activity was inferred from the number of steps taken per day 
(Table 10). On average, both groups exceeded 10 000 steps.day-1. Although the Lean group 
appeared to average more steps.day-1, there was no difference between groups (p = 0.43). 
This was owing to the considerable intra-group variation, particularly within the Overweight 
group (range: 6861 – 18 263 steps.day-1). The findings were similar when steps were 
Figure 9. Relationship between mean daily Energy Intake and estimated Total Energy Expenditure 
(kcal.day-1) in Overweight (n=10) and Lean (n=10) groups. Energy intake was determined from the 3DR, 
and TEE was estimated using Resting Metabolic Rate from indirect calorimetry and individual PAL factors 
of 1.8 or 2.0. p values were determined using paired t-tests for within-group differences. 
 

































expressed relative to minutes of daily wear time (Table 10). No measures of physical activity 











Sedentary behaviour was further analysed in regards to the time that Overweight and Lean 
groups spent specifically in ‘bouts’ of sedentary behaviour (≥ 20 consecutive minutes of 
zero activity). Table 10 suggests that there was a trend approaching statistical significance 
for Overweight participants to exhibit more sedentary bouts per day (p = 0.06) and spend 
more total time in sedentary bouts (p = 0.07). Interestingly, the former also exhibited a 
significantly positive correlation with BF% (Pearson r = 0.54, p < 0.05). The average length 
of a sedentary bout was similar between groups (p = 0.86).   
 
 
Figure 10. Proportion of wear-time spent in different activity levels by Overweight 
(n=10) and Lean (n=8) participants, collected using Actigraph GTX3+ accelerometers. 
Activity levels were determined by Matthews cut-points for counts per minute (cpm) in 
the vertical axis: sedentary (< 100 cpm), light (100 – 759 cpm), moderate (760 – 5998) and 

























Table 10. Overall daily activity in step counts and average sedentary behaviour, as 
measured using GTX3+ accelerometers in Overweight (n=10) and Lean (n=8) groups. 
 
Values are mean ± SD (range) or median (interquartile range). SED, sedentary. 
Where normally distributed, p values were determined using independent t-




Activity patterns were also explored for differences between weekdays (Monday to Friday), 
and weekend days (Saturday and Sunday). Chi-square analysis showed that the proportion 
of wear-time spent in different activity levels did not change between weekdays and 
weekend days (data not shown). When overall activity (steps.day-1) was compared between 
weekend days and weekdays (Figure 11), only the Overweight group (weekend, 15 907 ± 
7606 steps.day-1 vs. week, 8114 ± 2579 steps.day-1) was found to take significantly more 
steps on weekend days relative to their weekdays (paired t-test, p < 0.01). In fact, only two 
Overweight participants exceeded 10 000 steps on an average weekday compared to seven 
on an average weekend day. Lean participants also tended to be more active on weekends 
but the difference relative to their weekday activity (15 498 ± 7491 steps.day-1 vs. 10 217 ± 
3821 steps.day-1 respectively) was not statistically significant (paired t-test, p = 0.15). Three 
Variable Overweight  Lean  p value 
Number of SED bouts 
per day 
2.76 ± 1.26 (1.00 - 5.30) 1.71 ± 0.83 (0.60 - 2.80) 0.06 




89.2 ± 34.0 (32.9 - 149.5) 60.0 ± 27.4 (18.3 - 89.7) 0.07 
Average length of SED 
bouts (minutes)* 
32.4 (7.9)  32.1 (6.5)  0.86 
Steps per day 10 742 ± 3552 (6861 – 18 263) 12 073 ± 3273 (7256 – 16 726) 0.43 
Steps per minute wear 
time  
11.1 ± 5.3 (3.9 – 21.8) 12.3 ± 3.3 (8.4 – 18.5) 0.58 
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of the eight Lean participants averaged more than 10 000 steps on weekdays compared to 




The hourly activity (counts per minute in the vertical axis) of Overweight (n=10) and Lean 
(n=8) groups was averaged from valid days in order to construct a profile of activity 
fluctuations during an average wear day (Figure 12). The profiles were analysed using a 
repeated measures ANOVA with Bonferroni post hoc tests for possible between-group 
differences. Both groups exhibited clear changes in activity during the day (time effect, p < 
0.0001, F = 8.96, partial eta squared = 0.36). However, the profiles were similar in shape 
and there was no group effect (p = 0.28, F = 1.28, partial eta squared = 0.07) or interaction 
effect (p = 0.91, F = 0.62, partial eta squared = 0.04). Both groups tended to be very active 
in the early morning (06h00 – 08h00) and early evening (16h00 – 18h30), but were 
relatively inactive during the period between 10h00 – 15h30 and late evening (20h00-












*    p = 0.15











Figure 11. Differences in overall activity (mean steps.day-1) taken on weekdays compared 
to weekend days, in Overweight (n=10) and Lean (n=8) groups. p values were determined 





Figure 12. Profile of the average activity fluctuations throughout a typical day in 
Overweight (n=10) and Lean (n=8) groups. p values were determined using a repeated 
measures two-way ANOVA. 
 
3.11.) Sleep and Stress 
 
Table 11 shows the average bed time and wake time, time spent asleep, and indices related 
to sleep efficiency, as determined from 7-day actigraphy. There were no between-group 
differences in any of the indices assessed (p > 0.05). Both groups attained approximately 7 
hours of sleep per night, which was on the lower side of adult recommendations141. There 
was, however, wide variation: only three of the nine Overweight and three of the 10 Lean 
participants averaged at least 7 hours of sleep per night, whereas the remaining 13 
participants slept less than 7 hours per night (Figure 13). Despite this, no participants fell 
below the ‘short sleep’ threshold (< 6 hours.night-1) that has been linked with ill cardio-
metabolic health149,236. Furthermore, all except for one Overweight participant, who woke 
up frequently during the night, were found to have good sleep onset latency (< 20 minutes) 
and good sleep efficiency (≥ 85%) (Table 11). This would suggest that they fell asleep 
quickly and spent most of their time in bed asleep. Objective sleep parameters did not 
exhibit meaningful associations with BF% or metabolic parameters. 






Time p < 0.0001
Group          p = 0.28






















Table 11. Average sleep duration and quality in Overweight (n=9) and Lean (n=10) groups, 
as assessed using 7-day actigraphy. 
 
Values are mean ± SD. All parameters were normally distributed 










Variable Overweight  Lean  p value 
Time gone to bed (hh:mm) 22:45 ± 0:39 22:28 ± 0:41 0.36 
Wake-Up Time (hh:mm) 06:24 ± 0:31 06:01 ± 0:43 0.21 
Time in Bed (hh:mm) 07:39 ± 0:42 07:34 ± 0:35 0.75 
Total Sleep (hh:mm) 07:01 ± 0:48 06:52 ± 0:34 0.64 
Onset Latency (minutes) 7.3 ± 5.8 5.8 ± 3.5 0.49 
Sleep Efficiency (%) 91.55 ± 4.38 90.72 ± 2.79 0.62 
Time awake (minutes) 21.3 ± 7.7 25.9 ± 6.9 0.19 














The Actiwatch results were in slight contrast to the results of the Pittsburgh Sleep Quality 
Index (PSQI) Questionnaire.  Overweight (n=10) and Lean (n=10) groups exhibited average 
scores of 5.7 ± 3.1 and 5.1 ± 2.6 respectively and there was no between-group difference in 
median (interquartile range) (5.0 (6.3) vs. 4.5 (3.8), p = 0.85). This would suggest that on 
average both groups perceived that they were ‘bad’ sleepers (PSQI > 5)211. Notably, four of 
the participants who perceived their sleep the worst, qualitatively reported using 
medication to help them fall asleep. When compared with the objective measures of sleep 
duration and sleep quality, PSQI score exhibited no association with objective sleep 
duration but correlated significantly and negatively with objective sleep efficiency (Pearson 






















Figure 12. Distribution of average sleep duration (hours per night) during the 7-day 
Actiwatch recording period. Data are presented as individual 7 day means (markers) and as 
the group 7-day mean ± SD (lines ± whiskers). Grey lines represent the range for 
recommended hours of sleep per night for the adult population; the black line represents 
the threshold for ‘short-sleep’ associated with ill metabolic health236. 
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Participants completed the Perceived Stress Questionnaire (PSQ), to evaluate their recent 
levels of stress. There was no between-group difference in mean PSQ score (Overweight, 
61.40 ± 16.67 vs. Lean, 61.90 ± 15.34, p = 0.95), likely owing to the considerable intra-group 
variation. Of a possible score between 30 and 120, Overweight participants scored 
between 34 and 89, whilst Lean participants scored between 47 and 87. These scores 
would be interpreted as ‘reduced’ to ‘average’ levels of stress226. Figure 14 shows that a 
higher level of perceived stress was associated with poorer perceived sleep quality. 
Specifically, there was a strong positive correlation between the PSQ score and the PSQI 
score of sleep pathology, both when groups were combined (Spearman r = 0.78, p < 
0.0001) and within individual groups (Overweight, r = 0.83, p < 0.01 and Lean r = 0.66, p < 
0.05). PSQ also had a significantly positive correlation with CRP (inflammation) across both 
groups (Pearson r = 0.55, p = 0.01). 
 
 
Figure 13. Relationship between individual scores of Overweight (n=10) and Lean (n=10) 
groups on the Perceived Stress Questionnaire (PSQ) and Pittsburgh Sleep Quality Index 
(PSQI) Questionnaire. Dotted vertical line, PSQI score > 5 was used to identify ‘bad 
sleepers’211. Dotted horizontal lines, used to separate levels of stress according to PSQ score: 
30 to 60 represents ‘Reduced’ stress, 60 to 90 represents ‘Average’ stress, and 90 to 120 
represents ‘High’ stress226. Correlations were investigated using the Spearman r, and 
significance was set at p < 0.05.  
 

















r = 0.83, p < 0.01











3.12.) Eating habits and attitudes 
 
Questionnaires were used to explore participants’ eating habits and food-related 
psychology. Figure 15 illustrates the similar mind-sets that were exhibited by Overweight 
(n=10) and Lean (n=10) groups, as per the Three-Factor Eating Questionnaire (TFEQ). There 
was no between-group difference (p = 0.68) in median (interquartile range) of total TFEQ 
score (Overweight, 6.95 (1.52) vs. Lean, 5.95 (2.80)). Group medians were also similar in 
the three separate domains of the TFEQ: emotional eating (Overweight, 2.2 (1.4) vs. Lean, 
2.0 (1.8), p =0.57) uncontrolled eating (Overweight, 2.0 (0.4) vs. Lean, 1.8 (0.8), p=0.70) and 
cognitive restraint (Overweight, 2.7 (0.4) vs. Lean, 2.6 (0.9), p = 0.70)). Both groups on 
average exhibited ‘cognitive restraint’ most strongly of the three domains. 
 
 
 In response to the Gastrointestinal Symptoms Questionnaire (Table 12), Overweight and 
Lean participants did not report frequent or severe gastrointestinal distress (neither during 
normal daily activities nor during running). The Overweight group tended to report more 
gastrointestinal problems during normal daily activities compared to the Lean group 
(Mann-Whitney-U, p =0.06 for Total Score), however, there was considerable inter-
individual variation. Participants typically reported that they had experienced problems 
Figure 14. Three Factor Eating Questionnaire (TFEQ) domain scores in Overweight (n=10) 
and Lean (n=10) groups. Data are presented as median ± interquartile range (marker ± 
whiskers). Minimum – maximum for each domain is 1 – 4, and higher scores indicate 
greater propensity for that trait. p values were determined using Mann-Whitney-U tests. 











with one gastrointestinal symptom, therefore, the between-group difference was not 
statistically significant. Further, the symptoms had typically not been experienced recently 
since most participants reported having foregone the foods that had normally elicited the 
symptoms. The most frequent gastrointestinal complaint was bloating, which was 
associated with consumption of wheat-containing foods such as bread, pasta and pizza. 
These foods were also commonly linked with symptoms of abdominal pain and 
constipation, while sugar-sweetened beverages seemed to have elicited heartburn in a few 
participants. Gastrointestinal complaints specific to running were also rare, and when 
reported, had only been experienced rarely. Sugar-sweetened beverages, such as 
carbonated and energy drinks, as well as the energy sweets and gels that are typically 
consumed during running events, were the primary causes of discomfort from bloating and 


















Table 12. Gastrointestinal complaints reported during normal daily activities and 
independently during running in Overweight (n=10) and Lean (n=10) groups. 
 












During Daily Activities 
   
 
 
Abdominal Pain 5 1.0 (1.25)  1.0 (1.0)  0.86 White bread, pizza 
Esophageal symptoms (e.g. 
heartburn/dysphagia) 
10 2.0 (3.0)  2.0 (0.25)  0.46 Sugar-sweetened drinks 
Upper dysmotility symptoms 
(e.g. early satiety, bloating, 
nausea, vomiting) 
25 7.0 (5.3)  6.5 (2.3)  0.44 
Pasta, bread, pizza, 
Beer or cider 
Bowel symptoms (Diarrhoea 
or Constipation symptoms) 
30 12.0 (3.8)  11.0 (3.0)  0.17 
 
Diarrhoea symptoms ( ≥ 3 
Bowel movements / day, loose 
stools, urgency) 
15 4.5 (3.0)  4.0 (2.3)  0.61 Coffee, nuts 
Constipation symptoms (< 3 
bowel movements / week, 
hard stools, anal blockage) 
15 3.5 (2.3)  3.0 (1.0)  0.23 Wheat, bread, pasta 
Total during daily activities 70 33.0 (7.7)  28.5 (5.8)  0.06 
 
During Running 27 2.0 (3.5)  3.5 (2.2)  0.32 
Energy drinks, sweets, 
gels, bread 
Eating too close to a run 
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The Detailed Participant Questionnaire (Appendix C) asked participants the extent to which 
certain food selections and/or omissions applied to them. Figure 16 indicates the 
percentage of participants that reported to have been making an effort to limit their caloric 
intake, fat intake and refined carbohydrate intake. There were no between-group 
differences in any of the three practices (chi-square tests, p = 0.66, p = 1.0 and p = 0.47 
respectively). The majority of participants were making an effort to reduce their intake of 
all three, in particular refined carbohydrates (reportedly all ten Overweight participants 
and eight of the Lean participants). 
 
Participants were also asked to describe their typical nutritional practices leading up to and 
on the day of long training runs and races (Figure 16). Of the commonly-adopted practices, 
only carbohydrate - loading was somewhat recognised and practised by participants: by 
50% of both groups (chi-square test, p = 1.0). These participants used pasta and sugar-
sweetened energy drinks as their primary carbohydrate sources. A couple of participants 
from both groups also reported consciously increasing their energy intake on the day 
before a long run or race (‘calorie-loading’, p = 0.67). This typically coincided with 
carbohydrate-loading since they would consume larger portions of carbohydrate sources 
such as pasta and potatoes. A few Overweight participants indicated that they had recently 
started fat-adapting prior to long runs. However, when asked to elaborate, they indicated 
that they would consume slightly more fat in addition to their normal diet during the day 
before a long run, and ensure a large portion of protein the night before. Since this was not 
in line with the scientific notion of ‘fat-adapting’237, these responses were deemed invalid. 
















There were notable food items reportedly consumed by participants in the period 
surrounding a long run or race. Table 13 provides a snap-shot of the most common foods 
participants consumed before, during and after a run, in order of how often they were 
reported in each group. The majority of items were common amongst Overweight and Lean 
runners, for example, both groups had pasta and larger portions than normal on the days 
leading up to a run, both prioritised energy and/or carbonated drinks as well as energy 
sweets or energy bars during the run, and their most common food consumed post-run 
was a chocolate milkshake. However, only the Overweight participants indicated that they 
consumed energy drinks on the days leading up to, and including the morning of the run. 
Furthermore, whereas most Overweight participants had peanut butter on toast, and an 
energy drink immediately before a run, Lean participants tended to eat oatmeal or an 
energy cereal (e.g. Futurelife or ProNutro). Finally, only the Overweight participants 
indicated that they consumed carbonated and/or recovery drinks post-run. In contrast, the 
Figure 15. Percentages of participants within Overweight (n=10) and Lean (n=10) groups 
that reported to follow select nutritional practices, during daily living or specifically 
leading up to a long run or race. Values are percentages of participants within each group 

































































Lean group did not report any processed foods post-run other than the chocolate 
milkshake.  
 
Table 13. Foods and drinks commonly consumed by Overweight (n=10) and Lean (n=10) 
participants during the days leading up to a long training run or race, immediately before, 
during and after the run. 
 







Pre-run During Post-run 
Days 
before 
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Yoghurt with fruit 
 
Oatmeal Sandwiches 
Eggs and bacon 
on toast  
Banana Sandwiches 
 





Finally, the Detailed Participant Questionnaire asked participants to indicate their 
perception of their individual weight, appearance and dietary habits (Table 14). Participants 
from the Lean group tended to be more satisfied with their current appearance (Mann-
Whitney-U, p = 0.16), they reported significantly greater satisfaction with their current 
weight (Mann-Whitney-U, p < 0.05) and the majority of them did not intend to lose weight. 
In contrast, the Overweight participants wanted to lose an average of 7.8 kg body weight 
(Mann-Whitney-U, p < 0.001). Further, the Lean participants reported having found it easier 
(Mann-Whitney-U, p < 0.001) to maintain their weight (on average ‘Easy’) compared to the 
Overweight participants (on average ‘Difficult’). This was reflected in the larger weight 
fluctuations that had been experienced by the Overweight participants during the prior 10 
years (independent t-test, p = 0.01). Both groups appeared uncertain as to how they 
perceive their current dietary practices (‘Fairly Healthy’), however, the Overweight group 
was less satisfied with their current diet (Mann-Whitney-U, p < 0.05) and tended to have a 


















Table 14. Self-perceptions of current weight, physical appearance and dietary habits in 
Overweight (n=10) and Lean (n=10) groups. 
 
Values are expressed as median (interquartile range)(*), except (#) which is normally 
distributed and expressed as mean ± SD. p values were determine using Mann-Whitney-U 
tests (*), except (#) where an independent t-test was used. Bold p values indicate 





Variable Range Overweight Lean p value 
Satisfaction with appearance * 
1 = Very dissatisfied 
5 = Very satisfied 
2.5 (1.5)  4.0 (1.5)  0.16 
Satisfaction with weight * 2.0 (0.3)  4.0 (3.0)  0.02 
Ease of maintaining weight * 
1 = Very difficult 
5 = No problem 
2.0 (0.3)  3.0 (2.0)  < 0.001 
Weight change during last 10 years kg? (#) 
 
12.9 ±  3.8 8.6 ± 2.9 0.01 
Target weight loss (kg) *  
 9.5 (5.2)  1.8 (2.3)  < 0.001 
Health of current diet * 
1 = Very unhealthy 
5 = Very healthy 
3.0 (0.0)  3.0 (0.3)  0.36 
Satisfaction with Diet * 
1 = Very dissatisfied 
5 = Very satisfied 
2.5 (2.0)  4.0 (1.3)  0.02 
Desire to change diet * 
1 = Not at all 
5 = Definitely 





4.1.) Adiposity and metabolic health 
 
This thesis was intended to be a pilot study that would inform a subsequent weight-loss 
intervention in the emerging ‘overweight runner’ phenotype. Specifically, it was designed 
to better characterise the phenotype, assess the feasibility of recruiting overweight 
runners, estimate the necessary sample size and inform the overall design of the 
intervention. Our primary aim was to determine whether or not overweight runners would 
present with metabolic or alternative abnormalities compared to lean runners, and thus 
whether or not it would be worthwhile to implement a dietary intervention.  Secondly, we 
sought to explore potential factors that may have contributed to their weight-gain, and 
that could be subsequently investigated in the intervention. The main finding of this study 
was that Overweight female runners did not present with metabolic abnormalities, despite 
their elevated adiposity. Two Overweight participants were insulin-resistant, but no 
participants exhibited the MetS. As far as the author of this thesis is aware, this was the 
first metabolic profiling of overweight recreational runners. This may be an important step 
towards understanding the causes of weight-gain in athletic individuals.  
 
Overweight and Lean runners were well matched in terms of age, running experience and 
running calibre. Participants were recruited based on BMI, waist circumference and 
skinfold-based estimates of BF%, all of which were expectedly higher in the Overweight 
group and distinct from the Lean participants. According to DXA, the gold-standard 
measurement of body composition238,  Overweight runners did have a significantly higher 
BF%, and this exceeded the threshold of 30% that has been commonly used for identifying 
excess body fat in the general population197. Lean runners had a ‘good’ average BF%197. The 
latter was considerably lower than that reported (mean 28.4%) in recreational half-
marathon female runners by Knechtle et al. (2014)239. This may suggest that the Lean group 
was representative of reasonably athletic ‘recreational’ runners. However, they were not as 
‘lean’ as more competitive runners who have been typically reported to exhibit less than 
15% body fat197,240.  This may have been expected, however, since the study population was 
over 35 years of age, and was probably less perturbed about other lifestyle factors that 
influence body fat (e.g. sleep, stress, diet) as professionally athletic individuals.  
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On an individual level, a lower threshold of 35% body fat has been used for identifying 
obesity in women241. Three Overweight participants were, therefore, ‘Obese’ and four were 
‘Overweight’ according to these criteria. Surprisingly, DXA revealed that the remaining 
three Overweight runners had less than 30% body fat. Conversely, four Lean runners 
unexpectedly exhibited greater than 25% body fat. These findings highlight the limitations 
of having recruited participants according to BMI, waist circumference and skinfold-based 
estimates of BF%.  
 
Firstly, it has been well-recognised that BMI provides a limited indication of body 
composition, given that it is highly correlated with both muscle and fat mass and is unable 
to differentiate between the proportion and distribution of lean and fat tissue240,241. This 
means that, as observed in the present study, individuals with a low BMI may have had 
significant fat mass and vica versa214. Waist circumference may also be limited by providing 
only a regional estimate of body fatness (abdominal)242. Skinfold thicknesses have been 
reported to lose precision when taken from overweight adults243, and the predictive 
equations  used to estimate BF% from skinfolds have been reported to have a 3% to 7% 
standard error240. Interestingly, in agreement with their greater waist circumference, DXA 
revealed that the Overweight group had a greater proportion of fat mass in the ‘android’ 
(chest and abdominal) region relative to the ’gynoid’ (hips, buttocks and thighs) region. 
Furthermore, ‘athletic’ lean women have been reported to accumulate fat predominantly 
in the lower body with very little in the upper body240. In this light, regions of body fat of 
some Lean, athletic runners may not have been captured by waist circumference or the 
upper-body skinfolds used to estimate BF% by the Durnin and Wormersley equation199. 
Therefore, although BMI, waist circumference and skinfolds were the most convenient and 
cost-effective measurements to use during recruitment, they were less accurate than 
anticipated in predicting whole body fatness.  
 
This was exemplified by the anomaly of the Lean participant with the low BMI (19.7 kg.m-2) 
and waist circumference (67.0 cm) but highest BF% (27.6%). Potential explanations for her 
elevated adiposity may include her past history of smoking244, her low caloric intake260,261, 
particularly low protein intake (mean 45.8 g/day)245,246, and high consumption of sugar 
(mean 132 g/day)40,75.  Interestingly, her other metabolic parameters were well within 
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healthy ranges, and she was not ‘Metabolically Unhealthy Normal Weight’. This was likely  
attributable to her history of regular exercise247. Ultimately, finding her adiposity to overlap 
with the Overweight participants meant that the two groups were less separated in terms 
of body composition than originally desired. As detailed in the Results section, however, 
excluding her from the analysis did not alter the findings of the present study. Regardless, 
finding significantly higher mean adiposity in the Overweight group and predominant 
adipose tissue accumulation in the trunk relative to the lower body, would have implicated 
worse insulin-resistance and greater cardio-metabolic risk compared to the Lean 
runners169,248. 
 
In contrast to this train of thought, the Overweight group did not present with clinically 
meaningful metabolic abnormalities relative to the Lean group. The primary outcome 
measures of metabolic health were those assessing insulin-sensitivity (or resistance) from 
both fasting plasma glucose and serum insulin and the responses during the OGTT. It is 
important at this point to discuss the possible limitations of using surrogate OGTT-derived 
measures of insulin-sensitivity. Firstly, the Matsuda index, hepatic and skeletal muscle 
insulin-sensitivity indices were derived in attempt to relate the OGTT (a test of glucose 
tolerance) to insulin-sensitivity.  Whilst they have been validated against the gold-standard 
measure of insulin-sensitivity (insulin clamp)232,249, these validations were based on 
correlation analyses. Indeed, this may show that two variables vary together in a given 
population, but they fail to indicate the two measures are quantitatively equivalent250. This 
may obscure the relationship between the surrogate measure and consequent metabolic 
risk. Secondly, although the OGTT mimics the physiological response to glucose ingestion 
well, the target measure of insulin-sensitivity may be obscured by the influence of the rate 
of gastric emptying, glucose absorption from the gut, incretin effects, recent diet and 
hormonal / menstrual status251,252. This means that the exact effect of insulin, or sensitivity 
to its signal, is difficult to deduce from an OGTT. Despite these concerns, however, the 
OGTT indices used in the present study were most feasible and have been shown to 
correlate strongly with direct measures and have been comparable to the latter in their 
relation to cardio-metabolic risk factors253. Therefore, although not perfect we believe they 




Fasting levels of glucose and insulin, prior to glucose ingestion, may provide an indication 
of hepatic insulin-sensitivity249. Both groups exhibited normal fasting glucose and insulin 
levels in relation to clinical norms15,229. In comparison to prior literature, mean fasting 
insulin in both groups was below that reported in quartile one (4.9 mU.L-1) in a study of 
prediabetes risk in a predominantly white obese female population254.  Consistent with 
these findings, both HOMA-IR and the surrogate of hepatic insulin-resistance were 
comparable between groups and suggestive of normal insulin-sensitivity230. The mean 
hepatic insulin-resistance index of both groups (Overweight, 16.8 and Lean, 13.3) was 
similar to that reported (14.1) in a Lean, healthy cohort of males and females aged 
approximately 40 years231. Notably however, one Overweight participant had a fasting 
insulin result (9.8 mU.L-1) that was similar to quartile two of the aforementioned study, 
which was associated with a 2-fold increased risk of prediabetes254. The same participant 
presented with the highest HOMA-IR (2.25) and hepatic insulin-resistance index (42.0), 
which may suggest impending prediabetes or impaired glucose tolerance for this 
individual230–232.  
 
Based on these findings and prior validation of the hepatic insulin-sensitivity index against 
direct assessment of hepatic function with the insulin clamp (as described in the Methods 
section)249,  it could be inferred that both groups had normal hepatic insulin function. This 
may seem surprising given the significant between-group difference in abdominal adipose 
tissue, which has been regularly linked to hepatic insulin-resistance255. However, both 
fasting insulin and HOMA-IR correlated significantly and positively with BF% across groups. 
Given the spectrum of BF%, this would suggest that relative hepatic insulin-resistance, 
although within normal levels, may have contributed to increased adiposity of affected 
participants. More recently, liver fat accumulation, as opposed to abdominal fat, has been 
suggested to be a better predictor of insulin-resistance and CVD risk256,257.  Although not 
assessed in this study, liver fat may have been healthy in both groups. This would be 
corroborated by the comparable serum levels of ALT (a marker of liver function) that was 
found in both groups. Our findings were similar to the mean ALT (15 IU.L-1) that was 
reported in a previous study of 723 middle-aged, lean healthy women258. However, mean 
ALT in both groups were significantly lower than that reported in normal-weight (26 ± 14 
IU.L-1) and overweight (32 ± 18 IU.L-1) women who consumed moderate (less than 40 g.day-
1) alcohol259. Interestingly, two Lean participants had higher than normal ALT levels (> 30 
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IU.L-1). Given that they had less than 20% body fat and had good hepatic insulin-sensitivity, 
it seems unlikely that they had pathological liver fat depots. Notably they were also the 
highest and third highest consumers of alcohol according to the 3DR. It may have been that 
their regular alcohol consumption, which may have included the night two days prior to the 
fasting blood draws, contributed to this finding259. In regards to the remaining participants, 
especially in the Overweight group, regular exercise would have conferred a protective 
effect against the accumulation of liver fat and associated hepatic insulin-resistance260. As 
will be discussed later, this has been documented as a trait of the MHO phenotype129. 
 
Increased adiposity, particularly in the visceral region, has also been associated with 
peripheral and whole-body insulin-resistance26. Consistent with this notion and previous 
literature18,248, we found a significantly positive correlation between total IAUC during the 
OGTT and BF%, and a negative correlation between the latter and whole-body insulin-
sensitivity (by Matsuda) 231,232. This further supported the hypothesis that insulin-resistance 
may have contributed to fat gain in the participants with greater adiposity26. The group-
level OGTT results were relatively surprising. Firstly, the mean glucose response was almost 
identical between groups, but there was considerable within-group variation. The latter is 
consistent with previous findings of inter-individual disparity in the ‘metabotype’ (the 
characteristic response of one’s metabolism to a dynamic challenge, as measured using 
various physiological markers) and corresponding glucose response during an OGTT261,262.  
Similarly, recent evidence showed that different individuals had highly individual post-
prandial glucose responses to identical food items89. Within-individual responses to 
identical oral glucose loads (e.g. OGTT or white bread), have also been reported to vary 
when retested after a few weeks263,264. This phenomenon may be attributed to widespread 
factors, including physiological stress at the time of testing, recent sleep, exercise and 
dietary factors263. Therefore, the variable glucose and insulin responses in the present 
study were not unusual, and likely reflected both inter- and intra- individual variability.  
 
Interestingly, one participant from each group exhibited impaired glucose tolerance, but 
they were otherwise distinct. The Overweight participant was obese by BF% (35.7%), pre-
hypertensive (blood pressure of 137 / 83 mmHg) and insulin-resistant by the Matsuda 
index (4.54). In contrast, the Lean participant had the lowest body fat percentage (16.4%), 
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and otherwise normal metabolic markers, including a normal Matsuda score of 8.64. The 
latter had self-reported following a low-carbohydrate dietary pattern, which was 
corroborated by her 3-day diet (15.1% of her total caloric intake was derived from 
carbohydrate)151. This finding was consistent with multiple studies that have shown low-
carbohydrate intake to reduce glucose tolerance in healthy individuals265–267. Importantly, it 
appears that this finding merely reflects an altered metabolic state rather than a 
pathological state of insulin-resistance268,269. Specifically, individuals on a low-carbohydrate 
diet favour fat oxidation over carbohydrate oxidation and will direct ingested glucose 
preferentially to glycogen storage268–270. Collectively, these may slow the rate of glucose 
disposal compared to individuals on a mixed macronutrient diet268–270.  Therefore, it is 
proposed that the Overweight participant with impaired glucose tolerance was at risk of 
prediabetes, but the Lean participant had adapted to an alternative metabolic state and 
was metabolically healthy. 
 
The insulin responses during the OGTT were similarly variable within both groups, in 
particular the Overweight group.  There was, however, a tendency for a higher insulin 
response and IAUC in the Overweight group. Contrary to the past focus of OGTT 
interpretation on the plasma glucose response, it appears that the insulin response may be 
more indicative of the metabolic health of the individual271,272. This is because a normal 
glucose response may be achieved by relative hyperinsulinaemia, which has been 
implicated to be the primary driver of metabolic pathology18,20,87. Having performed 
approximately 15 000 OGTTs, Dr Joseph Kraft proposed the concept of ‘Diabetes in situ’, 
which incorporated four distinct pathological insulin responses to an OGTT271,272. Although 
we did not measure insulin for the length of time used by Dr Kraft (5 hours), it appears 
from the individual responses that only one Overweight participant exhibited an insulin 
profile that resembled Diabetes in situ271,272. Of the remaining nine insulin responses in the 
Overweight group, the majority were comparable to the Lean participants, and only two 
were appreciably higher. Therefore, the tendency for higher insulin in the Overweight 
group may be attributed to the greater insulin secretion that was required to normalise 




Interestingly, the results of whole-body (Matsuda) and skeletal-muscle insulin-sensitivity 
indices were not necessarily in agreement with those of hepatic insulin function. Some 
participants with normal hepatic insulin-sensitivity had reduced peripheral insulin-
sensitivity and vice versa. This finding was consistent with Reaven (2012), who suggested 
that different tissues of a given individual may have varying levels of insulin-resistance and 
that the sequence in which tissues develop pathology may vary between inividuals18,24. On 
average, however, both Matsuda and skeletal-muscle insulin-sensitivity were comparable 
between groups. This finding contrasted our hypothesis that the increased weight of the 
Overweight participants would be explained by underlying insulin-resistance18,20,255. 
However, lower Matsuda scores (indicating worse insulin-resistance) did correlate 
significantly with higher BF%. This discrepancy may have resulted from the unexpected 
spectrum of BF% we obtained across Overweight and Lean groups. Taken together, the 
results appear to support the notion that increasing insulin-resistance and 
hyperinsulinaemia promote fat gain18, but that insulin-resistance per se is unable to explain 
the past weight-gain of all Overweight participants. Indeed, Matsuda indicated that only 
two Overweight participants were insulin-resistant and of them also had the highest 
HOMA-IR.  Overall, we found that the majority of Overweight participants were not insulin-
resistant, however, and this likely contributed to their largely normal metabolic outcomes. 
 
Overweight and obesity typically present with a cluster of related metabolic disturbances 
that together increase risk for T2D and CVD12,14. However, the present study measured 
multiple cardio-metabolic markers and found that they were both comparable between the 
Overweight and Lean groups, and well within healthy ranges. This included HbA1c, as a 
measure of glucose control, uric acid, ALT as mentioned above, as well as serum HDL-C, TG 
and FFA concentrations. Median systolic blood pressure and CRP were both significantly 
higher in the Overweight group. However, the former was comparable between most 
Overweight participants and the Lean group, and mean blood pressure was within the 
normal range. CRP was also within the clinically normal range for all participants235. 
Similarly, both total- and LDL-cholesterol concentrations were higher in the Overweight 
group. However, mean LDL-C was normal, and recent evidence and scientific opinion 
indicate that these parameters are not reliable predictors of cardio-metabolic risk58,87,273. In 
contrast to popular thought, low total cholesterol has in fact been associated with 
increased mortality274.  
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Rather atherogenic risk has been strongly linked to high TG and low HDL-C concentrations 
(and a consequently low TG / HDL-C ratio)273. In addition, the specific distribution of LDL 
particles rather than LDL-C concentration has become more accepted for identifying 
atherogenic risk; with smaller dense particles having been considered pro-
atherogenic12,24,275. All participants had normal TG and HDL-C concentrations and normal 
TG / HDL-C ratios, and there was no between-group difference in LDL particle size 
distribution. In fact, all participants had a vast predominance of large buoyant LDL particles, 
which has been considered to be a healthy LDL profile276. Taken together, our results 
indicate that the groups were largely comparable in terms of the metabolic parameters 
that have been closely linked to overweight and obesity, particularly glucose control and 
lipid profile. Again this was consistent with our finding of similar and normal insulin-
sensitivity in Overweight and Lean groups12,20. 
 
Despite the mean metabolic profile of the Overweight group being normal, it seems worth 
discussing some between-group differences that did exist with regards to potential 
pathology in this group. Firstly, despite having a ‘normal’ lipid profile, HDL-C concentrations 
tended to be lower in the Overweight group. HDL-C also tended to contribute 
proportionally less to total cholesterol, as compared to the Lean group.  HDL-C has been 
described as the ‘good’ cholesterol and high levels have been associated with reduced 
atherogenic risk32. Therefore, one may speculate that reduced HDL-C in the Overweight 
group, particularly in participants with higher BF%, was suggestive of early dyslipidaemia, 
but the actual HDL-C levels were well within the normal range. Furthermore, HDL particles 
are heterogeneous, in that they exhibit varying structures, apolipoprotein compositions 
and concentrations of esterified cholesterol 275. Whilst large HDL particles appear to be 
potently anti-atherogenic, smaller dense HDL particles may be pro-atherogenic275.  The 
present study found a predominance of large and intermediate HDL particles in both 
groups, with minor contributions from small HDL. This would suggest that the HDL-C 
profiles were healthy in both groups, and this was corroborated by the impressively low TG 
levels in all participants276.  
 
In contrast, IDL-C was found to contribute proportionally more to total cholesterol in the 
Overweight group, as compared to the Lean group.  There is limited research on IDL-C, but 
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it appears that IDL particles are primarily produced in the vasculature as remnant particles 
from partial lipolysation of VLDL particles and postprandial chylomicrons32. In the context 
of dyslipidaemia, where VLDL-TG production increases and both VLDL and chylomicron 
clearance are reduced, the presence of IDL particles increases32. Earlier investigations 
associated IDL particle mass with atherogenic progression32. More recently, in a cohort of 
Japanese men, IDL was suggested to be a useful clinical marker of atherogenic risk in the 
context of increased non-HDL-C (comprised of LDL-C and TG-rich lipoprotein-cholesterol, 
including VLDL, IDL and chylomicrons) 277. The purported risk relates to the relative small 
size of IDL (similar to VLDL) that enables penetration of and retention by the arterial wall277. 
However, the latter finding was in the context of reduced HDL-C and high TG, both of which 
were absent in the present study32. Further, Maki et al. (2012) reported atherogenic 
progression to be associated with increased small dense LDL particles, reduced HDL-C, and 
increased TG-rich lipoprotein-cholesterol, with the latter having been explained by 
increased VLDL rather than IDL particles278.  Therefore, given such uncertainty concerning 
IDL-C in atherogenic progression, and the otherwise healthy lipid profiles of the Overweight 
participants, their increased proportion of IDL-C to total cholesterol was unlikely to be of 
clinical concern.  
 
As alluded to earlier, the Overweight group had higher levels of inflammation and higher 
systolic, but not diastolic, blood pressure. Although not a criterion for MetS, elevated 
inflammation has been recognised as predisposing to increased risk of hypertension, MetS 
and CVD16 . Both increased adiposity and insulin-resistance, independently, have been 
associated with a low-grade pro-inflammatory state279. In the present study, the increased 
CRP of the Overweight group may have been due to their greater fat mass, since insulin-
resistance was not identified. Indeed, CRP correlated significantly with increasing BF%.  The 
fact that CRP remained within the acceptable range, however, indicated that participants 
did not have a pathological inflammatory state. Median systolic blood pressure was also 
slightly higher in the Overweight group but within the normal range. This finding was 
consistent with the reportedly close link between inflammation and endothelial function23. 
Similarly, finding neither insulin-resistance nor hypertension, was consistent with the close 
link between insulin-resistance and endothelial dysfunction14,18. This was further exhibited 
by the two Overweight participants who were found to be both insulin-resistant and pre-
hypertensive, and the significant degree of variation in blood pressure that was accounted 
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for by IAUC during the OGTT. Insulin-resistance was, therefore, the most plausible cause of 
weight-gain and pre-hypertension in these two participants. Although they did not satisfy 
the MetS criteria at the time of testing, they are likely to be at increased risk of developing 
MetS in the near future179,180 . 
 
Overall, the present findings would suggest that the Overweight runners we investigated 
were comparable to the subgroup of obese individuals that have been referred to as 
Metabolically Healthy Obese (MHO)102. Although none of the Overweight runners were 
clinically obese by BMI (≥ 30 kg.m-2), and only three were obese by BF%, they clearly had 
increased fat mass relative to the Lean group. However, on average, they did not present 
with any of the metabolic abnormalities commonly associated with this discrepancy12,170. 
Similar to previous findings in MHO persons170,174,175, the Overweight runners had normal 
glucose control, lipid and hepatic enzyme profiles, inflammation and apart from two 
runners, normal insulin-sensitivity. This may have been related to a favourable adipose 
tissue distribution in the Overweight runners. Specifically, MHO persons have typically 
presented with lower visceral fat (particularly intra-abdominal adipose tissue and hepatic 
fat) compared to unhealthy persons of similar adiposity129,169,174. However, these were not 
measured in the present study.  
 
The most plausible explanation for the generally good metabolic health of the Overweight 
runners is their history of regular exercise and consequent cardiorespiratory 
fitness127,129,174,175. Overweight and obese persons who have been found to be metabolically 
healthy reportedly spent significantly more time physically active and less time sedentary 
compared to metabolically unhealthy obese counterparts128,174,175. Greater 
cardiorespiratory fitness, in fact, may have explained why MHO persons were at no greater 
disease risk than metabolically-healthy, normal-weight individuals127. It is well-known that 
regular exercise and maintaining a good fitness level confers a multitude of cardio-
metabolic health benefits independent of body fatness110,112. This includes improved 
insulin-sensitivity across multiple tissues, reduced blood pressure, beneficial lipid 
responses, and reduced metabolic disease risk126,128,280. The underlying mechanisms appear 
to be widespread, but likely include increased lean muscle mass, improved muscle insulin-
signalling, oxidative and glycogen storage capacity124,126,128, enhanced endothelial 
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function125,281 as well as a systemic reduction in oxidative stress and inflammation128,282. In 
particular, an acute exercise bout and exercise training have been shown to have potent 
insulin-sensitising effects283.  For example, Heath et al. (1983) showed that 10 days without 
exercise in trained, lean individuals caused a 100% increase in the insulin response during a 
100 g OGTT283. Therefore, despite the increased body weight and fatness of the Overweight 
participants, their consistent exercise routine, which at the time of testing qualitatively 
involved running, cycling, swimming, weight training, squash and hockey, would have 
probably been profoundly protective against the development of pathogenic insulin-
resistance126–128,280.  
 
The characteristics of our active, yet Overweight participants were inconsistent with 
conventional thought that exercise and increased energy expenditure promote weight-
loss105. On the other hand, exercise intervention trials with ad libitum food have rarely 
reported meaningful weight loss113,284. Excess dietary intake, in these instances, probably 
offset the potential weight-loss effects of exercise. Furthermore, recent scientific opinion 
has expressed that physical activity, despite its numerous health benefits, plays a limited 
role in weight-loss41,56,117. This has been supported by evidence that energy balance and 
body weight may be centrally regulated by hormonal hunger-satiety mechanisms that act 
at the hypothalamus, including gut-brain signals (such as ghrelin) and adipose tissue-brain 
signals (such as leptin)37,41,117. In this regard, increased physical activity (energy 
expenditure) would promote compensatory increases in caloric intake to maintain energy 
balance117. Factors that disrupt such regulation (such as highly palatable high-sugar, high-
fat foods), however, may have promote excess caloric intake and consequent weight-gain 
in spite of regular exercise and normal metabolic health in our Overweight 
participants35,37,41.  
 
Therefore, different mechanisms may have contributed to the weight-gain experienced by 
different Overweight participants. For the two insulin-resistant (and pre-hypertensive) 
participants, it is possible that the insulin-sensitising benefits of exercise had become 
overwhelmed both by considerable predisposition to insulin-resistance56,190, and 
aggravating external factors (such as diet) that were not captured at the time of testing188. 
For example, in the context of their underlying insulin-resistance, the finding that both 
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individuals consumed approximately 50 grams of added sucrose per day may have been 
more detrimental, relative to participants who were more insulin-sensitive285,286. Recent 
evidence would suggest that a lower-carbohydrate dietary approach may be highly 
beneficial in negating the effects of their underlying predisposition87,270,287. Finding 
significant correlations between indices of insulin-resistance or hyperinsulinaemia with 
increased adiposity, would suggest that relative insulin-resistance had contributed to fat 
gain in affected individuals (Lean and Overweight). However, it could not explain the prior 
weight-gain of all Overweight participants. It may be speculated that certain genetic and 
environmental factors predisposed these participants to disrupted appetite regulation (i.e. 
leptin-resistance)33,35. This may have caused them to consume more calories than they had 
been expending during exercise and gain weight41,188,190. Diet-induced leptin-resistance in 
particular appears to result primarily from the highly palatable, processed foods that have 
become common-place in the modern Western diet37. As shall be discussed, however, the 
results of the present study were unable to identify such factors. 
 
4.2.) Potential causes of weight-gain in the Overweight group 
 
4.2.1.) Genetic influence 
 
It is well-established that obesity and associated metabolic diseases have considerable 
heritable components42,50. Although we did not explore specific obesity-associated genetic 
loci or SNPs, we obtained qualitative reports of familial disease history. There was a 
tendency for a greater proportion of the Overweight group to have had parents or siblings 
with obesity or T2D. These were consistent with the elevated adiposity and tendency for 
elevated IAUC during the OGTT in the Overweight group. This was consistent with the cited 
literature that reported genetic influence accounting for approximately 40% of the obesity 
phenotype, and 46 to 90% of the insulin-resistant phenotype40. Therefore, one may 
speculate that the six Overweight participants with a positive family history of obesity were 
predisposed to weight-gain, increased adiposity and insulin-resistance. It would be 
intriguing to investigate which genetic loci may influence body-weight regulation in this 




4.2.2.) Resting Metabolic Rate 
 
RMR represents the metabolic cost of supporting normal physiological processes in the 
resting, post-absorptive body288. This includes maintaining the transmembrane ion 
gradients, cardio-respiratory activity and recovery processes, and RMR accounts for a 
significant proportion (approximately 60% to 75%) of total daily energy expenditure49,288,289.  
Therefore, factors that alter RMR (including age, sex, genetics, body composition, 
temperature, energy balance, hormonal and emotional states) would influence daily energy 
balance, and individuals with a low RMR may be predisposed to weight-gain288,290. In the 
present study, the mean absolute RMR (kcal.day-1) of both groups was comparable to prior 
findings in both young active females289 and healthy active premenopausal women aged 35 
to 50 years291. However, in contrast to the literature290,292, the RMR of the Overweight 
group was remarkably comparable to that of the Lean group. This was surprising since 
Overweight individuals generally present with higher absolute RMR, owing to greater 
cardio-respiratory work and a larger mass of adipose tissue289,290. The latter has been 
suggested to raise energy expenditure via an increased presence of leptin292, however this 
could not be surmised from the results of this study. However, it seems to make more 
sense when one considers that the two groups were similar in terms of the primary active 
tissue, fat-free-mass (FFM). 
 
FFM is the primary metabolically active component of the body and has been reported to 
explain between 53% and 88% of the variance in RMR292. Adipose tissue only contributes 
15% to 20% of the energy expenditure that is contributed by an equivalent amount of 
FFM292. Normalising for total bodyweight , therefore, would erroneously suggest that 
overweight people have a lower RMR compared to leaner individuals as a consequence of 
this higher proportion of adipose tissue289,292. Therefore, consistent with the literature, 
RMR in the present study was normalised for FFM292. The Lean group presented with a 
mean relative RMR (kcal.kg FFM-1.day1) that was comparable to Lean athletic females in 
prior studies288,291. However, the Overweight group had a significantly lower relative RMR 




Firstly, this finding may represent a physiological response to long-term caloric 
deficit289,293,294. Overweight participants had clearly struggled with weight fluctuations and 
they perceived themselves to be restrictive of food intake. Furthermore, as will be 
discussed later, their self-reported food intake suggested a daily caloric deficit. Although 
the literature is conflicting in this regard, studies have suggested that energy restriction and 
consequent weight-loss cause an adaptive down-regulation of RMR and activity energy 
expenditure, that is considerably greater than that predicted by actual changes in weight 
and body composition289,293.  Further, the adaptation has been found to persist long after 
the period of dynamic weight-loss293. This has been used as evidence of an adaptive 
compensatory response to return to the body’s original weight289,293. Hence, an adaptive 
reduction in RMR has been proposed to underlie the tendency for weight-reduced persons 
to regain weight289,293. In support thereof, enhanced ‘energy efficiency’, characterised by 
reduced relative RMR, has been reported in male tri-athletes who maintained stable 
weights despite daily caloric deficits (self-reported and confirmed in a controlled metabolic 
chamber)291,295.  
 
However, other studies have suggested that this altered metabolic state was a function of 
energy-restriction rather than weight-reduction294,296. Specifically, caloric restriction was 
accompanied by concurrent reductions in thyroid hormone and leptin levels as well as 
RMR, which returned to initial levels after restoration of energy balance294,296. Caloric 
deprivation with reduced adiposity has been found to increase hunger and reduce energy 
expenditure, apparently to conserve energy and promote weight-regain296.  When leptin 
has been administered in this weight-reduced state, however, RMR and thyroid hormones 
were maintained at pre-weight-loss levels, and this prevented weight-regain296. These 
findings would suggest that measuring RMR in individuals who are not in energy balance, as 
may have been the case for a number of the participants in the present study, could have 
provided a misleading impression that they were ‘hypometabolic’ and prone to weight 
regain294,296. Unfortunately neither leptin nor thyroid hormones were measured in this 
study, and as will be discussed later, the accuracy of the self-report diet intake was 
uncertain.  Furthermore, the Lean group similarly reported a caloric deficit, and relative 
RMR did not exhibit any meaningful relationship with BF%. This evidence would oppose the 
existence of an adaptive down-regulation of RMR. Regardless, it would be speculative to 




It is also possible that the lower relative RMR found in the Overweight group was an 
artefact of potential sources of error in the RMR measurements. Firstly, periodic ethanol 
calibration burns suggested that the Quark RMR equipment was operating properly and 
reproducibly, since the calculated error (coefficient of variation) of total CO2 emitted and 
RER were consistently below 3% throughout the testing period (Appendix I). Despite this, 
the RER values were admittedly low (< 0.70) during a few of the RMR measurements. 
Under typical metabolic conditions with stable respiration, RER typically exists between 
0.70 and 1.00297. These values have conventionally been used to indicate predominant fat 
oxidation and carbohydrate oxidation respectively297. Values below 0.70 may be unusual 
and have been reported to result from inaccurate gas analysers298, but have also been 
found after prolonged fasting298, and in individuals consuming a VCLHF ketogenic diet92. 
Therefore, finding such values in the present study, although not physiologically impossible, 
were surprising given that none of the participants were following a ketogenic diet, and 
they had not fasted for more than 14 hours. Despite the positive calibration results, 
therefore, this raised concern about the precision of the RMR results themselves. 
 
Independently, measuring RMR in itself is prone to measurement error288,291.  Despite the 
good reproducibility from the calibration burns288, reliability measurements were not 
performed on actual participants in this study. Therefore, one may speculate that the small 
between-group difference we identified was smaller than the actual degree of error 
associated with the measurement288. Factors pertaining to the individual participants may 
have also altered the RMR results, including recent physical activity, energy balance, 
menstrual status, sleeping arrangements and food intake288. In the present study, we did 
preclude exercise for 36h prior to the RMR measurement , since oxygen consumption may 
be elevated for up to 24 hours after an exercise bout288. However, we did not account for 
the menstrual status of the participants. RMR is typically lower during the late follicular 
phase compared to the late luteal phase288,291. In hindsight our measurements would have 
been more accurate had we standardised measurement days to a specific period of the 
menstrual cycle288,291. Furthermore, RMR measurements may have been affected by 
varying quality of sleep on the night prior to testing, and the possible sense of anxiety on 
the morning of testing.  Prior studies have found RMR to be lower when assessed during a 
third testing session compared to two earlier habituation trials. Although participants in the 
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present study had visited the laboratory at least once before the RMR measurement, it is 
possible that anxiety artificially elevated some RMR outcomes288. A final source of error 
may have been the energy balance of the participants during testing. Particularly in 
habitually active persons, prior studies have reported a high probability of participants 
consuming excess calories on the day of relative inactivity that precedes visiting the 
laboratory288. Similarly, knowledge of foregoing breakfast the following day may have 
altered the food intake of some participants by encouraging them to over-eat the night 
before testing. This may have had variable effects on different individual RMRs, but would 
typically inflate RMR above actual values288. Therefore, multiple factors may have 
influenced the RMR measurements and to a more or lesser degree for different 
participants.  Taking these concerns into account, it seems reasonable to merely state the 
between-group difference that we observed, but make no assumptions about its 
physiological implications. 
 
4.2.3.) Dietary Intake, Eating Habits and attitudes 
 
Dietary intake as analysed from the 3DR was comparable between Overweight and Lean 
groups, both in terms of absolute caloric value and macronutrient composition. 
Interestingly, both groups attained approximately 43% of their calories as fat and only 33% 
to 36% of calories as carbohydrate. This finding was surprising given that conventional 
nutrition advice, globally299,300 and in South Africa301,302,  has advocated a diet higher in 
carbohydrates (approximately 50% of caloric intake) and lower in total fat (approximately 
20% to 35%, or 30% in South Africa) for optimum cardiovascular health and weight 
maintenance. Reported intakes in both rural and urban South African populations have 
previously been closer to these guidelines (50% to 65% carbohydrate and 20% to 30% 
fat)301,302. High-carbohydrate intake has been more actively emphasised in the endurance 
sport context, in light of the general consensus that saturating muscle glycogen stores prior 
to exercise and maintaining high carbohydrate availability during exercise, are crucial to 
performance193,194.  
 
There has been limited research on the dietary practices of recreational runners. However, 
Butterworth et al. (1994) conducted a 3-day food record in a sample of runners who 
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participated in the Los Angeles Marathon of 1987303. They found that of daily caloric intake, 
52% was derived from carbohydrate and 31% from fat303. Similarly, Nogueira et al. (2005) 
reviewed seven studies that had investigated nutritional strategies in endurance athletes, 
and concluded that the female athletes had obtained 51% to 60% of their energy intake 
from carbohydrate and 26% to 33% from fat304. Mahoney et al. (2016) recently reported 
that a sample of ultra-marathon runners habitually consumed a diet that was slightly lower 
in carbohydrate (45% of daily energy) and higher in fat (36% of energy)305  compared to the 
earlier studies. Interestingly, Nogueira et al. had already stated that the relative 
carbohydrate intake (4.4 to 7.2 g.kg-1.day-1 in females) they found was generally lower than 
recommendations304, while Mahoney et al. alluded to a high proportion of runners having 
self-selected a ‘low-carbohydrate’ diet305.  The carbohydrate intakes found in the present 
study, therefore, were not unique in being lower than convention. However, they were 
both lower than expected, and lower than the cited studies, with a respective intake of 
approximately 2.2 g.kg-1.day-1 and 3.4 g.kg-1.day-1 in the Overweight and Lean groups. 
Conversely, the contribution of fat to energy intake was higher than expected and higher 
than previously reported303–305.  Such findings did not support our hypothesis that weight-
gain in the Overweight group had resulted from excess carbohydrate intake in the context 
of insulin-resistance87,286.  Perhaps, in the context of the relative insulin-sensitivity that we 
found, their moderate-carbohydrate, moderate-fat (‘mixed’) diet contributed to their 
weight gain. Alternatively, similar to Mahoney and colleagues305, in light of recent media 
attention that has espoused the benefits of low-carbohydrate diets for health, weight-loss 
and potentially endurance performance56,190,305, our results may reflect a recently modified 
dietary approach. Unfortunately it was not possible to accurately assess their dietary intake 
during weight-gain, which makes any interpretation speculative. 
 
The three dietary assessment tools used in the present study also showed no evidence of 
increased caloric intake in the Overweight group compared to the Lean group. Both groups 
exhibited a surprisingly low caloric intake (approximately 2000 kcal.day-1), particularly 
considering their high level of physical activity. Although the estimated TEE (Methods 
section) would have had a degree of error from both the determination of RMR and the 
assigned PAL factors, our results suggested that all but two of the twenty participants were 
in caloric deficit. This may have multiple explanations: the runners may have been actually 
under-eating306, they may have (systematically) under-reported their food intake306–308, or it 
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may reflect the inherent error associated with dietary assessment tools206,309,310. Firstly, 
considerable evidence has implicated genuine under-eating in the female endurance 
community relative to respective energy requirements307,311. This may relate to both the 
performance benefits of reduced body weight and the desirability to adhere to the almost 
expected ‘lean’ physique of a female runner306,311. Recent years have in fact seen an 
increase in the prevalence of the Female Athlete Triad279. This refers to a cluster of health 
complications, primarily low bone mineral density and menstrual dysfunction, from 
perpetual under-eating and consequent insufficient energy availability for normal bodily 
functions and exercise training312,313. It has been shown to affect both professional female 
athletes and recreational athletes alike312. It is possible, therefore, that participants, in 
particular the single Lean participant who presented with lower than age-predicted bone 
mineral density, were under-eating. This would be consistent with the runners’ self-
reported restrained eating habits, and consequent attempt to limit caloric intake, fat and 
refined carbohydrate consumption. However, an accurate determination of energy intake 
and energy balance would have required a controlled environment and assessments with 
doubly labelled water. 
 
Self-reported food intake in scientific studies has been consistently, and often considerably, 
lower than both energy expenditure, and actual energy intake measured using doubly 
labelled water306,308,310. A review by Trabulsi et al. (2001), for example, found that studies 
using 3-day food records had an under-reporting bias of between 10% and 32%. The results 
of the present study were comparable to the upper end of this range.  Certain physiological 
and psychological traits have been commonly associated with greater propensity to under-
report food intake, including increased adiposity306, the female gender306, athletic pursuits 
(especially female endurance athletes)307, greater eating restraint306, as well as social 
desirability and body dissatisfaction314. Interestingly, all such traits were present in this 
study population, particularly the Overweight group. An intriguing precedent in this regard 
was set by Edwards et al. (1993) who assessed dietary intake and energy balance in nine 
trained female endurance runners315.  Mean daily energy expenditure (approximately 2990 
kcal) and energy intake (approximately 2037 kcal) and the consequent caloric imbalance 
(32%), were remarkably similar to the findings of the present study. Edwards and 
colleagues also found lower self-reported energy intake in runners with higher body weight 
and a negative body image315. This was in agreement with the Overweight participants 
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having reported low satisfaction with their appearance and body weight. One may 
speculate that such feelings would have in fact been more pronounced in the Overweight 
runners compared to the lean runners assessed by Edwards’ group, and may have 
increased their tendency to under-report.  
 
Estimating habitual dietary intake accurately was predicted to be difficult since this is a 
ubiquitous problem in dietary research206. The analytical approach of the present study was 
consistent with the notion that combining multiple assessment tools (3DR, 24HR and FFQ) 
would improve accuracy206.  On average, the three tools all indicated that the two groups 
consumed comparable diets, both in terms of energy intake and proportional 
macronutrient composition. Although the latter was relatively consistent across tools, total 
caloric intake varied considerably. For example, the FFQ tended to under-report 
significantly at lower energy intake, yet over-report at higher intakes, and the agreement 
between the 3DR and FFQ worsened with increasing energy intake. These findings were in 
agreement with both reports of significant (20% to 30%) day-to-day variation in individual 
caloric intake307, as well as reports of similar systematic bias with increasing energy intake 
from the FFQ316.  The latter would suggest that the FFQ functions better at estimating 
energy intake at a group level rather than on an individual basis316. In regards to the 
macronutrient composition according to the 3DR and FFQ, interestingly, the Overweight 
group appeared to have consumed a greater proportion of energy from fat and less from 
alcohol during the 3DR, whereas the Lean group only exhibited a tendency in this regard. 
Proportional carbohydrate consumption in the Overweight group, in contrast, tended to be 
lower during the 3DR compared to the FFQ.  One may speculate that participants, 
particularly from the Overweight group, had been influenced by the increasing attention 
drawn to low-carbohydrate diets, and may have recently attempted to increase their fat 
intake and reduce their carbohydrate intake.  Furthermore, the reduced alcohol 
consumption may imply a recent attempt by Overweight participants to adopt healthier 
nutritional practices. However, such interpretations should be made with caution, since our 





The 3DR and FFQ have a number of inherent differences and associated limitations. The 
3DR should not be affected by recall bias but it may lend itself to under-reporting and 
deliberate changes to dietary choices206,309. This may result because of the burden 
associated with recording food intake, the anticipation of one’s diet being analysed and the 
consequent desire to be perceived as healthier than normal, or the social stigma attached 
to over-eating 206,309,317. Although assessed over multiple days, the 3DR may also be biased 
by a limited perspective of current as opposed to habitual intake, particularly given the 
typical degree of within-individual variation from day-to-day206,309. This was qualitatively 
expressed by a few participants in the present study. The FFQ, on the other hand, was used 
to obtain a better perspective of usual intake over the previous 6 months, but would have 
been limited by inaccurate recall and the closed-ended nature of the questions and food 
items206. In light of such limitations, Subar et al. (2015) recently summated that FFQs “have 
a finite list of foods or portions with little detail, and [3DRs] are reactive”317.  The authors 
went on to conclude that self-reported energy intake should not be used as measure of 
actual energy intake317. Therefore, our dietary findings likely had a degree of validity, which 
was supported by the similarity of the average results across the three tools. However, it is 
important to acknowledge that the self-report measures of intake were firstly, estimations 
of intake, and secondly, likely to have been different from the participants’ past dietary 
habits. This precluded confident conclusions being made about dietary components that 
may have contributed to prior weight-gain in the Overweight runners.  
 
Aspects of food-related psychology and eating habits were also explored. Interestingly, 
there were no differences in any of the three domains of the Three-Factor-Eating-
Questionnaire (TFEQ). Of the three constructs, cognitive restraint was most strongly 
reported in both groups. This may initially seem surprising to have found in the Overweight 
group. However, literature has suggested that ‘restrained eating’ reflects the tendency to 
consciously restrict food intake rather than relying on physiological cues of hunger and 
satiety318. Thus, restrained eaters do not necessarily consume less calories than 
‘unrestrained eaters’, merely less than they desire318. In fact, restrained eating has been 
positively correlated with increased weight318, potentially because it masks underlying 
appetite dysregulation and predisposes to episodes of overeating38,207,318. Previous findings 
that elevations in adiposity precede changes in cognitive restraint318, suggest that the 
mechanisms may involve impaired leptin-signalling with adipose tissue enlargement38. The 
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Overweight participants, therefore, may have adopted a more restrained approach in 
response to unwanted weight-gain. We found similar restraint in the Lean participants. This 
may be related to their increased self-awareness and their perception of the ‘normal’ body 
image of a female runner307,312. Alternatively, they too reported previous weight 
fluctuations (on average 8.6 kg over the past 10 years) and may have become more 
restrained in the process of trying to lose said weight. Such speculations are consistent with 
indications from both groups that they attempted to limit overall calorie intake, as well as 
fat and refined carbohydrate consumption, both of which have an associated stigma for 
causing weight-gain40,319. It is tempting to speculate that the perception of being restrained 
in one’s eating habits contributed to the Overweight participants qualitatively reporting 
that they were dissatisfied with their diet and wanted to change it.  Although not explored 
in this thesis, such dissatisfaction may have resulted from feelings of depravity of certain 
foods that had previously triggered ‘reward’ or ‘pleasure’ neural pathways83,157. In 
combination with potentially disrupted appetite regulation, this perceived restraint may 
have caused them to feel perpetually hungry and understandably dissatisfied35,38,40. Overall, 
the psychological and neural contributions to eating behaviour and body-weight regulation 
should not be ignored. As alluded to earlier, disruptions in this regard may have 
contributed to the weight-loss struggles of some of our participants. 
 
Interestingly, participants reported that they had infrequently experienced unpleasant 
gastrointestinal symptoms. When they had been experienced, most symptoms were 
associated with the consumption of wheat-containing, carbohydrate-rich foods such as 
bread, pizza and pasta, as well as sugar-sweetened beverages. This was in agreement with 
the recent trend for many people to avoid wheat- and gluten- containing foods in light of 
the associated actual or perceived gastrointestinal distress320,321. Although this appears to 
have had a dietary ‘fad’ component, and the mechanisms remain unclear, wheat allergy 
and non-celiac gluten sensitivity have been increasingly related to irritable bowel 
syndrome, chronic fatigue and auto-immunity320. Some have argued that wheat and gluten 
are harmful to all humans, that the human genome has not had adequate time to adapt to 
grain consumption and that specific components in modern grains are highly 
inflammatory320,322. Therefore, our finding of rare gastrointestinal distress reflected the 
participants’ attempt to limit their consumption of such foods or they had trained their 
guts adequately to handle such foods323.  
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Participants also reported only few incidences of gastrointestinal distress during running. 
These were associated with the energy gels, sweets and beverages that have been 
commonly advised for endurance sport and are provided during most organised 
events193,194. This finding was consistent with reports of gastrointestinal distress, including 
flatulence, diarrhoea and belching, experienced by endurance athletes consuming 
carbohydrate-based solutions323,324. This phenomenon is multifactorial and may be 
influenced by mechanical stress to the abdominal organs and gut ischaemia, as well as the 
osmolality, concentration and type of carbohydrate solution used, and the gut being 
‘untrained’ or ill-adapted to coping with such nutrients during exercise323. Although some 
participants would reportedly avoid carbohydrate-based solutions owing to prior distress 
(replacing them milk, nuts or biltong) the majority of participants continued to consume 
them. Thus, they may have ‘trained’ their guts towards this end. 
 
Both groups in the present study self-reported similar nutritional practices surrounding 
long runs. Interestingly, these did not necessarily reflect the dietary information we derived 
from the diet assessment tools. For example, in contrast to the relatively low consumption  
of carbohydrate during ‘normal living’, 50% of participants practised carbohydrate-loading 
during the days leading up to an event. Furthermore, the most commonly consumed food 
items before, during and after a race were largely carbohydrate-based. Specifically, both 
groups tended to consume pasta or potatoes the night before a race, energy cereal, toast 
and/or bananas on the morning of the race, energy sweets and beverages during the race 
and milkshakes afterwards. Further, many in the Overweight group, but not in the Lean 
group, reported consuming energy drinks the day before and after an event.  These reports 
were  consistent with advice from sporting authorities193, but contrasted the perceived 
restraint of refined carbohydrates from the questionnaire in this study. Together this 
evidence would suggest that the runners were more cognisant of restraining refined 
carbohydrates during normal daily living compared to during exercise. Potential 
explanations may include: the perceived importance of regularly consuming rapidly 
digestible carbohydrates to avoid ‘bonking’325, the exclusive availability of these food 
sources during race events, or believing they would have been able to ‘burn off’ any 
calories by exercising41,56. Regardless, the consequent high sugar intake during runs, 
particularly if performed regularly, may have contributed to weight-gain in some 
participants (particularly those with insulin-resistance)18,41,56,188. Since the participants were 
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not performing long training runs or events at the time of testing, such dietary choices 
were probably not captured during testing.  
 
4.2.4.) Physical Activity and Sedentary Behaviour 
 
Reduced physical activity has been commonly cited as a primary cause of the epidemics of 
obesity and MetS105. As discussed earlier, our results were consistent with the latter, since 
both Overweight and Lean groups exercised regularly and had favourable metabolic 
profiles independent of adiposity. However, our results were in disagreement with the 
notion that exercise protects against weight-gain. Firstly, participants were recruited as 
recreational runners who had taken part in at least half-marathon distance events for the 
previous five years. Given that both groups averaged over 6 recent consecutive years of 
running experience, we are satisfied that we had recruited adequately experienced 
runners. The participants’ running mileage at the time of testing was between 30 km and 
60 km, with a mean in both groups of approximately 43 km. This was in agreement with 
previously reported mileage in recreational male runners during an intense training block in 
preparation for a marathon326, and exceeded the average mileage (in km.week-1 and 
hours.week-1) that was found in female runners preparing for a half-marathon239. In 
addition, Rasmussen et al. (2013) regarded 30 to 60 km as an adequate mileage for 
avoiding injury in preparation for a marathon327.  The reported half-marathon finishing time 
in the Lean group was comparable to that of Swiss female runners competing in the Basel 
half-marathon in 2010 or 2011 (mean 115 minutes), who were similar in terms of age 
(mean 38.3 years), BMI (mean 21.7 kg.m-2) and running experience (mean 6.1 years)239. No 
precedent was found for half-marathon times in Overweight recreational runners, but they 
were significantly slower compared to the Lean group. This may have been expected, 
however, since increased BF% has been found to predict slower half-marathon 
performances239. When taking into account their respective bodyweights, however, the two 
groups were well-matched in terms of running calibre. Therefore, we believe that the 
participants were highly capable half or full marathon runners despite their considerable 
difference in body weight and composition. Such a pedigree of exercise training would have 




Habitual physical activity was assessed using accelerometry and it exceeded 10 000 
steps.day-1 in both groups. This met scientifically-based recommendations that “some 
physical activity is better than none” and that 10 000 steps.day-1 is a reasonable target for 
healthy adults to accrue cardio-metabolic health benefits, reduce morbidity and 
mortality328. Further, the activity of both groups was comparable to the “active” category 
found by Tudor-Locke et al. (2010) in normal-weight, overweight and obese US women 
(10 000 – 12 499 steps.day-1)329. In addition, it has been emphasised that a portion 
(approximately 3000) of the recommended 10 000 steps.day-1, be performed at a 
moderate-to-vigorous intensity  (at least 100 steps.minute-1 in bouts of at least 10 
minutes)328. Physical activity guidelines recommend accumulating 150 minutes of MVPA 
per week106. Given that we investigated active middle-aged women, it was not surprising 
that both groups exceeded recommendations considerably; specifically participants 
averaged approximately 90 minutes.day-1 of MVPA. Interestingly, MVPA represented a 
surprisingly insignificant portion of wear-time (Overweight, 11.1% and Lean, 13.5%). This 
was comparable to the MVPA of US adults in activity ‘Class 2’ (Class 1 to 6 represented the 
‘least active’ to ‘most active’ respectively) from the analysis of 2003-2006 NHANES data 
using the same cut-points as the present study330. This finding may have been due to the 
participants having performed less activity during the testing period compared to their 
habitual activity levels. Thirteen of the twenty participants indicated this qualitatively in 
their exercise logbooks. Alternatively, the MVPA we identified was lower than actual MVPA 
owing to the accelerometer being unable to register non-ambulatory activities217, including 
swimming and cycling, which were performed by a significant portion of both groups. 
Although overall step counts were adjusted in this regard, it would have been imprecise to 
adjust the times spent in various activity domains.  It is further plausible that apart from 
their designated ‘exercise session’ on a given day, the participants may have been largely 
sedentary and performed minimal other MVPA331.   
 
The proportion of wear-time spent in different physical activity domains (sedentary, light, 
moderate and vigorous) was highly comparable between groups. A vast majority of time 
was spent in sedentary behaviour (Overweight, 74.2% and Lean, 72.0%), and very little time 
was devoted to LIPA (Overweight, 14.0% and Lean, 14.6%). The former was comparable to 
the sedentary behaviour identified in the women of activity ‘Class 2’ NHANES (referred to 
earlier)330. This would suggest that the participants in the present study were relatively 
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inactive. However, it has been acknowledged that accelerometer-based estimates of 
physical activity may not be entirely accurate332,333. Further, Matthews cut-points have 
tended to over-estimate moderate physical activity and under-estimate both light and 
vigorous physical activity215. Although this would be unable to explain the relatively low 
proportion of time in MVPA.330, it may have contributed to the high proportion of 
sedentary behaviour and little LIPA in the present study215. On the other hand, this may 
have actually reflected the activity pattern of our participants. Whitfield et al. (2013) 
recently described a cohort of 218 recreational half-marathon and marathon runners 
(approximately 75% female) as being both “highly active and highly sedentary”331.  Their 
self-reported training (6.5 hours.week-1 including running and cross-training) was 
comparable to the present study331. Interestingly, they spent a considerable portion of 
waking hours sitting (approximately 10 hours on workdays and 8 hours on non-work days), 
during which they were working, reading or studying331. This was also comparable to the 
average sedentary times measured in the present study (Overweight, 674 minutes.day-1 
and Lean, 634 minutes.day-1). The average activity profiles of our groups also indicated 
relatively low levels of activity other than activity ‘spikes’ in the early morning and evening, 
which coincided with their exercise sessions. Together, these findings would suggest that 
both Overweight and Lean groups had largely sedentary lifestyles independent of their 
engagement in leisure-time physical activity and meeting physical activity 
recommendations108. 
 
Multiple factors may have contributed to this phenomenon. This may have included a 
predominantly sedentary (desk-based) work environment, motorised transport, screen-
based entertainment, or perceived fatigue amongst recreational runners outside of their 
training sessions331,334. Indeed, we observed lower activity during weekdays compared to 
weekend days. This may have reflected their sedentary employment having limited the 
available time participants had to be physically active. Furthermore, it seems reasonable to 
speculate that a morning exercise session would have increased perceived fatigue, while a 
scheduled training session in the evening may have motivated against other activity during 
the day. The consequence would be that runners prioritised and largely limited their daily 
MVPA to these brief training sessions. Ultimately, despite achieving adequate MVPA, it 
appears that the runners we studied simultaneously engaged in a significant amount of 
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sedentary behaviour. This would extend the “active couch potato” phenomenon that was 
described by Owen et al. (2010)134, to a particularly active population. 
 
There has been evidence to suggest that such sedentary behaviour increases cardio-
metabolic risk, independent of high MVPA131,133,134,137. ‘Too much sitting’ has been 
increasingly distinguished from ‘too little exercise’134, and although the mechanisms remain 
unclear, sedentary behaviour in itself has been found to be an independent risk factor for 
all-cause mortality132,335, the MetS133, T2D336,337 and CVD131,337. In a prospective cohort 
design, Patel et al. (2010) found a dose-response positive association between sitting time 
and all-cause mortality within five different levels of physical activity, even in individuals 
performing 2 hours of MVPA per day131,335. Although participants in the latter study were 
aged between 50 and 74 years, this evidence suggests that maintaining regular physical 
activity may not necessarily offset the detrimental health effects of prolonged sedentary 
behaviour131.  On average, we did not find this in the present study. This may have been 
due to the younger age of our participants, and perhaps metabolic abnormalities 
underpinned by sedentary behaviour and other factors (e.g. sugar intake) may develop 
with age179,180. Interestingly, when compared to the literature, both the number of 
sedentary ‘bouts’ and the accumulated time in sedentary bouts per day, were relatively low 
in both groups of the present study338,339. For example, Ekblom-Bak et al. (2015) recently 
reported an average sedentary time of 9.3 hours.day-1 in middle-aged Swedish women, of 
which 3.2 hours were accumulated in prolonged sedentary bouts339. Our participants spent 
more than 10 hours sedentary, yet Overweight and Lean groups accumulated only 89 and 
60 minutes.day-1 respectively in prolonged sedentary bouts.  However, in support of the 
cited concern surrounding prolonged sedentary bouts115,117, mean sedentary bouts per day 
was significantly correlated with higher BF% in the present study. Overall, this evidence 
would suggest that our participants interrupted their sedentary behaviour (e.g. sitting) 
frequently, and were rarely inactive for a prolonged period of time. Although research in is 
still emerging, breaking up sedentary time in this manner has been associated with more 
favourable cardio-metabolic health outcomes131,338,340, and may be one mechanism by 
which the high sedentariness in the present study was not accompanied by ill metabolic 
health. Participants who tended to be sedentary for prolonged periods more often, may 




On the other hand, there has been evidence down-playing the importance of sedentary 
behaviour itself, and that has instead implicated MVPA and cardiorespiratory fitness as the 
primary  determinants of cardio-metabolic health135,136.  For example, van der Velde et al. 
(2015) found significant associations between both MVPA and fitness with more favourable 
waist circumference, systolic blood pressure, CRP, HDL-C and TG, after adjustment for one 
another and sedentary behaviour135. In contrast sedentary behaviour did not exhibit 
independent associations when adjusted for MVPA and fitness135. This gives further 
credence to the interpretation that independent of their significant sedentary behaviour, 
maintaining regular MVPA and fitness would have promoted metabolic health in 
Overweight and Lean participants alike. Interestingly, a few studies have found that 
increased adiposity or longitudinal weight-gain predicted future sedentary behaviour and 
inactivity, independent of baseline activity and weight122,341.  This would raise the possibility 
that the Overweight participants, failing meaningful weight-loss, may be at risk of 
becoming less physically active in the forthcoming years, which would increase their risk of 
insulin-resistance and illness283. Instead of being the result of high levels of physical 
activity56,117, therefore, maintaining a healthy body weight, appears to be integral to future 
activity, health and longevity122,341. 
 
4.2.5.) Stress and Sleep 
 
This study found no differences between Overweight and Lean groups in either subjective 
or objective measures of sleep duration and sleep quality. In contrast to prior literature 
that reported positive associations between short sleep duration and both weight and 
adiposity gain146–148,342, it appears that short sleep did not contribute significantly to weight-
gain in the Overweight group. The objective Actiwatch recordings indicated that no 
participants had pathological ‘short sleep’ (less than 6 hours of sleep per night) as defined 
in the cited studies138,146–148,342. Despite considerable inter-individual variation, both groups 
averaged approximately 7 hours of sleep per night, which was near to the recommended 
sleep duration (7 to 8 hours.night-1) for maintaining a healthy weight and metabolism141. 
Short sleep duration has also been associated with impaired glucose control140,149, 
increased inflammation and endocrine disruptions139, that collectively appear to increase 
risk for MetS343 and T2D344. Therefore, the reasonable sleep duration of both groups would 




Indices of sleep quality, in particular onset latency (time taken to fall asleep) and sleep 
efficiency (proportion of hours slept to total hours in bed) have also been associated with 
obesity345 and metabolic disturbances346. This may not be surprising given that sleep and 
specific stages of sleep (i.e. sleep architecture) mediate many restorative processes that 
are integral to bodily health138–140.  The objective parameters of sleep quality were highly 
impressive in both groups: onset latency was below 8 minutes, and sleep efficiency was 
over 90%.  These were both consistent with acceptable research-based standards for sleep 
onset latency (5 to 20 minutes) and sleep efficiency (≥ 85%)211. They were also superior to 
the results generally reported in population-based cohorts347, adults348 and young-adult 
studies349. This would suggest that the Overweight and Lean participants had good sleep 
quality during testing.  
 
Prior literature would suggest that such sleep hygiene was partly attributable to their high 
levels of MVPA350–352. Although the relationship between exercise and sleep is bi-
directional, multiple studies have shown positive associations between greater physical 
activity and sleep quality352. Furthermore, exercise interventions have consistently 
conferred significant improvements in sleep duration and quality, concomitant with 
positive psychological changes350,351,353. The mechanisms appear to involve physiological 
changes that benefit homeostatic sleep regulation, enhanced circadian rhythmicity and 
improved psychological functioning352. Regardless, if representative of their prior and 
habitual sleeping habits, the observed sleep quality would have further benefitted 
metabolic health140,149.  
 
In contrast to our objectively-measured findings, our participants perceived their sleep in a 
less positive manner. According to the results of the Pittsburgh Sleep Quality Index (PSQI) 
questionnaire, both groups on average perceived themselves as “poor sleepers”210. One 
should be careful, however, not to oversimplify this finding.  Both groups were close to the 
threshold (≥ 5) used to separate ‘good’ from ‘poor’ sleepers, and 50% of participants in 
both groups were classified as ‘good’ or ‘poor’ sleepers. Nonetheless, the disagreement 
between Actiwatch and PSQI data was actually less pronounced than what has been 
observed previously354–356. The cited studies attributed the discrepancy, partly to the 
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temporal difference between the period of actigraphy and the PSQI reference period 
(previous month), but primarily to the inherent properties of the objective and subjective 
measures that effectively assess different aspects of sleep355. The PSQI is self-perceptive 
and appears to associate significantly with subjective mood state, cognitive and 
psychological functioning at the time of testing354,355. This has caused PSQI scores to diverge 
from objective reality354,355. For example, Landry et al. (2015) found very weak associations 
between PSQI scores and objective measures of sleep quality (duration, efficiency and 
disturbances), and the distinction between ‘good’ and ‘poor’ sleepers had no predictive 
value in determining the actigraph results355. Interestingly, although the PSQI was not 
associated with objective sleep duration in the present study, it did exhibit a significant and 
negative association with objective sleep efficiency. This would suggest that the self-
perceived worse sleepers had lower sleep efficiency. Our objective and subjective findings, 
therefore, showed greater levels of agreement compared to the cited studies. This may 
point to a more favourable psychological state in our participants, since the cited research 
had largely been conducted in elderly populations susceptible to cognitive and memory 
decline354–356. Overall, objective sleep duration and quality were on average impressive and 
comparable between groups, and this suggests that sleep pathology did not contribute to 
increased adiposity in the Overweight group. 
 
In a similar manner, our participants generally reported a ‘reduced’ to ‘average’ level of 
recent stress on the Perceived Stress Questionnaire (PSQ), and the results were highly 
comparable between Overweight and Lean groups. This contrasted the reported 
association between stress and increased adiposity152, and may have multiple explanations. 
Firstly, the PSQ provided a limited view of recent (past month) stress levels226, as opposed 
to lifetime stressors or stressful life events that may have influenced body weight and 
adiposity in years prior to this study154. Furthermore, higher levels of physical activity and 
exercise interventions have been associated with reduced stress levels357, improved mood 
and quality of life358. This may be partly mediated by the anti-inflammatory effect of regular 
exercise, particularly MVPA16,155,358. In agreement, CRP levels were low in both groups and 
were significantly positively correlated with the PSQ scores. Together, this evidence gives 




We observed a strong correlation between increased perceived stress (PSQ) and worse 
perceived sleep (PSQI). In other words, participants who self-reported higher levels of 
recent stress also perceived their recent sleep as less satisfying.  This reflected previous 
literature that highlighted the close relationship between short sleep duration and sleep 
disturbance with both psychosocial (e.g. PSQ) and physiological (e.g. salivary cortisol, 
serum norepinephrine) indices of stress360. Specifically, heightened physiological stress has 
been shown to precede shorter sleep duration and sleep disturbance361, as well as irregular 
sleep duration from night to night360.  Subjective stress indices, on the other hand, have 
tended to reflect perceived sleep indices closely but not necessarily objective sleep362,363. 
The cited studies postulated that this reflects a tendency towards negative emotional 
responses brought about by enduring distress363. This may bias self-reports of personal 
well-being to be either generally positive or negative363, which in the present study would 
have been enhanced by the temporal overlap of the PSQ and PSQI indices.  Ultimately,  the 
reduced to average levels of stress, good quality sleep, in combination with regular MVPA, 
represented healthy lifestyle habits that would have played a significant role in maintaining 




This study had two primary limitations. Firstly, the sample size was smaller than anticipated 
because we had difficulty recruiting eligible participants. We had intended to test twenty 
Overweight and twenty Lean participants, but the difficulty experienced meant that we 
could only test ten participants per group.  We particularly struggled to recruit the more 
overweight or obese recreational runners that had been reported anecdotally and whom 
we had previously witnessed at organised events. However, many seemingly overweight / 
obese runners we did approach had only recently taken up running and were therefore not 
eligible for this study. This would have contributed to our finding that the Overweight and 
Lean groups were less distinct in terms of adiposity than we had expected. Further, it is 
tempting to speculate that runners who are more overweight or obese (for example, BMI ≥ 
30 kg.m-2) would have been less metabolically healthy than both the Overweight and Lean 
runners in our study. Alternatively, the obese ‘experienced’ runners may be a rarer 
phenotype than we had predicted, or obese runners who became metabolically ill have 
tended to stop running. Nevertheless, our small sample size may have limited the statistical 
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power of the between-group comparisons, especially given the significant within-group 
variation. This would preclude our findings from being generalizable to all overweight 
athletic individuals. 
 
Owing to the cross-sectional nature of our study, the second limitation was that we were 
unable to identify causal factors explaining the Overweight participants’ weight-gain.  Given 
this was a pilot study, we aimed to identify potential factors associated with greater 
adiposity, with the intention to identify causal relationships in a subsequent intervention. 
Although we measured a variety of potentially contributory lifestyle factors (physical 
activity, diet, sleep and stress), we did not find meaningful associations. However, our 
findings may not have necessarily reflected the lifestyle habits of the Overweight 
participants during weight-gain. Specifically, the habits that we observed may have been 
healthier than what they had previously practised. Although this may not have influenced 
the between-group comparison of metabolic health parameters, it would have altered the 
potential explanatory variables that we explored. It was clear during testing that although 
not currently losing weight, the participants were conscious of their elevated adiposity and 
had probably altered certain lifestyle habits in an effort to lose weight. Qualitatively, the 
Overweight participants appeared to be interested and motivated to learn more about 
their own physiology and possible ways in which to improve their health. There may have, 
therefore, been a selection bias towards individuals who were more health conscious than 
other overweight runners. 
 
As have been discussed in more detail above, there were other potential causes of bias or 
error in this study. Briefly, the self-report dietary intake may have differed from actual 
intake; the accelerometers were unable to register MVPA from cycling and swimming; 
physical activity domain cut-points may have under- or over- estimated times spent in 
different domains; low RERs during a few RMR measurements raised concern about the 
RMR validity; and we did not strictly control for some potential confounders to RMR and 
glucose tolerance tests (including menstrual status, previous day’s diet and test anxiety). 
For example, evidence suggests that increased presence of progesterone and estrogen 
during the luteal phase of the menstrual cycle is concomitant with lower insulin-sensitivity 
compared to the follicular phase364. Further, testing was not standardised in relation to 
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participants’ training and event schedules, which means that the lifestyle data did not 
necessarily reflect participants at the same stage of training. Finally, the setting of the 
research laboratory and knowledge of having one’s lifestyle analysed, may have influenced 




We investigated the metabolic and lifestyle characteristics of Overweight female runners in 
comparison to Lean runners who were well-matched for age, running experience and 
running calibre. As far the author of this thesis is aware, this is the first time that the 
Overweight recreational runner phenotype has been studied, particularly in comparison to 
comparable Lean counterparts. We hypothesised that the elevated weight of the 
Overweight runners would be explained by underlying insulin-resistance and potentially 
present with related abnormalities, including hypertension, systemic inflammation and 
dyslipidaemia. Furthermore, we anticipated these conditions would have been promoted 
or aggravated by certain lifestyle differences between groups, in particular a diet too high 
in carbohydrate for the expected degree of insulin-resistance. 
 
While the Overweight group did exhibit greater adiposity than the Lean group, there were 
no clinically meaningful differences in either the metabolic or lifestyle characteristics of the 
two groups. Although inflammation and systolic blood pressure were higher in the 
Overweight group, both parameters were within the healthy ranges. However, most 
outcome measures exhibited considerable inter-individual variation within both groups, 
and our results suggest that the mechanisms of weight-gain within the Overweight group 
may have differed between individuals. Two Overweight participants were insulin-resistant 
and pre-hypertensive, and this have may be indicative of increased metabolic risk. There 
was also evidence that relative insulin-resistance contributed to increased adiposity across 
both groups. However, it is uncertain what primarily caused the remaining Overweight 
participants to gain weight. It is tempting to speculate that dysregulated appetite control 
played a key role.  The normal metabolic health of the Overweight runners probably 
resulted from healthy lifestyle behaviours, most importantly their history of consistent 
exercise training and consequent cardiorespiratory fitness, but also apparently adequate 
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and efficient sleep, infrequent prolonged sedentary bouts and reduced to average levels of 
stress.  We conclude, therefore, that the middle-aged Overweight female runners we 
investigated were not metabolically at risk compared to matched Lean runners, and that 
their RMR and lifestyle attributes were not meaningfully dissimilar to their Lean 
counterparts.  
 
4.2.8.) Future research considerations 
 
Despite not having found the expected differences between Overweight and Lean runners, 
the ‘overweight athlete’ remains an intriguing phenotype to explore. Future studies may 
benefit from a more thorough recruitment process to ideally include overweight runners 
with greater adiposity and secure a larger between-group distinction. For example, it is 
recommended that alternative equations be used to estimate BF%. Whereas the Durnin 
and Womersley formula that was used in the present study only incorporated upper-body 
skinfolds (bicep, tricep, iliac crest and subscapular)199, it has been found that including 
lower-limb skinfolds (thigh and calf) improves accuracy238,365. In hindsight, utilising these 
equations may have provided greater disparity in adiposity between Overweight and Lean 
groups. Alternatively assuming available funds, researchers would ideally perform DXA 
scans during the screening process to ensure that respondents fall safely within 
predetermined BF% criteria.  
 
Recruitment criteria may also need to be modified to secure a larger and more 
generalisable sample of overweight athletes. It may have been that the more overweight 
and obese runners that had been reported anecdotally, had not been running for at least 5 
years. Future studies may need to relax this criterion to include individuals who adopted 
running more recently, yet who have continued to struggle with weight-loss. Further, 
unpublished data from the 2014 Two Oceans Ultra and Half-Marathons suggested that 
there was a greater prevalence of overweight and obesity in male (52%) as compared to 
female (26%) runners. Researchers may hence experience less difficulty should they decide 
to recruit overweight male runners. Additionally, prior evidence would suggest that males 
tend to exhibit greater insulin-resistance compared to females366. Therefore, overweight 
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male runners may provide greater insight into the role of underlying insulin-resistance in 
promoting adiposity and metabolic illness in spite of exercise.  
 
Future studies should also address admitted methodological limitations from the present 
study. Firstly, it is recommended that the testing period be standardised across 
participants. This is primarily because lifestyle measurements (diet, sleep and physical 
activity) may be influenced by the timing of testing in relation to the participants’ 
respective training or race schedules, as well as changes in seasons or the weather. 
Metabolic tests in females should also ideally be standardised to a certain period of the 
menstrual cycle, since this has been reported to influence both glucose tolerance364 and 
RMR367. An interesting finding in the present study was that the qualitative eating habits 
during long runs or races, were rather distinct from (and less healthy than) the results of 
the diet assessment tools. Future studies may, therefore, benefit from exploring exercise-
related dietary intake and its implications for weight-loss. 
 
Additional factors need to be explored more thoroughly for potentially influencing 
metabolic health in overweight recreational athletes. The Overweight group of the present 
study shared similarities with the well-documented MHO phenotype170. Although our 
participants shared the high level of cardiorespiratory fitness reported in MHO persons178, 
we did not assess other common traits. It would be intriguing to explore adipose tissue 
distribution and morphology (using magnetic resonance imaging) and liver fat 
accumulation in Overweight runners compared to matched unhealthy-overweight 
persons169. Furthermore, we experienced difficulty separating the contrasting effects of 
increased body fatness and regular exercise (MVPA) on metabolic health. One may 
speculate that having had two additional comparative groups, lean-sedentary and 
overweight-sedentary, would have provided valuable insight into the complex interplay 
between these opposing factors.  As speculated above, this study did not explore appetite-
regulatory systems. This may have been performed, for example, by assessing gut-hormone 
secretion, leptin-signalling or neurological imaging. Given the cited literature that has 
implicated impaired appetite-control in promoting over-nutrition33,36,37,40, it is 
recommended that future studies explore the physiology and psychology of appetite-
regulation in the context of both weight-gain and dietary factors in recreational athletes. 
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Finally, in line with the original intention of this study, it seems reasonable to recommend 
randomised intervention trials in overweight endurance athletes. Insulin-resistance and 
appetite disruptions appear to have been the most plausible explanations for prior weight-
gain in the Overweight participants. However, the former only applied to two participants 
and the latter was speculative. Nonetheless, both abnormalities have been shown to be 
largely driven and aggravated by dietary factors, particularly refined high-sugar, high fat 
foods18,37. It would be intriguing to explore the weight and metabolic response to dietary 
interventions that target the mitigation of these disturbances. Indeed, this pilot study was 
intended to inform a subsequent trial where we would stratify overweight athletes into 
insulin-resistant and insulin-sensitive groups and randomise them to either a VLCHF diet 
(aimed at minimising insulin secretion)87 or a low-calorie, mixed macronutrient diet that 
would be minimally processed but rather based on natural (whole)-foods90,173,368. However, 
we did not find the level of insulin-resistance or ill metabolic health we expected. 
Therefore, to perform such a trial would require a slower, more overweight cohort, more 
likely to have metabolic disturbances, or it should be directed more to weight-loss and 
performance outcomes. Ultimately, the overweight-athlete paradox represents a unique 
opportunity to study the interplay between metabolic predisposition and lifestyle factors 
(especially diet and exercise) in relation to obesity and metabolic disease. The field is wide 
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AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire (PAR-Q) 
 
Participant Code:    Date and Time:    
 
Assess your health needs by marking all true statements. 
 
History:  You have had:      
__ a heart attack 
__ heart surgery       
__ cardiac catheterization 
__ coronary angioplasty (PTCA) 
__ pacemaker/implantable cardiac defibrillator/rhythm disturbance 
__ heart valve disease 
__ heart failure 
__ heart transplantation 
__ congenital heart disease 
 
Symptoms: 
__ You experienced chest discomfort with exertion. 
__ You experience unreasonable breathlessness. 
__ You experience dizziness, fainting, blackouts. 
__ You take heart medications. 
 
Other health issues: 
__ You have diabetes. 
__ You have lung disease. 
__ You have musculoskeletal problems. 
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__ You have concerns about the safety of exercise. 
__ You take prescription medication(s) 
 
If you marked any of the statements in this section, consult your healthcare provider 
before engaging in exercise.  
 
Cardiovascular Risk Factors: 
__ You are a man older than 45 years or a woman older than 55 years 
__ You smoke. 
__ Your blood pressure is > 140/90. 
__ You don't know your blood pressure. 
__ You take blood pressure medication. 
__ You have high cholesterol. 
__ You have a close blood relative who had a heart attack before age 55 (father or brother) 
or age 65 (mother or sister). 
__ You are physically inactive (i.e.: you get < 30 minutes of physical activity on at least 3 
days per week). 
__ You are > 9kg overweight. 
 
If you marked 2 or more of the statements in this section, consult your healthcare 
provider before engaging in exercise.  
__ None of the above is true. 
 












Participant Code:    Date and Time     
SECTION 1: PERSONAL INFORMATION 
Age:          yrs         Height:       cm   Weight:   kg 
 Are you pregnant? Yes  No Maybe 
SECTION 2: HEALTH 
1. Have you been diagnosed with Type 1 or Type 2 diabetes?  
 Yes            No 
2. Have you been diagnosed with other metabolic conditions (including thyroid disorders, 
chronic kidney disease, fatty-liver disease)? 
     Yes           No 
     Please specify:          
3. Have you suffered a coronary event (heart attack) and/or stroke (including a Transient 
Ischaemic Attack or Cerebrovascular event)? 
     Yes            No  
4. Do you currently have a pacemaker? 
Yes            No  
5. In the past 3 months have you taken chronic medication for any of the following? 
 High Blood Cholesterol   Yes            No  
 Diabetes (insulin therapy)    Yes            No  
 High Blood Pressure                Yes            No  
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 High Blood Sugar                        Yes            No  
 Hormonal/Thyroid problems     Yes            No  
 Other                 Yes            No Please specify     
6. Have you had an injury in the past month that prevented you from running? 
Yes            No  
If YES, please provide details:       
SECTION 3: DIET 
1. Have you started a new eating plan or significantly changed the type of foods that you 
typically eat, within the past 6 months?  
    Yes            No     
If YES, please describe what changes you have made:      
           
If YES, what were the reasons that you changed your diet:     
           
SECTION 4: WEIGHT CHANGE 
1. Within the past 3 months, has your body weight changed by more than 5% at any 
stage? For example, if you weigh ± 80 kg has your weight changed by 4kg (e.g. 78 to 82 
kg) within the last 3 months? 
 Yes             No   
If YES, what was your lowest and highest weight that you measured during this 
time?    
Lowest     Highest    
SECTION 5: RUNNING EXPERIENCE AND OTHER EXERCISE 
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1. For the past 6 months, have you run at least 3 times per week for at least 75% of the 
time?  
 Yes             No  
2. Have you completed at least 1 marathon and/or 2 half-marathons and/or one 30km 
trail run per year, for the past 5 years?  
       Yes             No           
If YES, where these: all races /all training runs / mixture of training and racing? 
(circle) 
If NO, but you have been close to completing these runs, please describe your 
distance running experience over the past 5 years. 
           
           
3. What were your fastest race times for a half, full and/or ultra -marathon that you ran 
within the past 12 months. Please indicate whether these were road or trail runs and 
the distance for other runs.* 
21.1 km time    (Road/Trail)    Race name/date:  
   
42.2 km time   (Road/Trail) Race name/date:  
   
Other  >21.1km   (Road/Trail)   Race dist/name/date   
4. What were your fastest race times that you have ever run for a half, full and/or ultra-
marathon. Please indicate whether these were road or trail runs and the distance for 
other runs.* 
21.1 km time    (Road/Trail) Race name/date:   
42.2 km time   (Road/Trail) Race name/date:   
Other >21.1km   (Road/Trail)   Race dist/name/date   
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5. Have you completed a half-marathon or longer race/training run within the past 6 
months? 
 Yes             No   If YES, Race or Training run. 
6. In total during your lifetime, how many years have you run for on a regular basis (at 
least 3 times per week for at least 75% of the time)? In other words, add the number of 
years that you have run regularly, excluding breaks of more than 3 months.* 
     
7. If you have taken a long break from running during your lifetime, then working back 
from present, how many years have you run for regularly (at least 3 times per week for 
at least 75% of the time) since taking a break for longer than 3 months? * 
     
8. Over the past 3 months, on average, how many hours have you run per week? * 
     
9. Over the past 3 months, on average, how many kms have you run per week? * 
      
10. Is running your primary form of exercise? 
 Yes             No  
11. Is there any other form of exercise that makes up more than one third of your 
exercise? 
 Yes             No    
If YES, what are these activities and how many hours do you spend on these 
activities per week?          
           




Detailed participant questionnaire 
 
Participant Code:    Date and Time       
 
Thank you for volunteering for this study. This questionnaire asks about your family health 
history, your personal health, your perceptions of your health, appearance and quality of 
life, as well as your dietary intake and running / training routines. 
Please answer all questions honestly. Where applicable, please circle the number which 
you think applies to you. If you are unsure about which response to give, please choose the 
one that appears most appropriate. Your results will be kept strictly confidential and will 
be stored in coded form. Only the official investigators of this study will be able to identify 
you.  
SECTION 1: PERSONAL DETAILS 
1. Ethnicity:   (a) Black      (b) White       (c) Mixed  (d) Indian      (e) Other   
2. Usual monthly income (before tax):   (a) R0 – R9 999     (b) R10 000 - R24 999      (c) more 
than R25 000 
3. Occupation (or degree/course if studying):         
4. Highest level of education completed:   
(a) primary school  (b) high school    (b) undergraduate tertiary (c) postgraduate tertiary 
5. How many people currently live in your household?       
6. How many rooms in total are there in your household? (Count an open plan area as the 




SECTION 2: FAMILY HEALTH HISTORY 
1. Has your mother or sister had heart disease (e.g. Heart attack / myocardial infarction, 
angina, heart      failure, arrhythmia)? 
before the age of 65?       Yes           No   
after the age of 65?          Yes           No   
2. Has your father or brother had heart disease (as above)? 
before the age of 55?       Yes             No  
after the age of 55?          Yes             No  
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3. As far as you are aware, have any of your close family members (i.e. brothers, sisters, 







BMI ≥ 30 kg.m-2 
Waist Circumference ≥ 94 cm 
  
Pre-diabetes      
(Impaired Fasting 
Glucose or Tolerance) 
Fasting blood glucose ≥ 5.6 mM 
2-hour OGTT* glucose 7.8 – 11.0 mM 
  
Type 2 diabetes 
Fasting blood glucose ≥ 7.0 mM 
2-hour OGTT* glucose ≥  11.1 mM 
  
High Blood Pressure 
Systolic ≥ 130 mmHg or  
Diastolic ≥ 85 mmHg 
  
High Blood  
Cholesterol 
Total cholesterol ≥ 5.2 mM 
  
*OGTT: Oral Glucose Tolerance Test (Blood glucose concentration is measured 2 hours 
after 75 grams of glucose is consumed) 
SECTION 3: PERSONAL HEALTH 
1. Do you have or have you ever had any of the following conditions? 
Glandular Fever     Yes         No   
Lung Disease      Yes         No 
Gout                                                                  Yes         No 
Epilepsy     Yes         No 
Celiac Disease     Yes         No 
Gluten sensitivity    Yes         No 
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Depression / Anxiety    Yes         No  
Asthma      Yes         No 
Chronic Obstructive Pulmonary Disorder Yes         No 
Heart murmur     Yes         No 
Arthritis / Osteoporosis    Yes         No 
Chrone’s Disease    Yes         No 
Drug or Alcohol Problems   Yes         No 
Prostrate cancer    Yes         No 
Other cancer     Yes         No  Specify   
Other condition     Yes         No  Specify   
2. Have you ever been diagnosed by a health care professional with any of the following? 
 High Blood Cholesterol                 Yes               No  
 High Blood Pressure              Yes               No  
 High Blood Sugar                            Yes               No  
 Abdominal Obesity                        Yes               No   
3. Are you currently seeing a practitioner/doctor for any injuries and /or illnesses? 
     Yes             No           
     If YES, please specify:         
SECTION 4: SMOKING 
1. Do you currently smoke any tobacco products, such as cigarettes, cigars, or pipes?  
     Yes            No                   If YES, for how long?          
If NO, have you smoked any tobacco products in the past?  
     Yes            No                   If YES, for how long?         
                                              When did you stop smoking?        
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If Yes to either of the above, how many cigarettes do/did you smoke per day? 
      (1) 1 – 4 / day   (2) 5 – 9 / day      (3) 10 – 19 / day    (4) 20 – 29 / day (5) ≥ 30 / day 
SECTION 5: ALCOHOL INTAKE 
Note:  1 “alcoholic drink” below is equal to 1 glass of wine OR 1 340ml beer OR 1 tot of 
spirits.  
1. Thinking back over the past 6 months, on average how many alcoholic drinks per week 
did you usually drink?  
         (1) 0 units  (2) 1 – 2 units  (3) 3 – 6 units  (4) 7 – 10 units  (5) 11 – 14 units (6) > 14 units 
2. Thinking back over the past 10 years, on average how many alcohol drinks per week did 
you usually drink? 
         (1) 0 units (2) 1 – 2 units  (3) 3 – 6 units   (4) 7 – 10 units  (5) 11 – 14 units (6) > 14 units 
 
SECTION 6: SUBJECTIVE HEALTH 
These questions relate to your experiences and feelings over the past 3 months. Please 
read each question and circle the number on the scale that gives the best answer for you.  
1. In general, would you say your health is: 
(1) Very poor (2) Poor    (3) Fair  (4) Good       (5) Very good 
2. How often do you have enough energy for everyday life? 
(1) None of the time  (2) A little of the time   (3) A good bit of the time 
  
(4) Most of the time     (5) All of the time 
3. Would you say your sleep quality is:  




4. In total, how many hours do you typically sleep (excluding lying awake) per day/night? 
  (1) ≤ 5 hours    (2) 5 - 6 hours    (3) 6 - 7 hours    (4) 7 - 8 hours  (5) > 8 hours   
5. How much stress have you felt over the past month? 
(1) Very little (2) Fair amount   (3) Large amount   (4) Extreme amount        
6. How satisfied are you with your bodily appearance? 
  (1) Very dissatisfied  (2) Dissatisfied  (3) Neither satisfied nor dissatisfied    
  (4) Satisfied    (5) Very satisfied 
7. How satisfied are you with your current weight?  
(1) Very dissatisfied  (2) Dissatisfied  (3) Neither satisfied nor dissatisfied   
(4) Satisfied    (5) Very satisfied 
8. Would you like to lose weight? 
Yes             No 
If Yes, how many kg would you like to lose?          
If Yes, how important is it to you to lose the weight? 
(1) Not at all   (2) Kind of important  (3) Important  (4) It is a priority 
If Yes, how motivated are you to lose the weight? 
(1) Not at all       (2) Kind of motivated  (3) Highly     (4) Very highly 
9. Have you previously tried (e.g. by exercise or diet) to lose weight? 
      Yes            No 
       If Yes, how much weight (kg) did you manage to lose?          
       If Yes, to what extent were you successful in achieving your target weight loss? 
         (1) Not at all   (2) To some extent    (3) About half-way   (4) Nearly fully   (5) Completely       
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10. In the past, how difficult/easy has it been to maintain a stable weight that you are 
satisfied with? 
(1) Very difficult        (2) Difficult        (3) Relatively Easy        (4) Easy        (5) No problem 
11. In the past 10 years, have you experienced major weight fluctuations (frequent ’ups’ 
and ‘downs’ of more than 5% body weight)? For example, repeatedly jumping between 
80 and 84 kg. 
         Yes              No     
12. Please indicate your highest and lowest weight in the past 10 years? 
         Lowest weight (kg)                  Highest weight (kg)          
SECTION 7: USUAL DIET 
This section refers to your general diet and section 8 refers specifically to your running 
related diet. 
1. Are you currently following, or have you followed in the past, any of these particular 
types of diets or eating patterns? If so, please indicate when and for how long you 
have eaten /ate this way. You may choose more than one.  
Ever?              Current?      How long?      When ended? 
Example diet   Yes     No     No        3 years                Dec 2013  
 
No particular diet but I choose healthy foods   Yes     No       
I don’t think much about what I eat   Yes     No       
Mixed or ‘balanced’ diet  Yes     No           
Low Fat    Yes     No           
Low GI     Yes     No           
Mediterranean   Yes     No           
Low Calorie mixed diet  Yes     No           
DASH (Dietary Approaches to  Yes     No          
             Stop Hypertension)  
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Vegetarian   Yes     No           
Vegan    Yes     No           
Very Low-Carb/ Atkins  Yes     No            
Low Carbohydrate  Yes     No           
Paleo    Yes     No           
Religious (e.g. Halal, Kosher) Yes     No           
Other, please specify……………………..................           
2. Do you think you generally eat too much food? 
 Yes              No 
3. Do you try to limit how many calories (how much food) that you generally eat?  
 Yes              No 
4. Do you try to limit the amount of fat in your diet (e.g. by eating low-fat dairy products 
and lean meats, avoiding fatty foods and cutting the fat off of pieces of meat)? 
Yes        No 
5. Do you try to limit the amount of refined carbohydrates in your diet (e.g. table sugar, 
white flour, sweets, cakes, biscuits, and sweetened beverages)? 
Yes        No  
6. How healthy would you say your current diet or eating pattern is? 
             (1)  Very unhealthy     (2) Unhealthy    (3) Fairly healthy   (4) Very healthy 
7. How satisfied are you with your current diet or eating pattern? 
(1)   Very dissatisfied    (2)   Dissatisfied   (3) Neither satisfied nor dissatisfied      
(4)   Satisfied              (5)   Very satisfied 
8. Do you think you should change your dietary habits? 
(1) Not at all  (2) Probably not  (3) Unsure  (4) Probably  (5) Definitely 
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9. What mineral / vitamin supplements (e.g. multivitamin or vitamin C / vitamin D and 
omega-3), if any, are you currently using? 
Name/ Type of supplement        amount / day              Period taken  
            
            
SECTION 8: RUNNING NUTRITION 
Questions 1 and 2 refer to your nutrition in the days or weeks leading up to a long run or 
race and Question 3 refers to your nutrition on the day of a long run or race. 
1. Do you change your usual eating pattern in the days or weeks before a long run? In 
other words, do you change the type and/or amounts of food/drinks you consume to 
prepare for a race? 
 Yes                 No           No, but I have in the past 
2. If YES, do you currently or have you in the past practiced any of the following 
strategies? You can choose more than 1. 
(a) Carbo-loading i.e. you eat a greater-than-normal amount of carbohydrate during 
the days leading up to a long run.        
Currently practicing:     Yes        No  If yes, for how long?    
  
Practiced in the past:    Yes        No      If yes, for how long and when did you 
stop?      
If YES, please describe how you carbo-load (what types of foods or drinks you 
choose and when you consume them)?       
           
           
For what reason do/did you carbo-load?       
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(b) Fat adapting i.e. you eat a greater-than-normal amount of fat and a less-than-
normal amount of carbohydrate during the days leading up to a long run, with or 
without a carbo-loading day. 
Currently practicing:     Yes        No  If yes, for how long?    
   
Practiced in the past:    Yes        No      If yes, for how long and when did you 
stop?      
If YES, please describe how you fat-adapt (what types of foods or drinks you choose 
and when you consume them?):       
           
           
For what reason do/did you fat-adapt?        
           
 
(c) Calorie loading i.e. you eat a more than a normal amount of food before a long 
run. 
Currently practicing:     Yes        No  If yes, for how long?     
Practiced in the past:    Yes        No      If yes, for how long and when did you 
stop?      
If YES, please describe how you calorie-load (what types of foods or drinks you 
choose and when you consume them?):      
           
            
For what reason do/did you calorie load?      




(d) Calorie restricting i.e. you eat less than a normal amount of food in the days/ 
weeks before a long run. 
Currently practicing:     Yes        No  If yes, for how long?     
Practiced in the past:    Yes        No      If yes, for how long and when did you 
stop?      
If YES, please describe what types of foods or drinks you restrict and when you 
restrict them:          
           
For what reason do/did you restrict calories?       
           
(e) Other pre race eating pattern  
Currently practicing:     Yes        No  If yes, for how long?     
Practiced in the past:    Yes        No      If yes, for how long and when did you 
stop?     
If YES, please describe          
           
           
For what reason do/did you follow this pattern?      
           
 
3. What foods, drinks and / or nutritional supplements (e.g. energade, coke, gels, sweets, 
electrolyte solutions) do you normally consume before, during and soon after training 
runs and / or races?  
       
 Before:           
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 During:           
           
 
 After:            
          
 
















The Three-Factor Eating Questionnaire (TFEQ-R21) 
Participant Code:    Date and Time    
Please circle the number which you think applies to you. Please answer honestly. 
1. I deliberately take small helpings to control my weight. 
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
2. I start to eat when I feel anxious. 
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
3. Sometimes when I start eating, I just can’t seem to stop. 
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
4. When I feel sad, I often eat too much. 
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
5. I don’t eat some foods because they make me fat. 
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
6. Being with someone who is eating, often makes me want to also eat. 
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
7. When I feel tense or “wound up”, I often feel I need to eat. 
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
8. I often get so hungry that my stomach feels like a bottomless pit. 
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
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9. I’m always so hungry that it’s hard for me to stop eating before finishing all of the food 
on my plate. 
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
10. When I feel lonely, I console myself by eating. 
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
11. I consciously hold back on how much I eat at meals to keep from gaining weight. 
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
12. When I smell a sizzling steak or see a juicy piece of meat, I find it very difficult to keep 
from eating — even if I’ve just finished a meal                                               
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
13. I’m always hungry enough to eat at any time. 
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
14. If I feel nervous, I try to calm down by eating. 
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
15. When I see something that looks very delicious, I often get so hungry that I have to eat 
right away. 
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
16. When I feel depressed, I want to eat. 
(1) Definitely true     (2) Mostly true     (3) Mostly false     (4) Definitely false 
17. How often do you avoid “stocking up” on tempting foods? 




18. How likely are you to make an effort to eat less than you want? 
(1) Unlikely               (2) A little likely    (3) Somewhat likely       (4) Very likely 
19. Do you go on eating binges even though you’re not hungry? 
(1) Never                  (2) Rarely              (3) Sometimes              (4) At least once a week 
20. How often do you feel hungry? 
(1) Only at mealtimes     (2) Sometimes between meals     (3) Often between meals   
(4) Almost always 
21. On a scale from 1 to 8, where 1 means no restraint in eating and 8 means total 
restraint, what number would you give yourself? 
Mark the number that best applies to you:     1       2       3       4       5       6       7       8. 















PITTSBURGH SLEEP QUALITY INDEX QUESTIONNAIRE 
 
Participant Code:    Date and Time     
 
Instructions: 
The following questions relate to your usual sleep habits during the past month only. Your 
answers should indicate the most accurate reply for the majority of days and nights in the 
past month. Please answer all questions. 
 
1. During the past month, when have you usually gone to bed at night? 
 Usual bed time:        
2. During the past month, how long, in minutes has it usually taken you to fall asleep  
each night? 
Number of minutes:        
3. During the past month, when have you usually gotten up in the morning? 
 Usual getting up time:       
4. During the past month, how many hours of actual sleep did you get each night? (This 
may be different than the number of hours you spend in bed) 
 Hours of sleep per night:       
 
For each of the remaining questions, check the one best response.  
Please answer all questions. 
 
5. During the past month, how often have you had trouble sleeping because you… 
 
(a) Cannot get to sleep within 30 minutes 
Not during the past month       Less than once per week  
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Once or twice a week   Three or more times a week     
(b) Wake up in the middle of the night or early morning 
Not during the past month       Less than once per week  
Once or twice a week   Three or more times a week           
(c) Have to get up to use the bathroom 
Not during the past month       Less than once per week  
Once or twice a week   Three or more times a week           
 (d) Cannot breathe comfortably 
Not during the past month       Less than once per week  
Once or twice a week   Three or more times a week           
 (e) Cough or snore loudly 
Not during the past month       Less than once per week  
Once or twice a week   Three or more times a week           
 (f) Feel too cold 
Not during the past month       Less than once per week  
Once or twice a week   Three or more times a week           
 (g) Feel too hot 
Not during the past month       Less than once per week  
Once or twice a week   Three or more times a week           
 (h) Had bad dreams 
Not during the past month       Less than once per week  
Once or twice a week   Three or more times a week           
 (i) Have pain 
Not during the past month       Less than once per week  
Once or twice a week   Three or more times a week           
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 (j) Other reason(s), please describe         
            
6. During the past month, how would you rate your sleep quality overall? 
 Very good     Fairly good    
 Fairly bad     Very bad    
7. During the past month, how often have you taken medicine (prescribed or “over the 
counter”) to help you sleep? 
Not during the past month       Less than once per week  
Once or twice a week   Three or more times a week           
8. During the past month, how often have you had trouble staying awake while driving, 
eating meals, or engaging in social activity? 
Not during the past month       Less than once per week  
Once or twice a week   Three or more times a week           
9. During the past month, how much of a problem has it been for you to keep up enough 
enthusiasm to get things done? 
No problem at all   Only a very slight problem   
Somewhat of a problem   A very big problem    
10. Do you have a bed partner or roommate? 
 No bed partner or roommate      
Partner/roommate in other room    
Partner in same room, but not same bed   
Partner in same bed      
If you have a roommate or bed partner, ask him/her how often in the past month you have 
had… 
(a) Loud snoring 
Not during the past month       Less than once per week  
Once or twice a week   Three or more times a week           
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 (b) Long pauses between breaths while asleep 
Not during the past month       Less than once per week  
Once or twice a week   Three or more times a week           
 (c) Legs twitching or jerking while you sleep 
Not during the past month       Less than once per week  
Once or twice a week   Three or more times a week           
 (d) Episodes of disorientation or confusion during sleep 
Not during the past month       Less than once per week  
Once or twice a week   Three or more times a week           
(e) Other restlessness while you sleep: please describe       
            
Not during the past month       Less than once per week  
Once or twice a week   Three or more times a week           
 














 The Perceived Stress Questionnaire 
 
Participant Code:    Date and Time     
Instructions: For each sentence, circle the number that describes how often it applies to 
you during the last month. Work quickly, without bothering to check your answers, and be 
careful to consider only the last month. 
 Almost never Sometimes Often Usually 
1. You feel rested 1 2 3 4 
2. You feel that too many demands are being made on you 1 2 3 4 
3. You are irritable and grouchy 1 2 3 4 
4. You have too many things to do 1 2 3 4 
5. You feel lonely or isolated 1 2 3 4 
6. You find yourself in situations of conflict 1 2 3 4 
7. You feel like you’re doing things you really like 1 2 3 4 
8. You feel tired 1 2 3 4 
9. You fear you may not manage to attain your goals 1 2 3 4 
10. You feel calm 1 2 3 4 
11. You have too many decisions to make 1 2 3 4 
12. You feel frustrated 1 2 3 4 
13. You are full of energy 1 2 3 4 
14. You feel tense 1 2 3 4 
15. Your problems seem to be piling up 1 2 3 4 











17. You feel safe and protected 1 2 3 4 
18. You have many worries 1 2 3 4 
19. You are under pressure from other people 1 2 3 4 
20. You feel discouraged 1 2 3 4 
21. You enjoy yourself 1 2 3 4 
22. You are afraid for the future 1 2 3 4 
23. You feel you’re doing things because you have to not 
       because you want to 
1 2 3 4 
24. You feel criticised or judged 1 2 3 4 
25. You are lighthearted 1 2 3 4 
26. You feel mentally exhausted 1 2 3 4 
27. You have trouble relaxing 1 2 3 4 
28. You feel loaded down with responsibility 1 2 3 4 
29. You have enough time for yourself 1 2 3 4 




Gastrointestinal Symptoms Questionnaire 
Participant Code:    Date and Time     
This questionnaire aims to determine whether or not you have typically experienced 
gastrointestinal (GI) symptoms associated with eating. SECTION A pertains to eating during 
normal meal times or snacks. SECTION B pertains specifically to eating during running / 
exercise. Please answer honestly and remember that your information will be kept strictly 
confidential and only the study investigators will be able to identify you. 
SECTION A: GI SYMPTOMS WHILE NOT DOING EXERCISE 
Please indicate the FREQUENCY of GI symptoms you have experienced within the past 3 
months, excluding the times that you have been exercising by circling the number which 
applies to you. Please try to recall the types of foods or drinks which have made you feel 
the discomfort (list specific foods or general types). 
Abdominal Pain or Discomfort                                                                                                     
(1) Not at all      (2)  Rarely     (3)  Sometimes    (4)  Often      (5)  Very often        
Food / Drink              
Early Satiety (Feeling full soon after starting to eat; the person is unable to finish a normal 
meal) 
(1) Not at all      (2)  Rarely     (3)  Sometimes   (4)  Often      (5)  Very often        
Food / Drink              
Postprandial Fullness (An unpleasant feeling of food staying in the stomach after a normal 
meal) 
(1) Not at all      (2)  Rarely     (3)  Sometimes  (4)  Often     (5)  Very often        
Food / Drink              
Bloating (A feeling as if the abdomen or stomach were swollen) 
(1) Not at all      (2)  Rarely     (3)  Sometimes  (4)  Often      (5)  Very often        
Food / Drink              
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Heartburn/Acid Reflux (A burning pain or discomfort behind the breastline rising up 
toward the throat) 
(1) Not at all      (2)  Rarely     (3)  Sometimes    (4)  Often      (5)  Very often        
Food / Drink              
Nausea                                                                                                                                           
(1) Not at all      (2)  Rarely     (3)  Sometimes   (4)  Often      (5)  Very often        
Food / Drink              
Vomiting 
(1) Not at all      (2)  Rarely     (3)  Sometimes   (4)  Often      (5)  Very often        
Food / Drink              
Dysphagia (Difficulty in swallowing, in which solid food or liquids stick on the way down) 
(1) Not at all      (2)  Rarely     (3)  Sometimes  (4)  Often      (5)  Very often        
Food / Drink              
Diarrhoea 
(1) Not at all      (2)  Rarely     (3)  Sometimes  (4)  Often      (5)  Very often        
Food / Drink              
Constipation  
(1) Not at all      (2)  Rarely     (3)  Sometimes  (4)  Often      (5)  Very often        
Food / Drink              
> 3 Bowel movements PER DAY 
(1) Not at all      (2)  Rarely     (3)  Sometimes (4)  Often      (5)  Very often        
Food / Drink              
< 3 Bowel movements PER WEEK 
(1) Not at all      (2)  Rarely     (3)  Sometimes (4)  Often      (5)  Very often        




Lumpy or hard stools 
(1) Not at all      (2)  Rarely     (3)  Sometimes  (4)  Often      (5)  Very often        
Food / Drink              
Loose or watery stools 
(1) Not at all      (2)  Rarely     (3)  Sometimes  (4)  Often      (5)  Very often        
Food / Drink              
Anal blockage (A feeling of blockage in the anus or back passage that makes it difficult to 
pass bowel movements) 
(1) Not at all      (2)  Rarely     (3)  Sometimes  (4)  Often      (5)  Very often        
Food / Drink              
Urgency (A need to have a bowel movement that makes the person rush to the toilet) 
(1) Not at all      (2)  Rarely     (3)  Sometimes (4)  Often      (5)  Very often        
Food / Drink              
Faecal Incontinence (Inability to control bowel movements, leading to an involuntary loss 
of bowel contents) 
(1) Not at all      (2)  Rarely     (3)  Sometimes (4)  Often      (5)  Very often        
Food / Drink              
 
SECTION B: RUNNING ASSOCIATED GI SYMPTOMS 
Have you experienced any of the following GI symptoms during a training run or race 
within the past year? If YES, please indicate how often you have experienced the symptom 
(circle the number which applies to you). Please indicate any food or drinks that you think 
may cause these symptoms during running? 
Abdominal pain           
Yes          No                (1) Once            (2) A couple of times            (3) Regularly          




Bloating (A feeling as if the abdomen or stomach were swollen)  
Yes          No                (1) Once            (2) A couple of times            (3) Regularly          
Food / Drink              
Heartburn / Acid Reflux (A burning pain or discomfort behind the breastline rising up 
toward the throat) 
Yes          No                (1) Once            (2) A couple of times            (3) Regularly          
Food / Drink              
Nausea  
Yes          No                (1) Once            (2) A couple of times            (3) Regularly          
Food / Drink              
Vomiting    
Yes          No                (1) Once            (2) A couple of times            (3) Regularly          
Food / Drink              
Dysphagia (Difficulty in swallowing, in which solid food or liquids stick on the way down)                                                                                                                                     
Yes          No                (1) Once            (2) A couple of times            (3) Regularly          
Food / Drink              
Diarrhoea 
Yes          No                (1) Once            (2) A couple of times            (3) Regularly          
Food / Drink              
Urgency (A need to have a bowel movement that makes the person rush to the toilet) 
Yes          No                (1) Once            (2) A couple of times            (3) Regularly          





Faecal Incontinence (Inability to control bowel movements, leading to an involuntary loss 
of bowel contents) 
Yes          No                (1) Once            (2) A couple of times            (3) Regularly          
Food / Drink              























MRC Food Frequency Questionnaire 
 
FOOD FREQUENCY QUESTIONNAIRE                        Participant Code:                                
For the completion of this questionnaire we would like you to think carefully of what you 
ate and drank, on average, within the LAST 6 MONTHS. 
In the table below you will find a list of foods and drinks (Column 1). We would like you to 
tick off: 
 How often you ate or drank the specified item during the past 6 months. 
 On average, how much (or portion size) you ate/drank of the specified item if you did 
eat it (Column 3). 
 
Guidelines are given in Column 3 to help you with portion size estimation. 
The standard (Std) portion size of each food item/drink is indicated in household measures 
(e.g. cups, spoons, grams) or a unit (e.g. a hamburger). Where possible the Std portion size 
is also shown in terms of visual aids, including a matchbox, a tennis ball, and a sketch of 
half a cup of dished up food. 
Sketches of these aids are attached to the questionnaire. 
Once you are sure about the size of the Std portion, tick one of the following options in 
Column 3: 
 If the portion you ate/drank of the specified item on average is ±the same as the 
Std portion size, tick the 1 x Std column; Or 
 If the portion you ate/drank of the specified item on average is less than the Std 
portion size, tick the ½ x Std column; OR 
 If the portion you ate/drank of the specified item on average is a little more than 
the Std portion size, tick the 1 ½ x Std; OR 
 If the portion you ate/drank of the specified item on average is much more than 
the Std portion size, tick the 2 x or 3 x Std column. 
 





Table spoon: Tbs 
Gram: g 
Milliliters: ml 
Etc – whatever is necessary 
 
 
Tennis ball:  




Please make sure that you tick every line. If you did not eat/drink a particular item in the 
last 6 months, make sure that you tick the “NO” column. Remember that if you ticked the 




























Quark RMR (COSMED) Alcohol Burns 
 
1. 29 July 2015 
 




hh:mm:ss l/min ml/min ml/min % % ml --- 
00:00:01 40.12658 9.2748 0 20.87186 0.069353 0 0 
00:00:06 40.17959 8.578101 0 20.87401 0.069261 0 0 
00:00:11 40.2326 8.969994 0 20.87286 0.06917 0 0 
00:00:16 40.2326 8.969994 0.814266 20.87286 0.072464 0.067853 0.090777 
00:00:21 40.12658 10.36339 0.875228 20.86856 0.072655 0.072933 0.084454 
00:00:26 42.51191 13.84688 3.857968 20.86035 0.081047 0.321485 0.278616 
00:00:31 43.30702 15.37091 3.40076 20.85679 0.079559 0.283385 0.221246 
00:00:36 43.25402 13.89043 2.342649 20.86091 0.076593 0.195213 0.168652 
00:00:41 43.20101 16.76431 3.461721 20.85276 0.079755 0.288465 0.206494 
00:00:46 43.13475 11.92008 3.499822 20.86636 0.079877 0.29164 0.293607 
00:00:51 43.13475 11.92008 1.322639 20.86636 0.073733 0.110215 0.110959 
00:00:56 43.20101 14.58713 1.284538 20.8589 0.07362 0.107041 0.08806 
00:01:00 43.13475 17.36304 3.499822 20.851 0.079877 0.29164 0.201567 
00:01:05 43.13475 14.09726 1.322639 20.86022 0.073733 0.110215 0.093822 
00:01:10 42.90947 18.96326 4.717956 20.8462 0.083385 0.393147 0.248794 
00:01:15 43.01548 34.98733 11.18854 20.80099 0.101664 0.932341 0.319788 
00:01:20 42.90947 34.20355 4.717956 20.80296 0.083385 0.393147 0.137938 
00:01:25 43.13475 30.42613 6.765597 20.81413 0.089094 0.563777 0.222361 
00:01:30 43.13475 23.89458 5.677005 20.83257 0.086022 0.473065 0.237585 
00:01:35 43.13475 20.62881 3.499822 20.84178 0.079877 0.29164 0.169657 
00:01:40 43.13475 24.98318 6.765597 20.82949 0.089094 0.563777 0.270806 
00:01:45 43.20101 23.29586 4.550313 20.83436 0.082822 0.379178 0.195327 
00:01:50 43.13475 19.54022 3.499822 20.84485 0.079877 0.29164 0.179109 
00:01:55 43.13475 22.80599 6.765597 20.83564 0.089094 0.563777 0.296659 
00:02:00 43.13475 41.31205 18.7401 20.78341 0.122888 1.561613 0.453623 
00:02:05 43.25402 28.04212 6.697015 20.82108 0.088848 0.558062 0.23882 
00:02:10 43.20101 27.65023 7.816087 20.82209 0.092025 0.651315 0.282677 
00:02:15 43.13475 20.62881 4.588413 20.84178 0.082949 0.382352 0.222427 
00:02:20 41.27949 133.1892 81.85664 20.50722 0.311396 6.821114 0.614589 
00:02:25 39.34472 564.119 370.3574 19.1546 1.215898 30.86188 0.656523 
00:02:30 39.23871 665.6629 445.5311 18.83485 1.452212 37.12611 0.669304 
00:02:35 39.07969 704.7651 473.926 18.70465 1.546287 39.49225 0.672459 
00:02:40 39.01343 665.0859 446.7493 18.82473 1.463995 37.22762 0.671717 
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00:02:45 39.11944 647.3636 433.6252 18.8855 1.419377 36.13399 0.669833 
00:02:50 39.06643 613.2254 406.4409 18.98915 1.336499 33.86872 0.662792 
00:02:55 39.01343 634.6053 422.8003 18.91984 1.389266 35.23195 0.666241 
00:03:00 39.02668 656.4751 435.8557 18.85229 1.429542 36.31986 0.663933 
00:03:05 38.96042 686.4658 457.6657 18.7551 1.5 38.13728 0.666698 
00:03:10 39.02668 658.6523 435.8557 18.8455 1.429542 36.31986 0.661739 
00:03:15 38.8014 667.8727 445.7826 18.80464 1.468579 37.14706 0.667466 
00:03:20 39.01343 649.8456 431.509 18.87228 1.41644 35.95764 0.664018 
00:03:25 38.96042 703.8833 469.6402 18.70068 1.537415 39.13512 0.667213 
00:03:30 38.64238 704.7977 469.8231 18.6797 1.550069 39.15036 0.666607 
00:03:35 38.8014 733.1882 489.3263 18.59973 1.605191 40.77556 0.667395 
00:03:40 38.8014 660.2526 433.8081 18.82855 1.431011 36.14923 0.657034 
00:03:45 38.74839 672.9238 445.8131 18.78591 1.470588 37.1496 0.662502 
00:03:50 38.76164 732.8943 487.1719 18.59829 1.6 40.59604 0.664723 
00:03:55 38.40384 712.8315 471.0488 18.64044 1.563147 39.2525 0.660814 
00:04:00 38.64238 698.2662 461.1143 18.70027 1.522634 38.42466 0.66037 
00:04:05 38.70863 724.8822 479.5823 18.62034 1.578227 39.96359 0.6616 
00:04:10 38.64238 725.481 480.709 18.61454 1.584362 40.05748 0.662607 
00:04:15 38.58937 768.6327 510.1314 18.47527 1.679258 42.50925 0.663687 
00:04:20 38.54961 750.9213 498.1798 18.5287 1.643176 41.51332 0.663425 
00:04:25 38.4436 741.4288 490.6206 18.55222 1.623578 40.88341 0.661723 
00:04:30 38.64238 717.8608 473.0888 18.63855 1.560357 39.42249 0.659026 
00:04:35 38.53636 711.6341 469.884 18.65199 1.554333 39.15543 0.660289 
00:04:40 38.43035 741.3309 490.6282 18.55172 1.624138 40.88405 0.661821 
00:04:45 38.43035 741.3309 489.5396 18.55172 1.62069 40.79334 0.660352 
00:04:50 38.37734 771.4195 511.3419 18.45304 1.691989 42.61012 0.662858 
00:04:55 38.4436 815.4531 539.6072 18.31782 1.778697 44.96547 0.661727 
00:05:00 38.37734 776.8625 512.4305 18.43577 1.695442 42.70084 0.659615 
00:05:05 38.28458 773.9995 511.3953 18.43891 1.696089 42.61457 0.660718 
00:05:10 38.45685 740.4382 487.3472 18.55617 1.612681 40.61064 0.658188 
00:05:15 38.24482 784.5915 519.0383 18.40263 1.722107 43.25146 0.66154 
00:05:20 38.19181 788.554 521.2459 18.38654 1.731437 43.43542 0.661015 
00:05:25 38.19181 783.111 516.8916 18.40389 1.717557 43.07258 0.660049 
00:05:30 38.31108 821.0049 542.9492 18.29125 1.795227 45.24396 0.661323 
00:05:35 38.13881 783.8077 515.8335 18.39819 1.71647 42.9844 0.658112 
00:05:40 38.33758 756.9739 497.2131 18.49637 1.648807 41.43277 0.656843 
00:05:45 38.17856 755.7982 497.3045 18.49011 1.655675 41.44039 0.657986 
00:05:50 38.05929 806.0803 533.2967 18.32173 1.775766 44.43961 0.661592 
00:05:55 38.27132 741.2438 486.3653 18.54224 1.617036 40.52882 0.656148 
00:06:00 37.97978 793.5179 523.545 18.35659 1.748081 43.62701 0.659777 
00:06:05 38.23157 817.1513 536.4634 18.29809 1.778163 44.70349 0.656504 
00:06:10 38.21832 761.5351 500.5475 18.47434 1.664355 41.71062 0.657287 
00:06:15 38.16531 779.6493 514.7296 18.41319 1.711806 42.89242 0.660207 
00:06:20 38.07255 784.4064 516.9602 18.39192 1.722938 43.07829 0.659046 
223 
 
00:06:25 38.12555 795.6842 524.5498 18.3594 1.744873 43.71074 0.659244 
00:06:30 38.07255 786.5836 516.9602 18.38496 1.722938 43.07829 0.657222 
00:06:35 38.07255 756.103 496.2769 18.48242 1.656805 41.35476 0.656361 
00:06:40 38.12555 801.1272 527.8156 18.34202 1.755301 43.98287 0.658841 
00:06:45 38.0858 774.7071 509.3324 18.4238 1.697982 42.44267 0.657452 
00:06:50 37.96653 790.1542 520.2869 18.36649 1.73822 43.35551 0.658462 
00:06:55 38.03279 779.7581 511.5401 18.40418 1.707317 42.62663 0.656024 
00:07:00 38.01954 756.7997 496.3074 18.47682 1.659115 41.3573 0.655798 
00:07:05 37.99303 781.6414 511.5629 18.39554 1.709104 42.62854 0.654473 
00:07:10 37.86052 741.4724 485.5129 18.51593 1.631082 40.45779 0.654796 
00:07:15 37.83401 764.1368 501.857 18.44133 1.684764 41.81975 0.656763 
00:07:20 38.01954 756.7997 496.3074 18.47682 1.659115 41.3573 0.655798 
00:07:25 37.87377 789.4684 518.1631 18.36249 1.735479 43.17853 0.656344 
00:07:30 37.71475 783.9383 512.8115 18.36964 1.725228 42.73259 0.654148 
00:07:35 37.92678 751.7596 489.8292 18.48707 1.642208 40.81747 0.651577 
00:07:40 37.83401 777.1999 508.3886 18.3993 1.705779 42.36402 0.654128 
00:07:45 37.92678 774.62 508.3352 18.4137 1.701607 42.35958 0.656238 
00:07:50 37.92678 757.2025 495.2721 18.4696 1.659679 41.27103 0.654081 
00:07:55 37.96653 752.0535 491.9835 18.48866 1.647469 40.99699 0.654187 
00:08:00 37.76775 715.749 464.883 18.59298 1.568421 38.7387 0.649506 
00:08:05 37.86052 749.0925 488.7787 18.49142 1.641582 40.72993 0.652494 
00:08:10 37.83401 746.7194 488.7939 18.49737 1.642732 40.7312 0.654589 
00:08:15 37.71475 788.2927 518.2545 18.35559 1.742797 43.18615 0.657439 
00:08:20 37.82076 748.7986 489.8902 18.48984 1.646811 40.82255 0.654235 
00:08:25 37.91352 752.7502 492.014 18.48305 1.649773 40.99953 0.653622 
00:08:30 37.71475 734.9517 479.0652 18.52776 1.616304 39.9205 0.651832 
00:08:35 37.76775 701.5973 455.0857 18.6386 1.536842 37.92229 0.648642 
00:08:40 37.86052 740.3838 483.3357 18.51943 1.624081 40.27637 0.652818 
00:08:45 37.82076 740.0899 484.4472 18.51787 1.629292 40.36898 0.654579 
00:08:50 37.96653 698.7125 453.8828 18.65969 1.525305 37.82205 0.649599 
00:08:55 37.7545 710.208 461.6249 18.61004 1.558442 38.4672 0.649985 
00:09:00 37.7545 705.8537 458.3591 18.62408 1.547912 38.19506 0.649368 
00:09:05 37.728 708.9235 459.4629 18.61257 1.552511 38.28705 0.648114 
00:09:10 37.82076 723.761 465.9411 18.57043 1.569727 38.82687 0.643778 
00:09:15 37.71475 708.8255 456.2048 18.61209 1.542516 38.01554 0.643607 
00:09:19 37.7545 702.5879 458.3591 18.63461 1.547912 38.19506 0.652387 
00:09:24 37.87377 688.2294 446.316 18.68789 1.504549 37.19151 0.648499 
00:09:29 37.70149 706.5504 460.5668 18.61863 1.557118 38.37903 0.651853 
00:09:34 37.76775 697.2429 450.7313 18.65263 1.522807 37.55944 0.646448 
00:09:39 37.71475 667.459 428.99 18.74561 1.454673 35.74774 0.642721 
00:09:44 37.86052 669.6253 429.9948 18.74694 1.452573 35.83146 0.642142 
00:09:49 37.7545 641.6268 411.5497 18.83117 1.396981 34.29443 0.641416 
00:09:54 37.82076 597.4844 377.7652 18.97687 1.285915 31.47918 0.63226 
00:09:59 37.67499 609.4698 387.6464 18.93071 1.322547 32.30257 0.636039 
224 
 
00:10:04 37.86052 590.1581 371.2108 19.00245 1.263563 30.933 0.629002 
00:10:09 37.86052 410.5405 247.1114 19.57998 0.864543 20.59179 0.601917 
00:10:14 38.33758 85.31292 29.11874 20.6291 0.162461 2.426464 0.341317 
00:10:19 38.28458 46.82032 4.11161 20.75112 0.083074 0.34262 0.087817 
00:10:24 38.40384 45.5249 2.954437 20.75569 0.079365 0.246193 0.064897 
00:10:29 38.33758 42.85785 2.992538 20.76391 0.079502 0.249368 0.069825 
00:10:34 38.33758 42.85785 2.992538 20.76391 0.079502 0.249368 0.069825 
00:10:39 38.33758 41.76926 2.992538 20.76737 0.079502 0.249368 0.071645 
        
     
Totals 3753.41 0.66 
     
% Error -1.74 -1.37 
 
2. 24 August 2015 
 




hh:mm:ss l/min ml/min ml/min % % ml --- 
00:00:01 41.29013 0.056253 1.454994 20.91983 0.054296 0.121245 25.86538 
00:00:06 41.35607 0.553871 0.34617 20.91837 0.05102 0.028846 0.625 
00:00:11 41.29013 1.138032 1.454994 20.91664 0.054296 0.121245 1.278517 
00:00:16 41.23738 0.739937 1.476629 20.91781 0.054365 0.123048 1.995614 
00:00:21 41.21101 2.704449 2.569227 20.912 0.0576 0.214094 0.95 
00:00:26 40.68351 3.050619 2.785583 20.91086 0.058347 0.232123 0.913121 
00:00:31 40.68351 3.050619 1.703803 20.91086 0.055105 0.141978 0.558511 
00:00:36 40.11644 3.098217 1.936386 20.91059 0.055884 0.161359 0.625 
00:00:41 40.05051 1.518819 1.96343 20.91538 0.055976 0.163613 1.292735 
00:00:46 39.99776 2.202504 3.066846 20.91329 0.059347 0.25556 1.392436 
00:00:51 39.99776 2.202504 3.066846 20.91329 0.059347 0.25556 1.392436 
00:00:56 39.945 2.886188 3.088481 20.91119 0.059426 0.257363 1.07009 
00:01:01 39.99776 2.202504 1.985066 20.91329 0.05605 0.165416 0.901277 
00:01:06 39.87907 1.30679 2.033746 20.91601 0.056217 0.169472 1.556291 
00:01:11 39.945 2.886188 2.006701 20.91119 0.056124 0.167218 0.695277 
00:01:16 39.99776 2.202504 3.066846 20.91329 0.059347 0.25556 1.392436 
00:01:21 39.945 2.886188 3.088481 20.91119 0.059426 0.257363 1.07009 
00:01:26 39.945 3.967968 3.088481 20.90789 0.059426 0.257363 0.778353 
00:01:31 39.945 3.967968 3.088481 20.90789 0.059426 0.257363 0.778353 
00:01:36 40.05051 1.518819 1.96343 20.91538 0.055976 0.163613 1.292735 
00:01:41 39.945 2.886188 3.088481 20.91119 0.059426 0.257363 1.07009 
00:01:46 39.99776 2.202504 3.066846 20.91329 0.059347 0.25556 1.392436 
00:01:51 39.87907 1.30679 3.115526 20.91601 0.059524 0.259617 2.384106 
00:01:56 39.945 3.967968 3.088481 20.90789 0.059426 0.257363 0.778353 
225 
 
00:02:01 39.99776 3.284283 3.066846 20.90999 0.059347 0.25556 0.933794 
00:02:06 41.31651 4.582419 2.525956 20.90648 0.057453 0.210488 0.551228 
00:02:11 43.13639 3.171778 2.861307 20.91104 0.058086 0.238433 0.902115 
00:02:16 43.13639 5.335338 3.943087 20.90492 0.061143 0.328577 0.739051 
00:02:21 43.20232 11.24185 7.161382 20.88828 0.070208 0.596758 0.637028 
00:02:26 43.08364 4.937243 3.964723 20.90603 0.061218 0.33038 0.803024 
00:02:31 43.03089 3.457368 2.904579 20.91021 0.058229 0.242039 0.840113 
00:02:36 43.08364 3.855463 2.882943 20.90909 0.058157 0.240236 0.747755 
00:02:41 43.08364 4.937243 3.964723 20.90603 0.061218 0.33038 0.803024 
00:02:46 43.13639 17.23491 13.6791 20.87129 0.088658 1.13988 0.793686 
00:02:51 43.13639 8.580677 6.106647 20.89575 0.067258 0.508867 0.711674 
00:02:56 42.97814 7.386392 4.007994 20.89905 0.061369 0.333986 0.542619 
00:03:01 40.05051 5.845938 3.04521 20.90221 0.059269 0.253757 0.52091 
00:03:06 40.05051 3.682378 3.04521 20.90879 0.059269 0.253757 0.826968 
00:03:11 39.99776 4.366063 3.066846 20.90669 0.059347 0.25556 0.702428 
00:03:16 39.99776 4.366063 3.066846 20.90669 0.059347 0.25556 0.702428 
00:03:21 40.05051 2.600598 3.04521 20.91208 0.059269 0.253757 1.170965 
00:03:26 39.945 5.049748 3.088481 20.90459 0.059426 0.257363 0.611611 
00:03:31 39.99776 4.366063 3.066846 20.90669 0.059347 0.25556 0.702428 
00:03:36 40.11644 5.261777 3.018165 20.90401 0.059172 0.251504 0.573602 
00:03:41 39.99776 3.284283 3.066846 20.90999 0.059347 0.25556 0.933794 
00:03:45 40.05051 2.600598 3.04521 20.91208 0.059269 0.253757 1.170965 
00:03:50 40.05051 2.600598 3.04521 20.91208 0.059269 0.253757 1.170965 
00:03:55 39.99776 3.284283 3.066846 20.90999 0.059347 0.25556 0.933794 
00:04:00 40.05051 3.682378 3.04521 20.90879 0.059269 0.253757 0.826968 
00:04:05 40.05051 3.682378 3.04521 20.90879 0.059269 0.253757 0.826968 
00:04:10 40.05051 4.764158 3.04521 20.9055 0.059269 0.253757 0.639192 
00:04:15 40.05051 4.764158 3.04521 20.9055 0.059269 0.253757 0.639192 
00:04:20 40.65713 8.26047 4.95996 20.89523 0.064872 0.413313 0.600445 
00:04:25 43.25507 7.312831 3.894407 20.89939 0.060976 0.324521 0.532544 
00:04:30 43.30782 5.547366 3.872771 20.90438 0.060901 0.322718 0.698128 
00:04:35 43.20232 6.914736 3.916043 20.90049 0.06105 0.326324 0.566333 
00:04:40 43.25507 6.231051 3.894407 20.90244 0.060976 0.324521 0.625 
00:04:45 42.95176 26.65938 17.00017 20.84434 0.09825 1.416624 0.637681 
00:04:50 39.45707 475.1869 323.4954 19.45187 1.049465 26.95687 0.680775 
00:04:55 39.33838 597.6141 412.25 19.06805 1.327523 34.35279 0.689827 
00:05:00 39.15375 662.2093 461.0058 18.8582 1.485349 38.41562 0.696163 
00:05:05 39.14057 666.4369 463.1748 18.84434 1.492588 38.59636 0.695002 
00:05:10 39.28563 649.1414 450.134 18.90567 1.446794 37.50966 0.69343 
00:05:15 39.28563 639.4054 441.4797 18.93588 1.41994 36.7885 0.690454 
00:05:20 39.2065 682.0794 473.9656 18.79919 1.523713 39.49555 0.694883 
00:05:25 39.16694 659.0635 455.5915 18.86869 1.468013 37.96444 0.691271 
00:05:30 39.11419 662.9925 457.7767 18.85367 1.476736 38.14653 0.69047 
00:05:35 39.37794 620.63 424.1334 18.99866 1.363027 35.34303 0.683392 
226 
 
00:05:40 39.00869 658.951 452.4111 18.86072 1.463827 37.69942 0.686563 
00:05:45 39.101 659.6476 453.455 18.86341 1.463744 37.78641 0.68742 
00:05:50 38.96913 718.1503 496.7803 18.67343 1.604061 41.3967 0.69175 
00:05:55 39.00869 702.2222 481.6191 18.72549 1.555105 40.13332 0.68585 
00:06:00 39.15375 654.6368 446.9427 18.88178 1.441563 37.24374 0.682734 
00:06:05 38.86363 755.2164 518.4592 18.55107 1.676281 43.2032 0.686504 
00:06:10 39.16694 670.9631 457.7551 18.83165 1.474747 38.14473 0.682236 
00:06:15 39.02188 703.4035 482.6955 18.72254 1.557959 40.22302 0.686229 
00:06:20 39.00869 692.4861 475.1285 18.75592 1.534821 39.59246 0.68612 
00:06:25 38.63944 755.688 518.5511 18.53584 1.686007 43.21086 0.686197 
00:06:30 38.82407 739.7729 506.5758 18.59715 1.640625 42.21296 0.684772 
00:06:35 38.86363 702.2092 479.5151 18.71734 1.554123 39.95799 0.682866 
00:06:40 38.7845 727.5747 496.856 18.63312 1.611697 41.40301 0.682893 
00:06:45 38.82407 671.6208 458.9775 18.81114 1.491168 38.2466 0.683388 
00:06:50 38.83725 753.9356 516.3064 18.55348 1.670628 43.02381 0.684815 
00:06:55 38.679 737.5964 504.4717 18.59529 1.639959 42.03763 0.68394 
00:07:00 38.7845 769.7642 524.9823 18.50051 1.700102 43.74677 0.682004 
00:07:05 38.63944 787.0597 536.9414 18.43686 1.744027 44.74332 0.682212 
00:07:10 38.679 789.5218 538.0069 18.43164 1.745653 44.83212 0.681434 
00:07:15 38.69219 776.64 529.3473 18.47307 1.717791 44.11051 0.681586 
00:07:20 38.59988 777.0251 529.3851 18.46601 1.7219 44.11366 0.681297 
00:07:25 38.69219 745.2683 507.7117 18.57192 1.649625 42.30761 0.681247 
00:07:30 38.59988 840.8501 572.6563 18.26443 1.858558 47.71945 0.681045 
00:07:35 38.74494 784.6105 533.6528 18.45133 1.729067 44.46928 0.68015 
00:07:40 38.61307 807.4144 547.77 18.3709 1.779372 45.64567 0.678425 
00:07:45 38.44163 845.0647 573.803 18.24014 1.86964 47.815 0.679005 
00:07:50 38.53394 837.1071 570.5198 18.27173 1.854894 47.54142 0.681537 
00:07:55 38.50757 804.4547 547.8133 18.37329 1.784247 45.64928 0.680975 
00:08:00 38.38888 880.3653 598.7056 18.12436 1.95122 49.89014 0.680065 
00:08:05 38.53394 800.3266 542.3935 18.38809 1.765914 45.19765 0.677715 
00:08:10 38.34931 807.5875 548.9599 18.35282 1.795048 45.74483 0.679753 
00:08:15 38.48119 791.2743 538.0881 18.4133 1.754626 44.83888 0.680027 
00:08:20 38.59988 788.9246 536.9576 18.42843 1.745815 44.74468 0.68062 
00:08:25 38.56032 791.8714 539.1374 18.41655 1.754446 44.92632 0.68084 
00:08:30 38.48119 797.7649 541.3334 18.39273 1.764907 45.10931 0.678563 
00:08:35 38.50757 801.2093 543.4861 18.38356 1.770548 45.2887 0.678332 
00:08:40 38.40206 817.7216 555.429 18.32418 1.813187 46.2839 0.67924 
00:08:45 38.3625 805.5235 546.791 18.36026 1.787556 45.56409 0.678802 
00:08:50 38.19106 837.7648 566.3333 18.24586 1.857735 47.19256 0.676005 
00:08:55 38.54713 805.835 545.6335 18.37154 1.775573 45.46764 0.677103 
00:09:00 38.30975 824.5974 557.6304 18.29604 1.824441 46.46734 0.676246 
00:09:05 38.38888 807.8861 546.7802 18.35452 1.786328 45.56319 0.676804 
00:09:10 38.40206 818.8034 554.3472 18.32074 1.809753 46.19375 0.677021 
00:09:15 38.34931 824.896 559.7777 18.2978 1.829436 46.64628 0.678604 
227 
 
00:09:20 38.34931 815.16 553.2871 18.32875 1.808803 46.10541 0.678747 
00:09:25 38.34931 778.3795 527.3243 18.44567 1.726272 43.94194 0.677464 
00:09:30 38.52075 758.0377 513.1909 18.52105 1.674084 42.7642 0.676999 
00:09:35 38.52075 814.2902 549.9714 18.34303 1.790483 45.82912 0.6754 
00:09:40 38.257 801.4819 541.4253 18.36608 1.77525 45.11697 0.67553 
00:09:45 38.11194 819.8592 554.4662 18.29758 1.823529 46.20367 0.676294 
00:09:50 38.40206 822.0487 556.5108 18.31044 1.816621 46.37404 0.67698 
00:09:55 38.45481 810.5473 547.8349 18.35048 1.786694 45.65108 0.675883 
00:10:00 38.24381 801.3824 541.4307 18.36552 1.775862 45.11742 0.675621 
00:10:05 38.20425 779.4483 525.2203 18.43286 1.725923 43.76661 0.673836 
00:10:10 38.24381 790.5646 533.8583 18.4 1.751724 44.48641 0.675287 
00:10:15 38.30975 800.7983 541.4037 18.37177 1.772806 45.11517 0.67608 
00:10:20 38.257 744.1476 503.5631 18.54878 1.654602 41.96191 0.676698 
00:10:25 38.21744 762.2393 515.4789 18.48861 1.694272 42.95485 0.676269 
00:10:30 38.257 762.5379 514.3808 18.49018 1.689073 42.86336 0.674564 
00:10:35 38.257 758.2108 513.2991 18.50396 1.685626 42.77321 0.676987 
00:10:40 38.17788 742.4687 500.3502 18.54922 1.647668 41.69418 0.673901 
00:10:45 38.19106 751.2225 507.9172 18.5221 1.671271 42.32474 0.676121 
00:10:50 38.05919 766.4539 517.7073 18.465 1.708247 43.14055 0.675458 
00:10:55 38.23063 753.6846 507.901 18.51673 1.669541 42.32339 0.673891 
00:11:00 38.17788 737.0598 497.1048 18.56649 1.637306 41.42375 0.674443 
00:11:05 38.27019 724.7751 488.4127 18.6113 1.605789 40.69943 0.673882 
00:11:10 38.27019 742.0836 500.3123 18.55617 1.643694 41.69102 0.674199 
00:11:15 38.05919 730.7552 494.9899 18.57935 1.635482 41.24751 0.677368 
00:11:20 37.96688 727.895 490.7007 18.58284 1.625564 40.89009 0.674137 
00:11:25 38.00644 722.7846 487.4391 18.60167 1.613463 40.6183 0.674391 
00:11:30 38.21744 721.1317 485.189 18.61974 1.597654 40.4308 0.672816 
00:11:35 37.92731 711.3697 478.8173 18.63352 1.589013 39.89985 0.673092 
00:11:40 38.19106 712.2784 477.6274 18.64641 1.574586 39.80069 0.670563 
00:11:45 38.08556 684.4377 459.2804 18.72922 1.520083 38.27184 0.671033 
00:11:50 38.07238 716.7916 483.085 18.62487 1.596813 40.25547 0.673955 
00:11:55 37.98006 698.7864 470.1415 18.67708 1.559028 39.17689 0.672797 
00:12:00 37.91413 686.3892 460.4325 18.71304 1.530435 38.36784 0.670804 
00:12:04 38.05919 693.9747 464.7001 18.69716 1.538462 38.72346 0.669621 
00:12:09 38.17788 653.7628 435.4434 18.83247 1.440415 36.2855 0.666057 
00:12:14 38.05919 624.7408 416.02 18.91892 1.382536 34.66695 0.665908 
00:12:19 37.92731 665.9349 446.3639 18.77955 1.484701 37.19551 0.670282 
00:12:24 38.00644 567.0083 369.5251 19.10132 1.235253 30.79253 0.65171 
00:12:29 38.11194 540.76 348.928 19.19031 1.16609 29.07617 0.645255 
00:12:34 38.08556 371.8034 234.2702 19.72992 0.799861 19.52174 0.630092 
00:12:39 38.70538 86.56401 38.21387 20.64736 0.170358 3.184362 0.441452 
00:12:44 38.63944 36.30453 7.951081 20.80546 0.075085 0.662564 0.219011 
00:12:49 38.63944 33.05919 6.869301 20.8157 0.071672 0.572419 0.207788 
00:12:54 38.75813 35.03668 6.820621 20.8098 0.071453 0.568362 0.194671 
228 
 
00:12:59 38.75813 35.03668 5.738841 20.8098 0.06805 0.478218 0.163795 
00:13:04 38.74494 34.93716 5.74425 20.81007 0.068074 0.478668 0.164417 
00:13:09 38.70538 35.72037 6.842257 20.8075 0.07155 0.570165 0.191551 
00:13:14 38.79769 34.25347 6.804394 20.81237 0.07138 0.56701 0.198648 
00:13:19 38.79769 34.25347 6.804394 20.81237 0.07138 0.56701 0.198648 
00:13:24 38.85044 34.65157 6.782759 20.81127 0.071283 0.565207 0.195742 
00:13:29 38.90319 33.96788 5.679344 20.81356 0.067797 0.47326 0.167197 
00:13:34 38.94275 34.26645 5.663117 20.81273 0.067728 0.471908 0.165267 
00:13:39 38.94275 34.26645 5.663117 20.81273 0.067728 0.471908 0.165267 
00:13:44 38.98232 34.56503 6.72867 20.81191 0.071042 0.5607 0.194667 
00:13:49 38.9955 34.66455 6.723261 20.81163 0.071018 0.560249 0.193952 
00:13:54 38.98232 33.48325 6.72867 20.81529 0.071042 0.5607 0.200956 
00:13:59 39.03507 34.96312 5.625255 20.81081 0.067568 0.468752 0.160891 
00:14:04 38.95594 33.2842 5.657708 20.81584 0.067705 0.471457 0.169982 
00:14:09 38.9955 34.66455 5.641481 20.81163 0.067636 0.470105 0.162745 
00:14:14 39.02188 32.70004 6.712443 20.81784 0.07097 0.559348 0.205273 
00:14:19 39.03507 33.88134 6.707034 20.81419 0.070946 0.558897 0.197957 
00:14:24 38.9955 33.58277 6.723261 20.81502 0.071018 0.560249 0.2002 
        
     
Totals 3837.052 0.67956 
     
% Error 0.45 1.88 
 
3. 23 October 2015 
 




hh:mm:ss l/min ml/min ml/min % % ml --- 
00:00:02 40.55947 14.39346 0.586631 20.87674 0.051763 0.048884 0.040757 
00:00:07 40.55947 15.46985 1.66302 20.8735 0.054998 0.138579 0.107501 
00:00:12 40.50698 16.15013 0.608159 20.8714 0.05183 0.050678 0.037657 
00:00:17 40.44137 13.50221 0.635069 20.8793 0.051914 0.05292 0.047034 
00:00:22 40.50698 13.99735 0 20.87787 0.048591 0 0 
00:00:27 40.50698 15.07374 0 20.87464 0.048591 0 0 
00:00:32 40.50698 15.07374 0 20.87464 0.048591 0 0 
00:00:37 40.50698 15.07374 0.608159 20.87464 0.05183 0.050678 0.040346 
00:00:42 40.55947 29.46289 12.4269 20.83145 0.08735 1.035534 0.421781 
00:00:47 40.50698 19.37929 2.760935 20.86168 0.058309 0.230069 0.142468 
00:00:52 40.61195 14.78957 0.565104 20.87561 0.051696 0.04709 0.03821 
00:00:57 40.50698 18.3029 2.760935 20.86492 0.058309 0.230069 0.150847 
00:01:02 40.55947 14.39346 0 20.87674 0.048528 0 0 
00:01:07 40.50698 26.91401 8.142876 20.839 0.074506 0.678546 0.302552 
229 
 
00:01:12 40.50698 23.68484 5.990099 20.84872 0.068027 0.499155 0.252909 
00:01:17 40.50698 19.37929 2.760935 20.86168 0.058309 0.230069 0.142468 
00:01:22 40.50698 32.29595 11.37204 20.82281 0.084224 0.947632 0.35212 
00:01:27 40.50698 39.83066 16.75398 20.80013 0.100421 1.396109 0.42063 
00:01:32 40.50698 21.53207 3.837323 20.8552 0.061548 0.319764 0.178214 
00:01:37 40.55947 34.84483 13.50329 20.81527 0.090586 1.125229 0.387526 
00:01:42 40.55947 50.99065 25.34356 20.76674 0.126173 2.111879 0.497024 
00:01:47 40.50698 31.21956 10.29565 20.82604 0.080985 0.857937 0.329782 
00:01:52 40.55947 19.7754 2.739408 20.86056 0.058234 0.228275 0.138526 
00:01:57 40.55947 18.69901 1.66302 20.8638 0.054998 0.138579 0.088936 
00:02:02 40.44137 14.5786 0.635069 20.87605 0.051914 0.05292 0.043562 
00:02:07 40.55947 23.00457 4.892184 20.85086 0.064704 0.407666 0.212661 
00:02:12 40.44137 21.03693 4.940621 20.85659 0.064893 0.411702 0.234855 
00:02:17 40.55947 16.54624 0.586631 20.87027 0.051763 0.048884 0.035454 
00:02:22 40.50698 34.44872 12.44843 20.81633 0.087464 1.037327 0.361361 
00:02:27 40.55947 44.53233 19.96162 20.78615 0.109997 1.663401 0.44825 
00:02:32 40.55947 41.30316 18.88523 20.79586 0.106762 1.573706 0.457234 
00:02:37 40.50698 66.74036 33.97619 20.71914 0.152251 2.831236 0.50908 
00:02:42 40.55947 62.83092 30.7255 20.73115 0.142349 2.560356 0.489019 
00:02:47 40.50698 81.8098 44.74007 20.67379 0.184645 3.72819 0.546879 
00:02:52 38.44686 221.2623 138.1544 20.21843 0.488055 11.51241 0.624392 
00:02:57 36.7279 548.4283 362.7482 19.09968 1.254019 30.2278 0.661432 
00:03:02 36.83288 583.665 389.6148 18.98824 1.339508 32.4666 0.667532 
00:03:07 36.34737 641.3551 433.9458 18.76895 1.505415 36.16071 0.676608 
00:03:12 36.62293 604.6847 405.8467 18.9072 1.400932 33.81921 0.671171 
00:03:17 36.57044 609.6705 406.9446 18.88769 1.40653 33.9107 0.667483 
00:03:22 36.55732 598.8076 399.4153 18.92319 1.38191 33.28328 0.667018 
00:03:27 36.67542 600.7752 400.4433 18.92308 1.381038 33.36894 0.666544 
00:03:32 36.55732 599.884 399.4153 18.9196 1.38191 33.28328 0.665821 
00:03:37 36.51795 635.1077 424.1884 18.79986 1.466044 35.34762 0.6679 
00:03:42 36.62293 621.9069 413.3814 18.84987 1.426012 34.44708 0.6647 
00:03:47 36.39986 626.6817 416.7021 18.8212 1.445566 34.72379 0.664934 
00:03:52 36.39986 627.7581 416.7021 18.81759 1.445566 34.72379 0.663794 
00:03:57 36.51795 624.3438 412.3481 18.83579 1.426518 34.36097 0.66045 
00:04:02 36.37361 599.574 394.1087 18.91053 1.370851 32.84108 0.657315 
00:04:07 36.34737 656.4245 437.175 18.71841 1.516245 36.42979 0.665994 
00:04:12 36.71478 675.3431 448.8646 18.67763 1.540386 37.40389 0.664647 
00:04:17 36.81976 685.8228 457.4326 18.64932 1.564505 38.11786 0.666984 
00:04:22 37.59394 626.0058 409.754 18.89005 1.378709 34.1448 0.654553 
00:04:27 37.62019 698.3218 463.5627 18.65713 1.552145 38.62868 0.663824 
00:04:32 37.88262 665.858 439.7745 18.77728 1.465189 36.64641 0.660463 
00:04:37 37.52833 680.4064 449.6073 18.70979 1.51049 37.46578 0.660792 
00:04:42 37.58082 695.872 461.426 18.66271 1.546788 38.45063 0.66309 
00:04:47 37.62019 717.6968 476.4793 18.59435 1.594001 39.70502 0.663901 
230 
 
00:04:52 37.33151 753.1918 501.3546 18.46046 1.68717 41.77788 0.66564 
00:04:57 37.58082 733.5455 486.183 18.5405 1.627095 40.51363 0.662785 
00:05:02 37.47585 742.4408 493.7607 18.5049 1.656162 41.14508 0.665051 
00:05:07 37.38399 747.1296 497.0276 18.48368 1.670762 41.41731 0.66525 
00:05:12 37.54145 708.4915 467.9005 18.61936 1.569381 38.99015 0.660418 
00:05:17 37.54145 717.1026 474.3588 18.5914 1.590353 39.52832 0.661494 
00:05:22 37.17404 804.7465 535.8636 18.28097 1.807271 44.65352 0.665879 
00:05:27 37.37087 751.3361 495.9566 18.4691 1.667837 41.32806 0.660099 
00:05:32 37.38399 790.1851 525.0137 18.34328 1.762022 43.74939 0.664419 
00:05:37 37.10844 769.8069 511.1336 18.39109 1.729137 42.59277 0.663976 
00:05:42 37.41024 740.8693 490.5585 18.50579 1.648544 40.87824 0.662139 
00:05:47 37.34463 747.9089 494.8909 18.47857 1.665495 41.23926 0.6617 
00:05:52 37.38399 747.1296 492.722 18.48368 1.656722 41.05853 0.659487 
00:05:57 37.18717 765.0191 505.7194 18.41214 1.707833 42.1416 0.661055 
00:06:02 37.4496 770.2288 507.7645 18.41275 1.702873 42.31202 0.659239 
00:06:07 37.01658 799.2526 530.5463 18.28784 1.797235 44.21042 0.663803 
00:06:12 37.17404 775.684 513.2595 18.37628 1.733145 42.76991 0.661686 
00:06:17 37.23965 828.9221 550.9062 18.20648 1.853418 45.90701 0.664605 
00:06:22 37.13468 790.4563 521.8867 18.32509 1.763251 43.48882 0.660235 
00:06:27 37.05595 792.0149 524.0718 18.31445 1.774079 43.6709 0.661694 
00:06:32 37.06907 816.8709 540.2123 18.23363 1.826549 45.01589 0.661319 
00:06:37 37.23965 764.3388 502.4687 18.4179 1.694856 41.87072 0.65739 
00:06:42 37.18717 816.6858 542.3166 18.24277 1.827805 45.19124 0.664046 
00:06:47 36.99034 786.1379 519.7932 18.32919 1.763037 43.31436 0.661198 
00:06:52 37.12156 795.7392 527.2741 18.30682 1.781548 43.93775 0.662622 
00:06:57 36.92473 828.6982 548.8826 18.18408 1.862118 45.73838 0.662343 
00:07:02 37.13468 797.991 527.2687 18.30035 1.780919 43.9373 0.660745 
00:07:07 37.08219 802.9769 530.5194 18.28025 1.794055 44.20818 0.660691 
00:07:12 37.0297 788.5877 521.9298 18.32388 1.768249 43.49241 0.661854 
00:07:17 36.67542 834.3514 552.214 18.14669 1.88551 46.01599 0.661848 
00:07:22 37.01658 800.329 528.3935 18.2843 1.790145 44.03103 0.66022 
00:07:27 36.85912 800.217 527.3817 18.27341 1.794233 43.94672 0.659048 
00:07:32 36.89849 806.9724 533.8239 18.25391 1.813656 44.48354 0.661514 
00:07:37 36.9641 780.5579 514.422 18.34576 1.746539 42.86678 0.659044 
00:07:41 36.78039 825.4562 544.6362 18.18409 1.855155 45.38454 0.6598 
00:07:46 36.80663 815.9667 539.2435 18.21747 1.836007 44.93516 0.660865 
00:07:51 36.9641 775.1759 511.1928 18.36351 1.735889 42.5977 0.659454 
00:07:56 36.85912 749.6268 494.0137 18.44073 1.683873 41.16616 0.659013 
00:08:01 37.0297 759.5252 499.3257 18.41956 1.693834 41.60881 0.657418 
00:08:06 36.81976 811.7602 536.009 18.23236 1.824661 44.66563 0.660305 
00:08:11 36.87224 794.9341 525.2235 18.29181 1.786477 43.76688 0.660713 
00:08:16 36.83288 788.1787 520.9341 18.31136 1.774136 43.40944 0.660934 
00:08:21 37.01658 791.7179 521.9352 18.31266 1.768876 43.49286 0.659244 
00:08:26 37.48897 758.6857 496.9845 18.45292 1.666083 41.41372 0.65506 
231 
 
00:08:31 37.27902 766.7887 503.5289 18.41253 1.696586 41.95907 0.656672 
00:08:36 37.23965 810.6235 534.7603 18.26638 1.800564 44.56158 0.65969 
00:08:41 37.22653 771.7745 507.856 18.39267 1.713077 42.31964 0.658037 
00:08:46 37.12156 792.5101 521.8921 18.31743 1.763874 43.48927 0.658531 
00:08:51 37.23965 766.4916 503.5451 18.41085 1.698379 41.96041 0.656948 
00:08:56 37.33151 768.2612 503.5074 18.41125 1.6942 41.95727 0.655386 
00:09:01 37.29214 760.4294 498.1416 18.4342 1.678395 41.51014 0.655079 
00:09:06 37.18717 751.0261 492.8027 18.45801 1.66549 41.06525 0.656173 
00:09:11 37.43648 756.1368 494.8533 18.45776 1.661409 41.23612 0.654449 
00:09:16 37.37087 742.725 485.1927 18.49719 1.632725 40.43111 0.65326 
00:09:21 37.60706 742.3547 480.7902 18.51361 1.608514 40.06425 0.647656 
00:09:26 37.33151 783.3306 509.9657 18.36204 1.71529 42.49545 0.651022 
00:09:31 37.48897 722.0885 465.7693 18.57193 1.564578 38.81255 0.645031 
00:09:36 37.27902 757.1012 489.5359 18.44421 1.650827 40.79303 0.646592 
00:09:41 37.52833 709.4689 457.142 18.61538 1.534965 38.09364 0.644344 
00:09:46 37.37087 722.2736 466.8941 18.5639 1.573034 38.90628 0.646423 
00:09:51 38.09257 744.9423 480.5911 18.536 1.588012 40.04766 0.645139 
00:09:56 38.0532 726.3467 467.6906 18.5931 1.548276 38.97266 0.643894 
00:10:01 38.0532 725.2703 467.6906 18.59655 1.548276 38.97266 0.64485 
00:10:06 38.15818 720.6805 462.2656 18.61761 1.526823 38.52059 0.641429 
00:10:11 38.04008 720.8657 463.3904 18.60987 1.535012 38.61433 0.642825 
00:10:16 37.9876 690.3307 441.8842 18.70466 1.468048 36.82221 0.640105 
00:10:21 38.27627 634.3844 399.7867 18.89955 1.323277 33.31422 0.630196 
00:10:26 38.09257 654.5257 414.9314 18.82535 1.377885 34.57624 0.633942 
00:10:31 38.68305 626.6903 389.9323 18.94505 1.278833 32.49306 0.622209 
00:10:36 38.69617 585.8866 360.8645 19.07426 1.186843 30.07084 0.615929 
00:10:41 38.81427 400.5627 234.8786 19.66193 0.787694 19.57244 0.586372 
00:10:46 39.12919 90.78687 28.08296 20.63716 0.137492 2.340153 0.309328 
00:10:51 39.28665 51.07246 5.414232 20.76152 0.0668 0.451168 0.106011 
00:10:56 39.40475 48.73455 3.213018 20.76923 0.05994 0.267741 0.065929 
00:11:01 39.33914 47.16302 3.239928 20.77385 0.06004 0.269983 0.068696 
00:11:06 39.28665 47.8433 3.261456 20.77154 0.06012 0.271777 0.06817 
00:11:11 39.40475 54.11649 3.213018 20.75258 0.05994 0.267741 0.059372 
00:11:16 39.45724 55.58898 3.191491 20.74825 0.05986 0.265947 0.057412 
00:11:21 39.33914 53.62135 3.239928 20.75384 0.06004 0.269983 0.060422 
00:11:26 39.50972 49.52677 3.169963 20.76719 0.059781 0.264153 0.064005 
00:11:31 39.6147 48.16621 3.126907 20.77178 0.059622 0.260565 0.064919 
00:11:36 39.68031 54.04329 3.099998 20.75397 0.059524 0.258323 0.057361 
00:11:41 39.6147 54.62454 3.126907 20.7519 0.059622 0.260565 0.057244 
00:11:46 39.6147 54.62454 3.126907 20.7519 0.059622 0.260565 0.057244 
        
        
     
Total 3769.41 0.66 
     




4. 23 November 2015 
 




hh:mm:ss l/min ml/min ml/min % % ml --- 
00:00:00 39.07998 1.559171 0.032303 20.91516 0.0501 0.002692 0.020718 
00:00:05 39.13219 0.878649 0.010768 20.91728 0.050033 0.000897 0.012255 
00:00:10 39.07998 1.559171 0.032303 20.91516 0.0501 0.002692 0.020718 
00:00:15 39.13219 0.878649 0.010768 20.91728 0.050033 0.000897 0.012255 
00:00:20 39.07998 1.559171 0.032303 20.91516 0.0501 0.002692 0.020718 
00:00:25 39.07998 1.559171 0.032303 20.91516 0.0501 0.002692 0.020718 
00:00:30 39.07998 1.559171 0.032303 20.91516 0.0501 0.002692 0.020718 
00:00:35 38.97556 2.920215 0.075374 20.91092 0.050234 0.006281 0.025811 
00:00:40 39.02777 2.239693 0.053839 20.91304 0.050167 0.004486 0.024038 
00:00:45 39.13219 1.955424 0.010768 20.91394 0.050033 0.000897 0.005507 
00:00:50 39.13219 1.955424 0.010768 20.91394 0.050033 0.000897 0.005507 
00:00:55 39.13219 0.878649 0.010768 20.91728 0.050033 0.000897 0.012255 
00:01:00 39.07998 1.559171 0.032303 20.91516 0.0501 0.002692 0.020718 
00:01:05 39.13219 1.955424 0.010768 20.91394 0.050033 0.000897 0.005507 
00:01:10 39.07998 1.559171 0.032303 20.91516 0.0501 0.002692 0.020718 
00:01:15 38.97556 2.920215 0.075374 20.91092 0.050234 0.006281 0.025811 
00:01:20 40.93347 2.70486 0.344568 20.91199 0.05102 0.028713 0.127389 
00:01:25 41.84717 2.101866 0 20.91391 0.049906 0 0 
00:01:30 41.84717 3.178641 0 20.91079 0.049906 0 0 
00:01:35 41.89938 3.574895 0 20.90966 0.049844 0 0 
00:01:40 40.48968 4.720584 0.52762 20.90587 0.05158 0.043967 0.11177 
00:01:45 39.07998 4.789498 1.109079 20.90514 0.05344 0.09242 0.231565 
00:01:50 41.56001 11.767 3.316469 20.88568 0.059673 0.276361 0.281845 
00:01:55 39.13219 262.5351 173.3716 20.10674 0.587058 14.44706 0.660375 
00:02:00 38.53177 518.5579 337.2892 19.28862 1.111111 28.10631 0.650437 
00:02:05 38.25766 603.6964 404.1623 19.00716 1.330604 33.67885 0.669479 
00:02:10 38.25766 576.777 385.8571 19.09246 1.272603 32.15347 0.668988 
00:02:15 38.10102 620.8128 418.225 18.94484 1.38061 34.85069 0.673673 
00:02:20 38.30987 614.8604 413.8318 18.97445 1.359455 34.4846 0.67305 
00:02:25 37.98355 628.5354 424.7341 18.91409 1.405498 35.39309 0.675752 
00:02:30 38.15324 591.0593 394.5144 19.04208 1.303455 32.87489 0.66747 
00:02:35 38.20545 637.7569 428.9497 18.89648 1.411001 35.74438 0.672591 
00:02:40 38.10102 627.2734 420.3786 18.92429 1.387461 35.03014 0.670168 
00:02:45 37.98355 633.9193 426.8877 18.89691 1.412371 35.57255 0.67341 
00:02:50 38.15324 642.7445 432.2015 18.87787 1.423195 36.01535 0.672431 
00:02:55 37.77471 701.2479 476.5055 18.66966 1.579129 39.7072 0.679511 
233 
00:03:00 37.94439 696.0751 469.9748 18.69625 1.551428 39.163 0.675178 
00:03:05 37.89218 655.8381 439.8467 18.82191 1.457113 36.65242 0.670663 
00:03:10 37.93134 664.7495 446.2912 18.7956 1.476256 37.18944 0.671367 
00:03:15 37.77471 713.0924 480.8126 18.63165 1.592951 40.06611 0.674264 
00:03:20 37.87913 663.2765 444.1591 18.79738 1.471399 37.01178 0.669644 
00:03:25 37.77471 712.0157 478.659 18.63511 1.58604 39.88666 0.672259 
00:03:30 37.60502 693.4994 465.8077 18.68448 1.551545 38.81576 0.671677 
00:03:35 37.72249 695.4678 465.7593 18.68512 1.546713 38.81172 0.669706 
00:03:40 37.77471 716.3228 480.8126 18.62129 1.592951 40.06611 0.671223 
00:03:45 37.82692 726.41 488.3285 18.59213 1.614907 40.69241 0.672249 
00:03:50 37.70944 729.8255 490.5305 18.5739 1.626861 40.8759 0.67212 
00:03:55 37.67028 718.7606 480.8557 18.60707 1.597367 40.0697 0.669007 
00:04:00 37.72249 729.9246 490.5251 18.57439 1.626298 40.87546 0.672022 
00:04:05 37.5006 730.3941 490.6166 18.559 1.635921 40.88308 0.671715 
00:04:10 37.72249 717.0033 479.7573 18.61592 1.591696 39.97818 0.669115 
00:04:15 37.44839 715.9997 479.8704 18.6023 1.603346 39.9876 0.67021 
00:04:20 37.65723 748.8112 502.3965 18.50953 1.667244 41.8647 0.670925 
00:04:25 37.51365 794.0229 532.6055 18.35421 1.771051 44.38201 0.670768 
00:04:30 37.44839 771.9921 517.5575 18.42105 1.72534 43.12807 0.670418 
00:04:35 37.55281 771.7078 516.4377 18.42892 1.717066 43.03475 0.669214 
00:04:40 37.60502 769.9505 516.4162 18.43804 1.714682 43.03296 0.670713 
00:04:45 37.51365 760.6429 511.07 18.46207 1.701461 42.58746 0.671892 
00:04:50 37.44839 793.5276 533.7092 18.35134 1.777623 44.47399 0.672578 
00:04:55 37.56586 800.8798 536.891 18.33565 1.782488 44.73913 0.670377 
00:05:00 37.5006 750.8528 502.4612 18.49286 1.674208 41.87009 0.669187 
00:05:05 37.55281 748.0187 500.2861 18.50539 1.664929 41.68884 0.668815 
00:05:10 37.30481 812.8966 544.5362 18.27852 1.819454 45.3762 0.669871 
00:05:15 37.5006 785.3096 528.3038 18.38148 1.757745 44.02355 0.672733 
00:05:20 37.55281 764.1704 511.0538 18.45325 1.699687 42.58611 0.668769 
00:05:25 37.25259 827.5752 554.2487 18.22705 1.853539 46.18554 0.669726 
00:05:30 37.39618 761.9048 508.9649 18.45026 1.699825 42.41204 0.668016 
00:05:35 37.51365 766.0267 511.07 18.44468 1.701461 42.58746 0.66717 
00:05:40 37.29175 775.1104 518.6989 18.40042 1.736087 43.22318 0.669194 
00:05:45 37.39618 788.8242 528.3468 18.363 1.762653 44.02714 0.66979 
00:05:50 37.13512 813.7623 544.6061 18.26362 1.827768 45.38203 0.669245 
00:05:54 37.35702 787.4503 526.2094 18.36478 1.757512 43.84903 0.668245 
00:05:59 37.34396 805.6564 536.9826 18.30479 1.793079 44.74676 0.666516 
00:06:04 37.34396 792.7351 529.4451 18.34673 1.768612 44.11866 0.667871 
00:06:09 37.26565 801.8317 534.8613 18.31173 1.789842 44.56999 0.667049 
00:06:14 37.18733 807.6979 540.2775 18.28712 1.811162 45.02132 0.66891 
00:06:19 37.23954 785.4819 525.1811 18.36313 1.759551 43.76334 0.66861 
00:06:24 37.18733 777.5482 518.742 18.3854 1.740962 43.22677 0.667151 
00:06:29 37.22649 782.1525 521.9562 18.37307 1.749649 43.49461 0.667333 
00:06:34 37.34396 763.6621 507.9096 18.4411 1.698707 42.32411 0.665097 
234 
 
00:06:39 37.23954 786.5587 523.0276 18.35962 1.752541 43.58389 0.664957 
00:06:44 37.22649 777.8454 519.8026 18.3871 1.742637 43.31515 0.66826 
00:06:49 37.23954 760.7161 507.9527 18.44374 1.70347 42.3277 0.66773 
00:06:54 37.23954 763.9464 507.9527 18.43323 1.70347 42.3277 0.664906 
00:06:59 37.29175 795.5691 529.4667 18.33392 1.771089 44.12046 0.665519 
00:07:04 37.2787 763.1668 507.9366 18.43838 1.701681 42.32635 0.665564 
00:07:09 37.29175 756.8052 504.7008 18.45992 1.690585 42.05672 0.666883 
00:07:14 37.08291 760.6041 506.9405 18.43365 1.707145 42.24336 0.666497 
00:07:19 37.23954 743.4877 495.0314 18.49982 1.661409 41.25097 0.665823 
00:07:24 36.95238 792.9935 526.3763 18.31862 1.776757 43.86294 0.663784 
00:07:29 37.13512 749.1558 498.3048 18.47452 1.676626 41.52374 0.665155 
00:07:34 37.18733 752.7824 499.36 18.46613 1.677782 41.61167 0.663352 
00:07:39 37.04375 748.4624 496.1889 18.47075 1.673714 41.34742 0.662944 
00:07:44 37.18733 744.1682 495.0529 18.49421 1.663742 41.25276 0.665243 
00:07:49 37.08291 743.3757 492.9425 18.48997 1.661387 41.07689 0.663114 
00:07:54 37.17428 744.0691 493.9815 18.49368 1.660815 41.16348 0.663892 
00:07:59 37.12207 729.6748 483.2353 18.53727 1.627989 40.268 0.662261 
00:08:04 37.14817 728.7961 481.071 18.54181 1.619817 40.08765 0.66009 
00:08:09 37.04375 753.8462 499.4193 18.45314 1.684285 41.61661 0.662495 
00:08:14 37.17428 706.382 467.0622 18.61657 1.573034 38.92029 0.661203 
00:08:19 36.99154 728.6842 482.2124 18.53211 1.630205 40.18276 0.661758 
00:08:24 37.17428 725.7639 481.0602 18.55337 1.61868 40.08675 0.662833 
00:08:29 37.06986 698.052 460.6446 18.63732 1.556338 38.38551 0.6599 
00:08:34 37.09596 699.3269 459.557 18.63476 1.551724 38.29489 0.657142 
00:08:39 37.13512 715.7758 472.4622 18.58348 1.592267 39.37027 0.66007 
00:08:44 37.08291 713.226 470.3302 18.58853 1.587469 39.19261 0.659441 
00:08:49 37.2787 686.7158 453.021 18.68697 1.523109 37.75024 0.659692 
00:08:54 36.92628 738.9566 489.7767 18.49417 1.65783 40.8131 0.662795 
00:08:59 37.08291 729.3776 482.1747 18.53573 1.626188 40.17962 0.661077 
00:09:04 37.22649 698.164 459.5032 18.64656 1.546283 38.2904 0.658159 
00:09:09 37.08291 684.153 449.8714 18.68356 1.520591 37.48779 0.65756 
00:09:14 37.17428 687 451.9873 18.67978 1.523876 37.6641 0.657915 
00:09:19 36.97849 686.5908 452.0681 18.66926 1.531945 37.67083 0.658424 
00:09:24 37.17428 670.8484 440.1428 18.73244 1.485253 36.6771 0.656099 
00:09:29 37.0307 644.9929 419.7433 18.8086 1.424039 34.97721 0.650772 
00:09:34 37.14817 634.0399 412.1574 18.85102 1.39494 34.34507 0.65005 
00:09:39 37.08291 511.8689 326.0422 19.24674 1.115804 27.1691 0.636964 
00:09:44 37.82692 114.8015 49.00405 20.5521 0.207039 4.083508 0.426859 
00:09:49 37.76165 55.08353 9.190279 20.74317 0.079502 0.765826 0.166843 
00:09:54 37.82692 49.11819 4.856258 20.76259 0.065562 0.404672 0.098869 
00:09:59 37.70944 46.07307 3.827937 20.77189 0.062305 0.318982 0.083084 
00:10:04 37.76165 45.39255 2.729626 20.77428 0.058763 0.22746 0.060134 
00:10:09 37.82692 46.96464 2.702707 20.7695 0.058661 0.225217 0.057548 
00:10:14 37.82692 46.96464 2.702707 20.7695 0.058661 0.225217 0.057548 
235 
 
00:10:19 37.93134 46.68037 3.736411 20.77082 0.061941 0.311355 0.080042 
00:10:24 37.98355 45.99985 3.714876 20.7732 0.061856 0.309561 0.080758 
00:10:29 37.87913 47.3609 3.757947 20.76844 0.062026 0.31315 0.079347 
00:10:34 37.93134 46.68037 3.736411 20.77082 0.061941 0.311355 0.080042 
00:10:39 37.87913 47.3609 2.681171 20.76844 0.05858 0.223422 0.056611 
00:10:44 37.82692 48.04142 3.779482 20.76605 0.062112 0.314944 0.078671 
        
     
Totals 3763.66 0.67 
     
% Error -1.47 -0.03 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
